{"title":"Anti-inflammatory drugs for mouth, throat and gums","description":"\u003cp\u003eAnti-inflammatory drugs and devices for the mouth and gums: chlorhexidine mouthwashes, gum gels, sprays for the oral mucosa, solutions for canker sores and stomatitis, products for inflamed or bleeding gums and for the pain of the first teeth. Fast shipping in 24\/48 hours.\u003c\/p\u003e","products":[{"product_id":"benagol-miele-e-limone-36-pastiglie-mal-di-gola","title":"Benagol Honey and Lemon 36 Tablets Sore Throat","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAntiseptic of the oral cavity.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. Do not administer to children under 6 years of age. BENAGOL Menthol-Eucalyptol flavor is contraindicated in children with a history of epilepsy or febrile convulsions. Do not administer BENAGOL Cold Mint flavor and BENAGOL Ginger and Spice flavor to children under 12 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBe careful with pre-school children as if the tablets are swallowed whole they may cause choking. In the event of the appearance of sensitization or irritation phenomena, administration should be discontinued and suitable treatment instituted. BENAGOL Menthol-Eucalyptol flavor contains terpene derivatives which, in excessive doses, can cause neurological disorders such as convulsions in infants and children. Treatment with BENAGOL Menthol-Eucalyptol flavor must not be prolonged for more than 3 days due to the risks associated with the accumulation of terpene derivatives, such as \u003ci\u003eexample camphor, cineol, niaouli, wild thyme, terpineol, terpine, citral, menthol and essential oils of pine needles, eucalyptus and turpentine\u003c\/i\u003e (due to their lipophilic properties the rate of metabolism and disposal is not known) in tissues and the brain, in particular neuropsychological disorders. A higher than recommended dose should not be used to avoid an increased risk of adverse drug reactions and disorders associated with overdose (see section 4.9). BENAGOL Menthol-Eucalyptol flavor is flammable, it should not be brought near flames. \u003ci\u003eImportant information about some excipients\u003c\/i\u003e \u003cu\u003eBENAGOL Ginger and Spice flavored tablets, BENAGOL Honey and Lemon flavored tablets\u003c\/u\u003e, \u003cu\u003eBENAGOL Menthol-Eucalyptol flavor tablets, BENAGOL Orange flavor tablets with Vitamin C, BENAGOL Cold Mint flavor tablets contain\u003c\/u\u003e Liquid glucose: - Patients suffering from rare hereditary problems of glucose-galactose malabsorption should not take this medicine. - To be taken into consideration in people suffering from diabetes mellitus: BENAGOL Ginger and Spice flavored tablets contains 1.10 g of glucose per tablet. BENAGOL Honey and Lemon flavored tablets contains 0.98 g of glucose per tablet. BENAGOL Menthol-Eucalyptol flavor tablets contains 1.01 g of glucose per tablet. BENAGOL Tablets with Vitamin C Orange flavor contains 0.97 g of glucose per tablet. BENAGOL Cold Mint flavor tablets contains 1.10 g of glucose per tablet. - Liquid glucose contains sulphites. These medicines can rarely cause serious hypersensitivity reactions and bronchospasm. - Liquid glucose contains wheat starch. These medicines contain only a very small amount of gluten (from wheat starch). These medicines are considered “gluten-free” and are very unlikely to cause problems if the patient has celiac disease. One tablet of BENAGOL Ginger and Spice flavored tablets contains no more than 22.04 micrograms of gluten. One tablet of BENAGOL Honey and Lemon flavored tablets contains no more than 19.52 micrograms of gluten. One tablet of BENAGOL Menthol-Eucalyptol flavor contains no more than 20.26 micrograms of gluten. One tablet of BENAGOL Tablets with Vitamin C Orange flavor contains no more than 19.38 micrograms of gluten. One tablet of BENAGOL Cold Mint flavor tablets contains no more than 22.04 micrograms of gluten. If the patient is allergic to wheat (a condition other than celiac disease) he should not take these medicines. Liquid sucrose: - Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine. - To be taken into consideration in people suffering from diabetes mellitus: BENAGOL Ginger and Spice flavored tablets contains 1.38 g of sucrose per tablet. BENAGOL Honey and Lemon flavored tablets contains 1.44 g of sucrose per tablet. BENAGOL Menthol-Eucalyptol flavor tablets contains 1.50 g of sucrose per tablet. BENAGOL Tablets with Vitamin C Orange flavor contains 1.44 g of sucrose per tablet. BENAGOL Cold Mint flavor tablets contains 1.38 g of sucrose per tablet. \u003cu\u003eBENAGOL Ginger and Spice flavored tablets, BENAGOL Menthol-Eucalyptol flavored tablets\u003c\/u\u003e, \u003cu\u003eBENAGOL Tablets with Vitamin C Orange flavor, BENAGOL Tablets Lemon flavor Without Sugar, BENAGOL Tablets Strawberry flavor Without Sugar\u003c\/u\u003e These medicines contain less than 1 mmol (23 mg) sodium per dose, i.e. essentially 'sodium-free'. \u003cu\u003eBENAGOL Lemon Flavor Tablets Without Sugar and BENAGOL Strawberry Flavor Tablets Without Sugar\u003c\/u\u003e These medicines contain liquid maltitol and isomalt. Patients with rare hereditary problems of fructose intolerance should not take this medicine. They may have a mild laxative effect. The caloric value of maltitol and isomalt is 2.3 kcal\/g. \u003cu\u003eBENAGOL Ginger and Spice flavored tablets\u003c\/u\u003e This medicine contains a flavoring which contains cinnamale, citral, citronellol, eugenol, farfalle, geraniol, isoeugenol and linalool. Cinnamale, citral, citronellol, eugenol, farfalle, geraniol, isoeugenol and linalool can cause allergic reactions. This medicine contains excipients that can cause a warm sensation in the mouth and throat when you suck the lozenge. \u003cu\u003eBENAGOL Honey and Lemon flavored tablets\u003c\/u\u003e This medicine contains a flavoring which contains citral, d-limonene, geraniol and linalool. Citral, d-limonene, geraniol and linalool can cause allergic reactions. This medicine contains honey (invert sugar). Patients suffering from rare hereditary problems of fructose intolerance, or glucose-galactose malabsorption, should not take this medicine. \u003cu\u003eBENAGOL Menthol-Eucalyptol flavor tablets\u003c\/u\u003e This medicine contains a flavoring which contains d-limonene. D-limonene can cause allergic reactions. \u003cu\u003eBENAGOL Orange flavored tablets with Vitamin C\u003c\/u\u003e This medicine contains a flavoring which contains citral, citronellol, d-limonene, geraniol and linalool. Citral, citronellol, d-limonene, geraniol and linalool can cause allergic reactions. This medicine contains 3 mg of propylene glycol per tablet. \u003cu\u003eBENAGOL Lemon flavored tablets without sugar\u003c\/u\u003e This medicine contains a flavoring which contains benzyl alcohol, citral, citronellol, d-limonene, geraniol and linalool. Benzyl alcohol, citral, citronellol, d-limonene, geraniol and linalool can cause allergic reactions. \u003cu\u003eBENAGOL Strawberry flavored tablets without sugar\u003c\/u\u003e This medicine contains a flavoring which contains benzyl alcohol. Benzyl alcohol can cause allergic reactions. This medicine contains 7.30 mg of propylene glycol in each tablet. \u003cu\u003eBENAGOL Cold Mint flavor tablets\u003c\/u\u003e This medicine contains a flavoring which contains benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool. Benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool can cause allergic reactions. This medicine contains 1.89 mg of propylene glycol in each tablet.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBENAGOL Menthol-Eucalyptol flavor must not be used in conjunction with other products (medicines or cosmetics) containing terpene derivatives, regardless of the route of administration (oral, rectal, cutaneous, nasal or inhalation).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBENAGOL Menthol - Eucalyptol flavour: due to the presence of menthol and in case of non-compliance with the recommended doses there may be a risk of convulsions in children and infants. Adverse reactions associated with the use of 2,4 dichlorobenzyl alcohol, amylmetacresol, levomenthol and ascorbic acid are listed below, divided by frequency and organ class. Frequencies are defined as: Very common (≥1\/10); Common (≥1\/100 and \u003c1\/10); Uncommon (≥1\/1000 and \u003c1\/100); Rare (≥1\/10000 and \u003c1\/1000); Very rare (\u003c1\/10000); Not known (frequency cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eClassification by systems and organs\u003c\/b\u003e | \u003cb\u003eFrequency\u003c\/b\u003e | \u003cb\u003eAdverse reactions\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eImmune system disorders | Rare | Hypersensitivity\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders | Rare | Glossitis\u003c\/p\u003e\n\u003cp\u003eNot known | Abdominal pain, nausea, gastrointestinal discomfort\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders | Not known | Skin rash\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":40207822946419,"sku":"016242149","price":16.09,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/reckitt-benckiser-benagol-miele-e-limone-36-pastiglie-mal-di-gola-farmacia-dottor-tili-1258975935.jpg?v=1790944321"},{"product_id":"froben-gola-spray-mucosa-orale-15-ml-flurbiprofene-0-25","title":"Froben Throat Oral Mucosa Spray 15 ml Flurbiprofen 0.25%","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFroben Gola is indicated for the symptomatic treatment of irritative-inflammatory conditions also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to flurbiprofen or to any of the excipients listed in section 6.1. Froben Gola is also contraindicated in: • patients who have previously experienced hypersensitivity reactions (e.g. asthma, urticaria) after taking aspirin or other NSAIDs. • patients with a history of gastrointestinal bleeding or perforation related to previous treatment with NSAIDs. • patients with active or anamnestic ulcerative colitis, Crohn's disease, recurrent peptic ulcer or gastrointestinal bleeding (defined as two or more distinct episodes of demonstrated ulceration or bleeding). • patients with severe cardiac, renal or hepatic insufficiency (see section 4.4). Froben Gola is contraindicated during the third trimester of pregnancy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eGeneral precautions \u003c\/b\u003e Undesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.2 and the sections below on gastrointestinal and cardiovascular risks). \u003cb\u003eUse in elderly patients \u003c\/b\u003e Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal. \u003cb\u003e \u003ci\u003e \u003cu\u003eGastrointestinal effects \u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Flurbiprofen should be administered with caution to patients with a history of peptic ulcers and other gastrointestinal diseases as these conditions may be exacerbated. Gastrointestinal bleeding, ulcer or perforation have been reported with all NSAIDs at any time during treatment. These adverse events can be fatal and can occur with or without warning symptoms or in case of a previous history of serious gastrointestinal events. The risk of gastrointestinal haemorrhage, ulcer or perforation is higher with increasing dosage of flurbiprofen in patients with a history of ulcer, particularly if complicated by haemorrhage and perforation, and in the elderly. These patients should start treatment with the lowest available dose. Concomitant use of protective agents (misoprostol or proton pump inhibitors) should be considered for these patients and also for patients taking low doses of aspirin or other drugs that may increase the risk of gastrointestinal events (see section below and section 4.5). Patients with a history of gastrointestinal disease, especially if elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) in the initial stages of treatment. When gastrointestinal bleeding or ulceration occurs in patients taking Froben Gola, treatment should be suspended. \u003cb\u003e \u003ci\u003e \u003cu\u003eRespiratory Disorders\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Cases of bronchospasm have been reported with flurbiprofen in patients with a history of bronchial asthma. \u003cb\u003e \u003ci\u003e \u003cu\u003eCardiac, renal and hepatic impairment \u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Particular caution must be taken when treating patients with severely compromised renal, cardiac or hepatic function, as the use of NSAIDs can lead to deterioration of renal function. In such patients the dosage should be kept as low as possible and renal function should be monitored. The administration of an NSAID can cause a dose-dependent reduction in the formation of prostaglandins, accelerating renal failure. Patients at highest risk of developing this reaction are those with impaired kidney function, heart failure and liver dysfunction, those taking diuretics and elderly people. Renal function should be monitored in these patients (see also section 4.3). Flurbiprofen should be administered with caution in patients with a history of heart failure or hypertension as cases of edema have been reported in association with the administration of flurbiprofen. \u003cb\u003e \u003ci\u003e \u003cu\u003eCardiovascular and cerebrovascular effects\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Adequate monitoring and appropriate instructions are necessary in patients with a history of hypertension and\/or mild to moderate congestive heart failure since, in association with the administration of flurbiprofen and treatment with NSAIDs, fluid retention and edema have been found. In these patients Froben Gola should be taken with caution. Clinical studies and epidemiological data suggest that the use of some NSAIDs, especially at high doses and for long-term treatments, may be associated with a modest increase in the risk of arterial thrombotic events such as myocardial infarction or stroke. There are insufficient data to exclude a similar risk for flurbiprofen. Patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should be treated with flurbiprofen only after careful consideration. Similar considerations must be made before starting long-term treatment in patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidemia, diabetes mellitus, smoking). \u003cb\u003e \u003cu\u003eSkin reactions\u003c\/u\u003e \u003c\/b\u003e Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs. In the early stages of therapy, patients appear to be at higher risk: the onset of the reaction occurs in most cases within the first month of treatment. Flurbiprofen should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. \u003cb\u003e \u003ci\u003e \u003cu\u003eRenal effects\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Caution should be used when initiating treatment with NSAIDs such as flurbiprofen in patients with considerable dehydration. \u003cb\u003e \u003ci\u003e \u003cu\u003eHematological effects\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Flurbiprofen, like other NSAIDs, can inhibit platelet aggregation and prolong bleeding time. \u003cb\u003e \u003ci\u003e \u003cu\u003eSystemic lupus erythematosus (SLE) and connective system diseases\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e An increased risk of aseptic meningitis may occur in patients with Systemic Lupus Erythematosus (SLE) and connective system disorders (see section 4.8). The effects reported above have been reported in particular after the administration of formulations based on Flurbiprofen for systemic use. At the recommended doses, swallowing FROBEN GOLA does not cause any harm to the patient as these doses are significantly lower than those of the single dosage of the product systemically. The use of FROBEN GOLA, especially if prolonged, can give rise to local sensitization or irritation phenomena; in such cases it is necessary to interrupt the treatment and consult the doctor to institute, if necessary, a suitable therapy. Flurbiprofen should not be used for prolonged treatments. It is necessary to inform patients to seek medical advice if after short periods of treatment without appreciable results. \u003cb\u003eImpairment of fertility\u003c\/b\u003e The use of flurbiprofen may impair female fertility and is not recommended in women trying to become pregnant. In women who have difficulty conceiving or who are undergoing infertility investigations, discontinuation of treatment with flurbiprofen should be considered. \u003cb\u003e \u003ci\u003e \u003cu\u003eImportant information about some excipients\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e \u003cu\u003eFROBEN THROAT 250mg\/100ml Mouthwash\u003c\/u\u003e contains: • \u003ci\u003eSorbitol (E420)\u003c\/i\u003e. Patients with hereditary fructose intolerance should not be given this medicine. • \u003ci\u003eEthanol\u003c\/i\u003e. This medicine contains 12 vol% ethanol (alcohol), e.g. up to 1 g per dose, equivalent to 24 ml of beer, 10 ml of wine per dose. It can be harmful to alcoholics. To be taken into consideration in pregnant or breastfeeding women, children and high-risk groups such as people with liver disease or epilepsy. For those who carry out sporting activities, the use of medicines containing ethyl alcohol can lead to positive anti-doping tests in relation to the blood alcohol concentration limits indicated by some sports federations. • \u003ci\u003ePatent blue dye V(E131)\u003c\/i\u003e which can cause allergic reactions. \u003cu\u003eFROBEN THROAT 250mg\/100ml Spray for oral mucosa\u003c\/u\u003e contains: • \u003ci\u003eSorbitol\u003c\/i\u003e. The additive effect of co-administration of medicinal products containing sorbitol (or fructose) and daily dietary intake of sorbitol (or fructose) should be considered. The sorbitol content in oral medicinal products may modify the bioavailability of other co-administered oral medicinal products. • \u003ci\u003eEthanol\u003c\/i\u003e. This medicine contains 12 vol% ethanol (alcohol), e.g. up to 40 mg per dose, equivalent to 1 ml of beer, 0.4 ml of wine per dose. For those who carry out sporting activities, the use of medicines containing ethyl alcohol can lead to positive anti-doping tests in relation to the blood alcohol concentration limits indicated by some sports federations. • \u003ci\u003ePatent blue dye V(E131)\u003c\/i\u003e which can cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCaution should be exercised in patients treated with any of the medicines listed below, as interactions have been reported in some patients. \u003cb\u003eDiuretics, ACE inhibitors and angiotensin II antagonists\u003c\/b\u003e: NSAIDs can reduce the effect of diuretics and other antihypertensive drugs. Diuretics may also increase the risk of NSAID nephrotoxicity. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit the cyclo-oxygenase system may lead to further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking Flurbiprofen concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in elderly patients. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy and on a periodic basis thereafter. \u003cb\u003eLithium salts:\u003c\/b\u003e decrease in lithium elimination. \u003cb\u003eMethotrexate: \u003c\/b\u003ecaution is advised in case of concomitant administration of flurbiprofen and methotrexate as NSAIDs can increase the levels of methotrexate and therefore its toxic effects). \u003cb\u003eAnticoagulants, such as warfarin: \u003c\/b\u003eincreased anticoagulant effect. \u003cb\u003eAnti-aggregating agents:\u003c\/b\u003e increased risk of gastrointestinal bleeding \u003cb\u003eSelective serotonin reuptake inhibitors (SSRIs):\u003c\/b\u003e increased risk of gastrointestinal bleeding. \u003cb\u003eAspirin:\u003c\/b\u003e As with other NSAID-containing medicines, concomitant administration of flurbiprofen and aspirin is generally not recommended due to the potential for increased side effects. \u003cb\u003eCardiac glycosides\u003c\/b\u003e: NSAIDs can exacerbate heart failure, reduce glomerular filtration rate and increase plasma levels of cardiac glycosides. \u003cb\u003eCyclosporins:\u003c\/b\u003e increased risk of nephrotoxicity with NSAIDs. \u003cb\u003eCorticosteroids:\u003c\/b\u003e increased risk of gastrointestinal ulcer or bleeding with NSAIDs. \u003cb\u003eCox-2 inhibitors and other NSAIDs:\u003c\/b\u003e Concomitant use of other NSAIDs, including selective cyclooxygenase-2 inhibitors, should be avoided due to potential additive effects. \u003cb\u003eMifepristone\u003c\/b\u003e: NSAIDs should not be taken for 8-12 days after administration of mifepristone as NSAIDs may reduce the effects of mifepristone. \u003cb\u003eQuinolone Antibiotics: \u003c\/b\u003eResults from animal studies suggest that NSAIDs may increase the risk of seizures associated with the use of quinolone antibiotics. Patients taking NSAIDs and Quinolones may have an increased risk of developing seizures. \u003cb\u003eTacrolimus\u003c\/b\u003e: possible increased risk of nephrotoxicity in case of co-administration with NSAIDs. \u003cb\u003eZidovudine\u003c\/b\u003e: increased risk of blood toxicity in case of co-administration with NSAIDs. There is evidence of an increased risk of haemarthrosis and haematoma in haemophilia patients affected by HIV in simultaneous treatment with Zidovudine and other NSAIDs. The interactions reported above have been reported in particular after the administration of Flurbiprofen-based formulations for systemic use. At the recommended doses of FROBEN GOLA, no interactions with other medicinal products or of any other nature have been reported. However, inform your doctor if you are taking other medicines.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe following adverse reactions, reported in particular after the administration of formulations for systemic use, are reported according to the MedDRA classification. Frequency groupings are classified according to the following convention: very common (≥ 1\/10), Common (≥1\/100 to \u003c1\/10), Uncommon (≥1\/1000 to \u003c1\/100), Rare (≥ 1\/10,000 to \u003c1\/1000), Very rare (\u003c1\/10,000) and Not Known (frequency cannot be estimated).\u003c\/p\u003e\n\u003cp\u003eSystem organ class according to MedDRA | Frequency | Adverse Reaction\u003c\/p\u003e\n\u003cp\u003ePathologies of the blood and lymphatic system | Uncommon | Anemia\u003c\/p\u003e\n\u003cp\u003eVery rare | Leukopenia, agranulocytosis, aplastic anemia, neutropenia, thrombocytopenia, hemolytic anemia.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders | Uncommon | Hypersensitivity\u003c\/p\u003e\n\u003cp\u003eRare | Anaphylactic reaction\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders | Rare | Depression, confusional state\u003c\/p\u003e\n\u003cp\u003eVery rare | Hallucination\u003c\/p\u003e\n\u003cp\u003eNervous System Pathologies | Municipality | Migraine, dizziness\u003c\/p\u003e\n\u003cp\u003eUncommon | Paresthesia\u003c\/p\u003e\n\u003cp\u003eRare | Drowsiness, Insomnia\u003c\/p\u003e\n\u003cp\u003eNot known | Optic neuritis, cerebrovascular accident, headache.\u003c\/p\u003e\n\u003cp\u003eEye diseases | Uncommon | Vision disorders\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders | Uncommon | Tinnitus, vertigo\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders | Uncommon | Asthma, dyspnea\u003c\/p\u003e\n\u003cp\u003eRare | Bronchospasm\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders | Municipality | Dyspepsia, diarrhoea, nausea, vomiting, abdominal pain, flatulence, constipation, melena, haematemesis, gastrointestinal haemorrhage\u003c\/p\u003e\n\u003cp\u003eUncommon | Gastritis, duodenal ulcer, gastric ulcer, mouth ulcer, gastrointestinal perforation\u003c\/p\u003e\n\u003cp\u003eVery rare | Pancreatitis\u003c\/p\u003e\n\u003cp\u003eNot Known | Colitis and Crohn's disease\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders | Very rare | Jaundice, cholestatic jaundice, abnormal liver function\u003c\/p\u003e\n\u003cp\u003eNot known | Hepatitis\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders | Uncommon | Rash, urticaria, pruritus, purpura, angioedema, photosensitivity reactions\u003c\/p\u003e\n\u003cp\u003eVery rare | Severe forms of bullous skin reactions (e.g. Erythema Multiforme, Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis)\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders | Rare | Nephrotoxicity in various forms i.e. interstitial nephritis, nephrotic syndrome, renal failure and acute renal failure. (see paragraph 4.4)\u003c\/p\u003e\n\u003cp\u003eNot known | Glomerulonephritis\u003c\/p\u003e\n\u003cp\u003eSystemic disorders and conditions relating to the administration site | Municipality | Fatigue, malaise, edema\u003c\/p\u003e\n\u003cp\u003eCardiac disorders | Uncommon | Heart failure\u003c\/p\u003e\n\u003cp\u003eVascular pathologies | Uncommon | Hypertension\u003c\/p\u003e\n\u003cp\u003eDiagnostic tests | Municipality | Abnormal liver function test, prolonged bleeding time\u003c\/p\u003e\n\u003cp\u003eMetabolism and nutrition disorders | Municipality | Fluid retention\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eImmune system disorders\u003c\/b\u003e Hypersensitivity reactions have been reported following treatment with NSAIDs. These consist of: a) non-specific allergic reactions and anaphylaxis; b) reactions affecting the respiratory tract including asthma, even severe, bronchospasm or dyspnoea, or c) various skin disorders, such as various types of skin rashes, itching, urticaria, purpura, angioedema and, very rarely, exfoliative and bullous dermatitis (including Toxic Epidermal Necrolysis and erythema multiforme). \u003cb\u003eCardiac and vascular pathologies\u003c\/b\u003e Cases of edema, hypertension and heart failure have been reported in association with treatment with NSAIDs. Clinical studies and epidemiological data suggest that the intake of some NSAIDs (especially if at high doses and in case of long-term treatment) may be associated with an increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4).\u003cb\u003eNervous System Pathologies \u003c\/b\u003e Aseptic meningitis (especially in patients with existing autoimmune disorders such as Systemic Lupus Erythematosus and connective tissue disorders) with symptoms such as stiff neck, headache, nausea, vomiting, fever or disorientation (see section 4.4). \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetti-reazione-avversa.\u003c\/p\u003e","brand":"Viatris Healthcare","offers":[{"title":"Default Title","offer_id":40207824158835,"sku":"042822027","price":12.28,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/mylan-italia-srl-froben-gola-spray-mucosa-orale-15-ml-flurbiprofene-0-25-farmacia-dottor-tili-1213792740.jpg?v=1767126746"},{"product_id":"benactiv-gola-arancia-16-pastiglie","title":"Benactiv Throat Orange 16 Lozenges","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e Symptomatic treatment of irritative-inflammatory states also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy. \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e Symptomatic treatment of irritative-inflammatory conditions also associated with oropharyngeal pain (e.g. gingivitis, stomatitis, pharyngitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not use the medicine in children under 12 years of age. Flurbiprofen is contraindicated in patients with known hypersensitivity to flurbiprofen or to any of the excipients listed in section 6.1. Patients who have previously shown hypersensitivity reactions (e.g. asthma, urticaria, allergy, rhinitis, angioedema, bronchospasm) towards ibuprofen, acetylsalicylic acid (aspirin) or other non-steroidal anti-inflammatory drugs (NSAIDs). Flurbiprofen is also contraindicated in patients with a history of gastrointestinal bleeding or perforation related to previous NSAID treatment. Flurbiprofen should not be taken by patients with active or anamnestic ulcerative colitis, Crohn's disease, recurrent peptic ulcer or gastrointestinal haemorrhage (defined as two or more distinct episodes of demonstrated ulceration or bleeding). Flurbiprofen is contraindicated in patients with severe heart failure, severe hepatic failure and renal failure (see section 4.4). Third trimester of pregnancy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAt the recommended doses, when using the medicine in its various pharmaceutical forms, any swallowing does not cause any harm to the patient, as the dose of flurbiprofen is significantly lower than that commonly used in systemic treatments. Elderly: Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal haemorrhage and perforation, which may be fatal. \u003ci\u003eRespiratory disorders \u003c\/i\u003e Cases of bronchospasm have been reported with flurbiprofen in patients with a history of bronchial asthma or allergies. Flurbiprofen should be used with caution in these patients. \u003ci\u003eOther NSAIDs \u003c\/i\u003e It is advisable not to combine the medicine with other NSAIDs (see section 4.5). \u003ci\u003eSystemic lupus erythematosus (SLE) and mixed connective tissue disease \u003c\/i\u003e Patients with systemic lupus erythematosus and mixed connective tissue disease may have an increased risk of aseptic meningitis (see section 4.8), however this effect is not usually seen with products intended for limited and short-term use such as flurbiprofen. \u003ci\u003eCardiac, hepatic and renal impairment \u003c\/i\u003e The medicine should be used with caution in patients with cardiac, renal or hepatic insufficiency. NSAIDs have been reported to cause various forms of nephrotoxicity, including interstitial nephritis, nephrotic syndrome, and renal failure. The administration of an NSAID can cause a dose-dependent reduction in the formation of prostaglandins and precipitate renal failure. Patients at highest risk of developing this reaction are those with impaired renal function, cardiac impairment, liver dysfunction, those on diuretic therapy and the elderly; however, this effect is not usually observed with products intended for limited and short-term use such as flurbiprofen. \u003ci\u003eCardiovascular and cerebrovascular effects \u003c\/i\u003e Before starting treatment in patients with a positive history of hypertension and\/or heart failure, caution is required (discuss with your doctor or pharmacist), since fluid retention, hypertension and edema have been reported in association with treatment with NSAIDs. Clinical studies and epidemiological data suggest that the use of some NSAIDs, especially at high doses and for long-term treatments, may be associated with a modest increase in the risk of arterial thrombotic events such as myocardial infarction or stroke. There are insufficient data to exclude a similar risk for flurbiprofen. Patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should be treated with flurbiprofen only after careful consideration. Similar considerations must be made before starting long-term treatment in patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidemia, diabetes mellitus, smoking). \u003ci\u003eEffects on the central nervous system \u003c\/i\u003e Analgesic-induced headache. In case of prolonged or irregular use of analgesics, headache may occur, which must not be treated by increasing the dose of the medicine. \u003ci\u003eGastrointestinal effects\u003c\/i\u003e Flurbiprofen should be administered with caution to patients with a history of peptic ulcers and other gastrointestinal diseases as these conditions may be exacerbated. The risk of gastrointestinal haemorrhage, ulcer or perforation is higher with increasing dosage of flurbiprofen in patients with a history of ulcer, particularly if complicated by haemorrhage and perforation, and in the elderly. These patients should start treatment with the lowest available dose. Gastrointestinal bleeding, ulcer or perforation have been reported with all NSAIDs at any time during treatment. These adverse reactions can be fatal and can occur with or without warning symptoms or in case of a previous history of serious gastrointestinal reactions. Patients with a history of gastrointestinal disease, especially if elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) in the initial stages of treatment. Undesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.2). Caution should be advised in patients receiving concomitant medicinal products that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking flurbiprofen, treatment should be discontinued. \u003ci\u003eDermatological effects\u003c\/i\u003e The use of the medicine, especially if prolonged, can give rise to sensitization or local irritation phenomena. In such cases it is necessary to interrupt treatment and consult a doctor to institute, if necessary, suitable therapy. Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). Flurbiprofen should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. \u003ci\u003eInfections\u003c\/i\u003e Since isolated cases of exacerbation of inflammation related to infections (e.g. development of necrotizing fasciitis) have been described in temporal association with the systemic use of drugs belonging to the NSAID class, patients are recommended to immediately consult a doctor in case of appearance or worsening of signs of a bacterial infection during flurbiprofen-based therapy. A possible indication for starting antibiotic therapy must be taken into consideration. If mouth irritation develops, treatment should be discontinued. BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain para-hydroxybenzoates which can cause allergic reactions (even delayed). BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain hydrogenated 40-polyoxyethylene castor oil which may cause localized skin reactions. BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain an aroma which in turn contains d-limonene. D-limonene can cause allergic reactions. BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain less than 1 mmol (23mg) sodium per 10 ml dose, i.e. essentially \"sodium-free\". BENACTIV GOLA Lemon and Honey flavored lozenges contain liquid glucose, liquid sucrose and honey (invert sugar). Patients suffering from rare problems of fructose intolerance, glucose-galactose malabsorption or sucrase isomaltase insufficiency should not take this medicine. To be taken into consideration in people with diabetes mellitus: this medicine contains 1.07 g of glucose and 1.41 g of sucrose per tablet. BENACTIV GOLA Lemon and Honey flavored lozenges contain sulphites. Rarely it can cause serious hypersensitivity reactions and bronchospasm. BENACTIV GOLA Lemon and Honey flavored lozenges contain only a very small amount of gluten (from wheat starch). This medicine is considered “gluten-free” and is very unlikely to cause problems for a celiac patient. One tablet contains no more than 21.38 micrograms of gluten. If a patient is allergic to wheat (condition other than celiac disease) he or she should not take this medicine. BENACTIV THROAT Lemon and Honey flavored lozenges contain an aroma which in turn contains citral, citronellol, d-limonene, farfalle, geraniol and linalool. Citral, citronellol, d-limonene, farfalle, geraniol and linalool can cause allergic reactions. BENACTIV THROAT Lemon and Honey flavored lozenges contain an aroma which in turn contains butylated hydroxyanisole which can cause localized skin reactions (e.g. contact dermatitis) or irritation to the eyes and mucous membranes. BENACTIV GOLA Sugar-Free Lozenges Orange flavor is instead indicated for those patients who need to control their intake of sugars and calories. BENACTIV GOLA Orange flavored sugar-free lozenges contain an aroma which in turn contains citral, citronellol, d-limonene, geraniol and linalool. Citral, citronellol, d-limonene, geraniol and linalool can cause allergic reactions. BENACTIV GOLA Orange flavored sugar-free lozenges contain liquid maltitol and isomalt. Patients with rare hereditary problems of fructose intolerance should not take this medicine. May have a mild laxative effect. The caloric value of maltitol and isomalt is 2.3 kcal\/g. Do not use for prolonged treatments beyond 7 days. If you do not notice appreciable results after 3 days of treatment, the cause could be a different pathological condition. In these cases it is advisable to consult your doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCaution should be exercised in patients treated with any of the medicines listed below, as interactions have been reported in some patients. However, inform your doctor if you are taking other medicines. Flurbiprofen should be avoided in association with: - Aspirin: unless the intake of low-dose aspirin (not exceeding 100 mg\/day or local prophylactic doses for cardiovascular protection) has been recommended by the doctor; As with other NSAID-containing medicinal products, concomitant administration of flurbiprofen and aspirin is generally not recommended due to the potential for increased side effects (see section 4.4). - Cox-2 inhibitors and other NSAIDs: concomitant use of other NSAIDs, including selective cyclooxygenase-2 inhibitors, should be avoided due to potential additive effects and an increased risk of adverse reactions (see section 4.4). Flurbiprofen should be used with caution in association with: - Anticoagulants: NSAIDs can potentiate the effects of anticoagulants such as warfarin (see section 4.4) - Antiaggregating agents: increased risk of gastrointestinal bleeding - Selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding - Antihypertensives (diuretics, ACE inhibitors and angiotensin II antagonists): i NSAIDs can reduce the effect of diuretics. Other antihypertensive drugs may potentiate nephrotoxicity caused by inhibition of cyclooxygenase, especially in patients with impaired renal function (these patients must be adequately hydrated) - Alcohol: may increase the risk of adverse reactions, especially bleeding in the gastrointestinal tract - Cardiac glycosides: NSAIDs may exacerbate heart failure, reduce GFR (glomerular filtration rate) and increase plasma levels of glycosides - Cyclosporine: increased risk of nephrotoxicity - Corticosteroids: increased risk of gastrointestinal ulcer or haemorrhage with NSAIDs (see section 4.4) - Lithium: there is evidence for a possible increase in plasma lithium levels - Methotrexate: there may be an increase in plasma levels of methotrexate - Mifepristone: NSAIDs should not be used for 8-12 days after administration of mifepristone, as NSAIDs may reduce the effect of mifepristone - Quinolone antibiotics: data obtained in animals indicate that NSAIDs may increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing seizures - Tacrolimus: possible increased risk of nephrotoxicity when NSAIDs are administered together with tacrolimus - Zidovudine: increased risk of haematological toxicity when NSAIDs are administered with zidovudine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity reactions to NSAIDs have been reported and these may consist of: (a) non-specific allergic reactions and anaphylaxis (b) respiratory tract reactivity, e.g. asthma, aggravated asthma, bronchospasm, dyspnoea (c) various skin disorders, including for example skin rashes of different types, pruritus, urticaria, purpura, angioedema and, more rarely, exfoliative and bullous dermatosis (including necrolysis epidermal and erythema multiforme). The most commonly observed adverse reactions are gastrointestinal in nature. Local use of the medicine, especially if prolonged, can give rise to local sensitization or irritation phenomena. The dissolution of the medicine in tablet form in the oral cavity may be accompanied by sensations of heat or tingling in the oropharynx. In such cases it is necessary to interrupt treatment and institute, if necessary, suitable therapy. The following side effects have been reported, particularly after the administration of formulations for systemic use. They refer to those detected with the use of flurbiprofen used short term and at doses compatible with the classification of self-medication medicines. When treating chronic conditions and for long periods of time, additional side effects may occur. The side effects associated with the use of flurbiprofen are divided below based on system organ classification and frequency. Frequency is defined as: very common (≥ 1\/10), common (≥1\/100, \u003c1\/10), uncommon (≥1\/1,000, \u003c1\/100), rare (≥1\/10,000, \u003c1\/1,000), very rare (\u003c1\/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eClassification by systems and organs\u003c\/b\u003e | \u003cb\u003eFrequency\u003c\/b\u003e | \u003cb\u003eAdverse reactions\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003ePathologies of the blood and lymphatic system | Not known | Anemia, thrombocytopenia, aplastic anemia and agranulocytosis\u003c\/p\u003e\n\u003cp\u003ePathologies of the nervous system | Municipality | Dizziness, headache, paraesthesia\u003c\/p\u003e\n\u003cp\u003eUncommon | Drowsiness\u003c\/p\u003e\n\u003cp\u003eNot known | Cerebrovascular accident, optic neuritis, migraine, confusional states, dizziness\u003c\/p\u003e\n\u003cp\u003eDisorders of the immune system | Rare | Anaphylactic reaction\u003c\/p\u003e\n\u003cp\u003eNot known | Angioedema, hypersensitivity\u003c\/p\u003e\n\u003cp\u003eEye diseases | Not known | Vision impairment\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders | Not known | Tinnitus\u003c\/p\u003e\n\u003cp\u003eCardiac disorders | Not known | Heart failure, edema\u003c\/p\u003e\n\u003cp\u003eVascular pathologies | Not known | Hypertension\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders | Municipality | Throat irritation\u003c\/p\u003e\n\u003cp\u003eUncommon | Asthma, bronchospasm and dyspnea, oropharyngeal vesicular rash, oropharyngeal hypoesthesia\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders | Municipality | Diarrhoea, mouth ulceration, nausea, oral pain, oral paraesthesia, oropharyngeal pain, oral discomfort (hot or burning sensation, tingling in the mouth)\u003c\/p\u003e\n\u003cp\u003eUncommon | Abdominal distension, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, glossodynia, dysgeusia, oral dysesthesia, vomiting\u003c\/p\u003e\n\u003cp\u003eNot known | Melena, haematemesis, gastrointestinal haemorrhage, colitis, exacerbation of Crohn's disease, gastritis, peptic ulcer, gastric perforation, ulcer haemorrhage\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders | Uncommon | Skin rash, itching\u003c\/p\u003e\n\u003cp\u003eNot known | Urticaria, purpura, bullous dermatitis (including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme)\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders | Not known | Toxic nephropathy, tubulointerstitial nephritis and nephrotic syndrome, renal failure (as with other NSAIDs)\u003c\/p\u003e\n\u003cp\u003eSystemic disorders and conditions relating to the administration site | Uncommon | Pyrexia, pain\u003c\/p\u003e\n\u003cp\u003eNot known | Discomfort, tiredness\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders | Not known | Hepatitis\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders | Uncommon | Insomnia\u003c\/p\u003e\n\u003cp\u003eNot known | Depression, hallucination\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":40207824552051,"sku":"033262078","price":13.49,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/reckitt-benckiser-h-it-spa-benactiv-gola-arancia-16-pastiglie-farmacia-dottor-tili-1213792732.webp?v=1767126886"},{"product_id":"alovex-protezione-attiva-spray-15-ml","title":"Alovex Active Protection Spray 15 ml ","description":"\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy use Alovex Active Protection Spray 15 ml? What is it for?\u003c\/h3\u003e\u003cp\u003eAlovex Active Protection Spray 15 ml form a \u003cstrong\u003eprotective film\u003c\/strong\u003e that \u003cstrong\u003eisolates the lesions\u003c\/strong\u003e of the mouth e \u003cstrong\u003ereduces pain and risk of further irritation\u003c\/strong\u003e. The combination of high molecular weight hyaluronic acid and Aloe vera promotes \u003cstrong\u003enatural wound healing. \u003c\/strong\u003e \u003cbr\u003eAlovex Active Protection Spray 15 ml is indicated in case of \u003cstrong\u003ecanker sores, aphthous stomatitis, widespread canker sores, small lesions\u003c\/strong\u003e traumatic injuries to the mouth (such as those due to contact with orthodontic appliances, fixed and removable prostheses) e \u003cstrong\u003einjuries of surgical origin\u003c\/strong\u003e.\u003cbr\u003eAlovex Active Protection Spray 15 ml does not cause burning, does not contain alcohol and is \u003cstrong\u003esuitable for adults and children of all ages\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Alovex Active Protection Spray 15 ml contain?\u003c\/h3\u003e\u003cp\u003eWater, polyvinylpyrrolidone, maltodextrin, propylene glycol, aloe vera, potassium sorbate, sodium benzoate, ethoxylated hydrogenated castor oil 40 OE, EDTA sodium salt, benzalkonium chloride, hyaluronic acid (sodium salt) *, flavouring, sodium saccharin, dipotassium glycyrrhizate.\u003c\/p\u003e\u003cp\u003e*hyaluronic acid (sodium salt) with high molecular weight.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Alovex Active Protection Spray 15 ml?\u003c\/h3\u003e\u003cp\u003eBefore using the product for the first time, remove the protective cap and apply the director.\u003cbr\u003eDirect the sprayer towards the lesion inside the mouth and spray 3 times or more, as needed, to create the protective film.\u003cbr\u003eThanks to the director, the product can also reach lesions located in the back part of the mouth, as in the case of humidity positioned in the back part of the tongue.\u003cbr\u003eApply the product 3-4 times a day or more as needed.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Alovex Active Protection Spray 15 ml?\u003c\/h3\u003e\u003cp\u003eIf the problem persists, consult your doctor. The product is harmless even in case of voluntary ingestion. Do not use if the packaging is not intact and\/or open. Keep out of reach of children. Avoid contact with eyes.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003eWhen should Alovex Active Protection Spray 15 ml not be used and what side effects can it cause?\u003c\/h3\u003e\u003cp\u003eThe use of the product is contraindicated in patients with a known hypersensitivity to any of the components.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Alovex Active Protection Spray 15 ml stored?\u003c\/h3\u003e\u003cp\u003eValidity with intact packaging: 24 months.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Alovex Active Protection Spray 15 ml?\u003c\/h3\u003e\u003cp\u003e15 ml bottle with director.\u003c\/p\u003e","brand":"Recordati","offers":[{"title":"Default Title","offer_id":40207841984627,"sku":"930625506","price":13.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/recordati-alovex-protezione-attiva-spray-15-ml-farmacia-dottor-tili-1254203897.jpg?v=1786721561"},{"product_id":"benactiv-gola-miele-limone-16-pastiglie","title":"Benactiv Throat Honey Lemon 16 Lozenges","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e Symptomatic treatment of irritative-inflammatory states also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy. \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e Symptomatic treatment of irritative-inflammatory conditions also associated with oropharyngeal pain (e.g. gingivitis, stomatitis, pharyngitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not use the medicine in children under 12 years of age. Flurbiprofen is contraindicated in patients with known hypersensitivity to flurbiprofen or to any of the excipients listed in section 6.1. Patients who have previously shown hypersensitivity reactions (e.g. asthma, urticaria, allergy, rhinitis, angioedema, bronchospasm) towards ibuprofen, acetylsalicylic acid (aspirin) or other non-steroidal anti-inflammatory drugs (NSAIDs). Flurbiprofen is also contraindicated in patients with a history of gastrointestinal bleeding or perforation related to previous NSAID treatment. Flurbiprofen should not be taken by patients with active or anamnestic ulcerative colitis, Crohn's disease, recurrent peptic ulcer or gastrointestinal haemorrhage (defined as two or more distinct episodes of demonstrated ulceration or bleeding). Flurbiprofen is contraindicated in patients with severe heart failure, severe hepatic failure and renal failure (see section 4.4). Third trimester of pregnancy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAt the recommended doses, when using the medicine in its various pharmaceutical forms, any swallowing does not cause any harm to the patient, as the dose of flurbiprofen is significantly lower than that commonly used in systemic treatments. Elderly: Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal haemorrhage and perforation, which may be fatal. \u003ci\u003eRespiratory disorders \u003c\/i\u003e Cases of bronchospasm have been reported with flurbiprofen in patients with a history of bronchial asthma or allergies. Flurbiprofen should be used with caution in these patients. \u003ci\u003eOther NSAIDs \u003c\/i\u003e It is advisable not to combine the medicine with other NSAIDs (see section 4.5). \u003ci\u003eSystemic lupus erythematosus (SLE) and mixed connective tissue disease \u003c\/i\u003e Patients with systemic lupus erythematosus and mixed connective tissue disease may have an increased risk of aseptic meningitis (see section 4.8), however this effect is not usually seen with products intended for limited and short-term use such as flurbiprofen. \u003ci\u003eCardiac, hepatic and renal impairment \u003c\/i\u003e The medicine should be used with caution in patients with cardiac, renal or hepatic insufficiency. NSAIDs have been reported to cause various forms of nephrotoxicity, including interstitial nephritis, nephrotic syndrome, and renal failure. The administration of an NSAID can cause a dose-dependent reduction in the formation of prostaglandins and precipitate renal failure. Patients at highest risk of developing this reaction are those with impaired renal function, cardiac impairment, liver dysfunction, those on diuretic therapy and the elderly; however, this effect is not usually observed with products intended for limited and short-term use such as flurbiprofen. \u003ci\u003eCardiovascular and cerebrovascular effects \u003c\/i\u003e Before starting treatment in patients with a positive history of hypertension and\/or heart failure, caution is required (discuss with your doctor or pharmacist), since fluid retention, hypertension and edema have been reported in association with treatment with NSAIDs. Clinical studies and epidemiological data suggest that the use of some NSAIDs, especially at high doses and for long-term treatments, may be associated with a modest increase in the risk of arterial thrombotic events such as myocardial infarction or stroke. There are insufficient data to exclude a similar risk for flurbiprofen. Patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should be treated with flurbiprofen only after careful consideration. Similar considerations must be made before starting long-term treatment in patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidemia, diabetes mellitus, smoking). \u003ci\u003eEffects on the central nervous system \u003c\/i\u003e Analgesic-induced headache. In case of prolonged or irregular use of analgesics, headache may occur, which must not be treated by increasing the dose of the medicine. \u003ci\u003eGastrointestinal effects\u003c\/i\u003e Flurbiprofen should be administered with caution to patients with a history of peptic ulcers and other gastrointestinal diseases as these conditions may be exacerbated. The risk of gastrointestinal haemorrhage, ulcer or perforation is higher with increasing dosage of flurbiprofen in patients with a history of ulcer, particularly if complicated by haemorrhage and perforation, and in the elderly. These patients should start treatment with the lowest available dose. Gastrointestinal bleeding, ulcer or perforation have been reported with all NSAIDs at any time during treatment. These adverse reactions can be fatal and can occur with or without warning symptoms or in case of a previous history of serious gastrointestinal reactions. Patients with a history of gastrointestinal disease, especially if elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) in the initial stages of treatment. Undesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.2). Caution should be advised in patients receiving concomitant medicinal products that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking flurbiprofen, treatment should be discontinued. \u003ci\u003eDermatological effects\u003c\/i\u003e The use of the medicine, especially if prolonged, can give rise to sensitization or local irritation phenomena. In such cases it is necessary to interrupt treatment and consult a doctor to institute, if necessary, suitable therapy. Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). Flurbiprofen should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. \u003ci\u003eInfections\u003c\/i\u003e Since isolated cases of exacerbation of inflammation related to infections (e.g. development of necrotizing fasciitis) have been described in temporal association with the systemic use of drugs belonging to the NSAID class, patients are recommended to immediately consult a doctor in case of appearance or worsening of signs of a bacterial infection during flurbiprofen-based therapy. A possible indication for starting antibiotic therapy must be taken into consideration. If mouth irritation develops, treatment should be discontinued. BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain para-hydroxybenzoates which can cause allergic reactions (even delayed). BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain hydrogenated 40-polyoxyethylene castor oil which may cause localized skin reactions. BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain an aroma which in turn contains d-limonene. D-limonene can cause allergic reactions. BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain less than 1 mmol (23mg) sodium per 10 ml dose, i.e. essentially \"sodium-free\". BENACTIV GOLA Lemon and Honey flavored lozenges contain liquid glucose, liquid sucrose and honey (invert sugar). Patients suffering from rare problems of fructose intolerance, glucose-galactose malabsorption or sucrase isomaltase insufficiency should not take this medicine. To be taken into consideration in people with diabetes mellitus: this medicine contains 1.07 g of glucose and 1.41 g of sucrose per tablet. BENACTIV GOLA Lemon and Honey flavored lozenges contain sulphites. Rarely it can cause serious hypersensitivity reactions and bronchospasm. BENACTIV GOLA Lemon and Honey flavored lozenges contain only a very small amount of gluten (from wheat starch). This medicine is considered “gluten-free” and is very unlikely to cause problems for a celiac patient. One tablet contains no more than 21.38 micrograms of gluten. If a patient is allergic to wheat (condition other than celiac disease) he or she should not take this medicine. BENACTIV THROAT Lemon and Honey flavored lozenges contain an aroma which in turn contains citral, citronellol, d-limonene, farfalle, geraniol and linalool. Citral, citronellol, d-limonene, farinasol, geraniol and linalool can cause allergic reactions. BENACTIV THROAT Lemon and Honey flavored lozenges contain an aroma which in turn contains butylated hydroxyanisole which can cause localized skin reactions (e.g. contact dermatitis) or irritation to the eyes and mucous membranes. BENACTIV GOLA Sugar-Free Lozenges Orange flavor is instead indicated for those patients who need to control their intake of sugars and calories. BENACTIV GOLA Orange flavored sugar-free lozenges contain an aroma which in turn contains citral, citronellol, d-limonene, geraniol and linalool. Citral, citronellol, d-limonene, geraniol and linalool can cause allergic reactions. BENACTIV GOLA Orange flavored sugar-free lozenges contain liquid maltitol and isomalt. Patients with rare hereditary problems of fructose intolerance should not take this medicine. May have a mild laxative effect. The caloric value of maltitol and isomalt is 2.3 kcal\/g. Do not use for prolonged treatments beyond 7 days. If you do not notice appreciable results after 3 days of treatment, the cause could be a different pathological condition. In these cases it is advisable to consult your doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCaution should be exercised in patients treated with any of the medicines listed below, as interactions have been reported in some patients. However, inform your doctor if you are taking other medicines. Flurbiprofen should be avoided in association with: - Aspirin: unless the intake of low-dose aspirin (not exceeding 100 mg\/day or local prophylactic doses for cardiovascular protection) has been recommended by the doctor; As with other NSAID-containing medicinal products, concomitant administration of flurbiprofen and aspirin is generally not recommended due to the potential for increased side effects (see section 4.4). - Cox-2 inhibitors and other NSAIDs: concomitant use of other NSAIDs, including selective cyclooxygenase-2 inhibitors, should be avoided due to potential additive effects and an increased risk of adverse reactions (see section 4.4). Flurbiprofen should be used with caution in association with: - Anticoagulants: NSAIDs can potentiate the effects of anticoagulants such as warfarin (see section 4.4) - Antiaggregating agents: increased risk of gastrointestinal bleeding - Selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding - Antihypertensives (diuretics, ACE inhibitors and angiotensin II antagonists): i NSAIDs can reduce the effect of diuretics. Other antihypertensive drugs may potentiate nephrotoxicity caused by inhibition of cyclooxygenase, especially in patients with impaired renal function (these patients must be adequately hydrated) - Alcohol: may increase the risk of adverse reactions, especially bleeding in the gastrointestinal tract - Cardiac glycosides: NSAIDs may exacerbate heart failure, reduce GFR (glomerular filtration rate) and increase plasma levels of glycosides - Cyclosporine: increased risk of nephrotoxicity - Corticosteroids: increased risk of gastrointestinal ulcer or haemorrhage with NSAIDs (see section 4.4) - Lithium: there is evidence for a possible increase in plasma lithium levels - Methotrexate: there may be an increase in plasma levels of methotrexate - Mifepristone: NSAIDs should not be used for 8-12 days after administration of mifepristone, as NSAIDs may reduce the effect of mifepristone - Quinolone antibiotics: data obtained in animals indicate that NSAIDs may increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing seizures - Tacrolimus: possible increased risk of nephrotoxicity when NSAIDs are administered together with tacrolimus - Zidovudine: increased risk of haematological toxicity when NSAIDs are administered with zidovudine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity reactions to NSAIDs have been reported and these may consist of: (a) non-specific allergic reactions and anaphylaxis (b) respiratory tract reactivity, e.g. asthma, aggravated asthma, bronchospasm, dyspnoea (c) various skin disorders, including for example skin rashes of different types, pruritus, urticaria, purpura, angioedema and, more rarely, exfoliative and bullous dermatosis (including necrolysis epidermal and erythema multiforme). The most commonly observed adverse reactions are gastrointestinal in nature. Local use of the medicine, especially if prolonged, can give rise to local sensitization or irritation phenomena. The dissolution of the medicine in tablet form in the oral cavity may be accompanied by sensations of heat or tingling in the oropharynx. In such cases it is necessary to interrupt treatment and institute, if necessary, suitable therapy. The following side effects have been reported, particularly after the administration of formulations for systemic use. They refer to those detected with the use of flurbiprofen used short term and at doses compatible with the classification of self-medication medicines. When treating chronic conditions and for long periods of time, additional side effects may occur. The side effects associated with the use of flurbiprofen are divided below based on system organ classification and frequency. Frequency is defined as: very common (≥ 1\/10), common (≥1\/100, \u003c1\/10), uncommon (≥1\/1,000, \u003c1\/100), rare (≥1\/10,000, \u003c1\/1,000), very rare (\u003c1\/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eClassification by systems and organs\u003c\/b\u003e | \u003cb\u003eFrequency\u003c\/b\u003e | \u003cb\u003eAdverse reactions\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003ePathologies of the blood and lymphatic system | Not known | Anemia, thrombocytopenia, aplastic anemia and agranulocytosis\u003c\/p\u003e\n\u003cp\u003ePathologies of the nervous system | Municipality | Dizziness, headache, paraesthesia\u003c\/p\u003e\n\u003cp\u003eUncommon | Drowsiness\u003c\/p\u003e\n\u003cp\u003eNot known | Cerebrovascular accident, optic neuritis, migraine, confusional states, dizziness\u003c\/p\u003e\n\u003cp\u003eDisorders of the immune system | Rare | Anaphylactic reaction\u003c\/p\u003e\n\u003cp\u003eNot known | Angioedema, hypersensitivity\u003c\/p\u003e\n\u003cp\u003eEye diseases | Not known | Vision impairment\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders | Not known | Tinnitus\u003c\/p\u003e\n\u003cp\u003eCardiac disorders | Not known | Heart failure, edema\u003c\/p\u003e\n\u003cp\u003eVascular pathologies | Not known | Hypertension\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders | Municipality | Throat irritation\u003c\/p\u003e\n\u003cp\u003eUncommon | Asthma, bronchospasm and dyspnea, oropharyngeal vesicular rash, oropharyngeal hypoesthesia\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders | Municipality | Diarrhoea, mouth ulceration, nausea, oral pain, oral paraesthesia, oropharyngeal pain, oral discomfort (hot or burning sensation, tingling in the mouth)\u003c\/p\u003e\n\u003cp\u003eUncommon | Abdominal distension, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, glossodynia, dysgeusia, oral dysesthesia, vomiting\u003c\/p\u003e\n\u003cp\u003eNot known | Melena, haematemesis, gastrointestinal haemorrhage, colitis, exacerbation of Crohn's disease, gastritis, peptic ulcer, gastric perforation, ulcer haemorrhage\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders | Uncommon | Skin rash, itching\u003c\/p\u003e\n\u003cp\u003eNot known | Urticaria, purpura, bullous dermatitis (including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme)\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders | Not known | Toxic nephropathy, tubulointerstitial nephritis and nephrotic syndrome, renal failure (as with other NSAIDs)\u003c\/p\u003e\n\u003cp\u003eSystemic disorders and conditions relating to the administration site | Uncommon | Pyrexia, pain\u003c\/p\u003e\n\u003cp\u003eNot known | Discomfort, tiredness\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders | Not known | Hepatitis\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders | Uncommon | Insomnia\u003c\/p\u003e\n\u003cp\u003eNot known | Depression, hallucination\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":40720891445363,"sku":"033262027","price":13.49,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/reckitt-benckiser-h-it-spa-benactiv-gola-miele-limone-16-pastiglie-farmacia-dottor-tili-1213792527.webp?v=1767131032"},{"product_id":"oki-infiammazione-e-dolore-gola-spray-15ml","title":"Oki Inflammation and Pain Throat Spray 15ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSymptomatic treatment of irritative-inflammatory conditions also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOKi throat 0.16% spray for oral mucosa must not be administered in case of hypersensitivity to the active ingredient, to other non-steroidal anti-inflammatory drugs (NSAIDs) or to any of the excipients, to patients in whom substances with a similar mechanism of action (for example acetylsalicylic acid or other NSAIDs) cause asthma attacks, bronchospasm, acute rhinitis, or cause nasal polyps, urticaria or angioneurotic edema, in case of previous bronchial asthma, during pregnancy and breastfeeding.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use, especially if prolonged, of topical drugs could give rise to sensitization phenomena, in which case it is necessary to suspend the treatment and adopt suitable therapeutic measures. This medicine contains methyl parahydroxybenzoate, known to cause allergic reactions (including delayed reactions). This medicine contains mint flavouring, which in turn contains d-limonene, eugenol and linalool which may cause allergic reactions. This medicine contains the ever cool flavour, which itself contains linalool which may cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAt present there are no known interactions with other drugs: interactions which can also be excluded by considering the route of administration and the dosage of drug administered.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal side effects following topical administration on the oral mucosa of ketoprofen lysine salt solution are extremely rare and consist of irritative or allergic phenomena (angioneurotic edema), especially in subjects with hypersensitivity to NSAIDs. However, no systemic side effects emerged considering the route of administration and the dosage of drug administered. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/p\u003e","brand":"Dompé","offers":[{"title":"Default Title","offer_id":40740171087987,"sku":"041797022","price":11.44,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/dompe-farmaceutici-spa-oki-infiammazione-e-dolore-gola-spray-15ml-farmacia-dottor-tili-1213792514.webp?v=1767131207"},{"product_id":"aspi-mal-di-gola-spray-antidolorifico-15-ml-0-25","title":"Aspi Sore Throat Painkiller Spray 15 ml 0.25%","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eASPI THROAT Mouthwash\u003c\/b\u003e \u003cb\u003eASPI THROAT Spray for oral mucosa\u003c\/b\u003e Symptomatic treatment of irritative-inflammatory states also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFlurbiprofen is contraindicated in patients with known hypersensitivity (asthma, bronchospasm, urticaria or allergic type) towards flurbiprofen or to any of the excipients listed in paragraph 6.1, and towards acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). Flurbiprofen is also contraindicated in patients with a history of gastrointestinal bleeding or perforation related to previous NSAID treatment. Flurbiprofen should not be taken by patients with active or anamnestic ulcerative colitis, Crohn's disease, recurrent peptic ulcer or gastrointestinal bleeding (defined as two or more distinct episodes of demonstrated ulceration or bleeding). Flurbiprofen is contraindicated in patients with severe heart failure. Third trimester of pregnancy\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAt the recommended doses, when using the product in its various pharmaceutical forms, any swallowing does not cause any harm to the patient, as the dose of flurbiprofen is widely lower than that commonly used in systemic treatments. Use of the product, especially if prolonged, can give rise to sensitization or local irritation phenomena; in such cases it is necessary to interrupt the treatment and consult the doctor to institute, if necessary, a suitable therapy. In patients with renal, cardiac or hepatic insufficiency the product should be used with caution. It is advisable not to combine the product with other NSAIDs. Cases of bronchospasm have been reported with flurbiprofen in patients with a history of bronchial asthma. \u003ci\u003e \u003cu\u003eGastrointestinal effects\u003c\/u\u003e \u003c\/i\u003e Flurbiprofen should be administered with caution to patients with a history of peptic ulcers and other gastrointestinal diseases as these conditions may be exacerbated. The risk of gastrointestinal haemorrhage, ulcer or perforation is higher with increasing dosage of flurbiprofen in patients with a history of ulcer, particularly if complicated by haemorrhage and perforation, and in the elderly. These patients should start treatment with the lowest available dose. Gastrointestinal bleeding, ulcer or perforation have been reported with all NSAIDs at any time during treatment. These adverse events can be fatal and can occur with or without warning symptoms or in case of a previous history of serious gastrointestinal events. Patients with a history of gastrointestinal disease, especially if elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) in the initial stages of treatment. Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal. Undesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.2). \u003cb\u003eImportant information about some excipients\u003c\/b\u003e ASPI GOLA mouthwash and ASPI GOLA Spray contain para-hydroxybenzoates which can cause delayed allergic reactions, such as contact dermatitis; more rarely they can cause immediate reactions, with urticaria and bronchospasm. The dye patent blue V (E131) may cause allergic reactions. Polyoxyethylene Hydrogenated Castor Oil-40 may cause localized skin reactions. Both the mouthwash and the spray contain a small amount of ethyl alcohol, less than 100 mg per dose. Do not use for prolonged treatments. After short periods of treatment without appreciable results, consult your doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCaution should be exercised in patients treated with any of the medicines listed below, as interactions have been reported in some patients. However, inform your doctor if you are taking other medicines. \u003cb\u003eAspirin\u003c\/b\u003e: As with other NSAID-containing medicines, concomitant administration of flurbiprofen and aspirin is generally not recommended due to the potential for increased side effects. \u003cb\u003eAntiplatelet agents\u003c\/b\u003e: increased risk of gastrointestinal bleeding. \u003cb\u003eSelective serotonin reuptake inhibitors (SSRIs)\u003c\/b\u003e: increased risk of gastrointestinal bleeding. \u003cb\u003eCorticosteroids\u003c\/b\u003e: increased risk of gastrointestinal ulcer or bleeding with NSAIDs. \u003cb\u003eCox-2 inhibitors and other NSAIDs\u003c\/b\u003e: Concomitant use of other NSAIDs, including selective cyclooxygenase-2 inhibitors, should be avoided due to potential additive effects.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe following side effects have been reported, particularly after the administration of formulations for systemic use:\u003cb\u003ePathologies of the blood and lymphatic system\u003c\/b\u003e Thrombocytopenia, aplastic anemia and agranulocytosis \u003cb\u003eImmune system disorders\u003c\/b\u003e Anaphylaxis, angioedema, allergic reaction. \u003cb\u003eNervous system disorders\u003c\/b\u003e Dizziness, cerebrovascular accident, visual disturbances, optic neuritis, migraine, paraesthesia, depression, confusion, hallucination, vertigo, discomfort, fatigue and drowsiness. \u003cb\u003eEar and labyrinth disorders\u003c\/b\u003e Tinnitus \u003cb\u003eRespiratory, thoracic and mediastinal disorders\u003c\/b\u003e Respiratory tract reactivity (asthma, bronchospasm and dyspnea) \u003cb\u003eGastrointestinal disorders\u003c\/b\u003e The most commonly observed adverse events are gastrointestinal in nature. The following have been reported after administration of flurbiprofen: nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melena, haematemesis, ulcerative stomatitis, gastrointestinal haemorrhage and exacerbation of colitis and Crohn's disease. Less frequently, gastritis, peptic ulcer, perforation and ulcer bleeding have been observed. \u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e Skin disorders including rash, pruritus, urticaria, purpura and very rarely bullous dermatoses (including Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis and Erythema multiforme). \u003cb\u003eRenal and urinary disorders\u003c\/b\u003e Nephrotoxicity in various forms, including interstitial nephritis and nephrotic syndrome. As with other NSAIDs, rare cases of renal failure have been reported. Topical use of the product, especially if prolonged, can give rise to sensitization or local irritation phenomena. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/it\/responsabili.\u003c\/p\u003e","brand":"Bayer","offers":[{"title":"Default Title","offer_id":46368895500615,"sku":"041513021","price":11.02,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/bayer-spa-aspi-mal-di-gola-spray-antidolorifico-15-ml-0-25-farmacia-dottor-tili-1213792509.webp?v=1767131327"},{"product_id":"aspi-gola-dolact-8-75mg-dose-spray-per-mucosa-orale-15ml","title":"Aspi Gola Dolact 8.75mg\/dose oral mucosa spray 15ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAspigoladolact is indicated for the short-term symptomatic treatment of acute pain in sore throat in adults.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. - Patients who have previously shown hypersensitivity reactions (e.g., asthma, bronchospasm, rhinitis, angioedema or urticaria) in response to acetylsalicylic acid or other NSAIDs. - Patients with current or previous recurrent peptic ulcers\/haemorrhages (two or more distinct episodes of demonstrated ulceration) and intestinal ulcer. - Patients with a history of gastrointestinal bleeding or perforation, severe colitis, bleeding or haematopoietic disorders related to previous therapy with NSAIDs. - Severe heart failure, renal failure or hepatic failure (see section 4.4). - Last trimester of pregnancy (see section 4.6). - Children and adolescents under 18 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects can be minimized by using the lowest effective dose for the shortest duration of treatment needed to control symptoms. \u003cu\u003eInfections\u003c\/u\u003e Since isolated cases of exacerbation of inflammation related to infections (e.g. development of necrotizing fasciitis) have been described in temporal association with the systemic use of drugs belonging to the NSAID class, patients are recommended to immediately consult a doctor in case of appearance or worsening of signs of a bacterial infection during therapy based on flurbiprofen spray. A possible indication for starting antibiotic therapy must be taken into consideration. In case of purulent bacterial pharyngitis\/tonsillitis, the patient should consult the doctor for a re-evaluation of the treatment. Treatment should not be administered for more than 3 days. \u003cu\u003eRespiratory disorders\u003c\/u\u003e Bronchospasm may be precipitated in patients with or with a history of bronchial asthma or allergic disease. Flurbiprofen spray should be used with caution in these patients. \u003cu\u003eOther NSAIDs\u003c\/u\u003e The use of flurbiprofen spray should be avoided concomitantly with other NSAIDs, including selective cyclooxygenase-2 inhibitors (see section 4.5). \u003cu\u003eSystemic lupus erythematosus (SLE) and mixed connective tissue disease\u003c\/u\u003e Patients with systemic lupus erythematosus (SLE) and mixed connective tissue disease may be at increased risk of aseptic meningitis (see section 4.8), however this effect is not usually seen with products intended for short-term use such as flurbiprofen spray. \u003cu\u003eCardiovascular, renal and hepatic impairment\u003c\/u\u003e NSAIDs have been reported to cause various forms of nephrotoxicity, including interstitial nephritis, nephrotic syndrome, and renal failure. The administration of an NSAID can cause a dose-dependent reduction in prostaglandin formation and precipitate renal failure. Patients at highest risk of developing this reaction are those with impaired renal function, cardiac impairment, liver dysfunction, those on diuretic therapy and the elderly; this effect is not usually observed with products intended for short-term use such as flurbiprofen spray. \u003cu\u003eHepatic effects\u003c\/u\u003e Mild to moderate hepatic dysfunction (see sections 4.3 and 4.8). \u003cu\u003eCardiovascular and cerebrovascular effects\u003c\/u\u003e Before starting treatment in patients with a positive history of hypertension and\/or heart failure, caution is required (discuss with your doctor or pharmacist) since fluid retention, hypertension and edema have been reported in association with treatment with NSAIDs. Data from clinical and epidemiological studies suggest that the use of some NSAIDs (particularly at high doses and in long-term treatments) may be associated with a slight increase in the risk of arterial thrombotic events (for example myocardial infarction or stroke). There are insufficient data to exclude this risk with flurbiprofen when administered at a daily dosage of less than 5 doses (3 actuations for each dose). \u003cu\u003eEffects on the central nervous system\u003c\/u\u003e Headache induced by analgesics - In case of prolonged or irregular use of analgesics, headache may occur, which must not be treated by increasing the dose of the medicine. \u003cu\u003eGastrointestinal disorders\u003c\/u\u003e NSAIDs should be administered with caution in patients with a history of gastrointestinal diseases (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). Gastrointestinal bleeding, ulceration or perforation, which may be fatal, have been reported with all NSAIDs at any time during treatment, in the presence or absence of warning symptoms or a history of serious gastrointestinal events. The risk of gastrointestinal bleeding, ulceration or perforation is higher with increasing doses of NSAIDs, in patients with a history of ulcer, especially if complicated with the presence of haemorrhage or perforation (see section 4.3) and in the elderly; this effect is not usually observed with products intended for short-term use such as flurbiprofen spray. Patients with a history of gastrointestinal toxicity, particularly the elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) to their healthcare provider. Caution should be advised in patients receiving concomitant medicinal products that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking flurbiprofen, treatment should be discontinued. \u003cu\u003eHematological effects\u003c\/u\u003e Flurbiprofen, like other NSAIDs, can inhibit platelet aggregation and prolong bleeding time. Flurbiprofen spray should be used with caution in patients with potential bleeding abnormalities. \u003cu\u003eDermatological effects\u003c\/u\u003e Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported very rarely in association with the use of NSAIDs (see section 4.8). Flurbiprofen spray should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. This medicinal product contains less than 1 mmol (23 mg) sodium per dose (3 sprays), i.e. essentially 'sodium-free'. This medicine contains 0.22mg ethanol per dose (3 sprays), which is equivalent to 0.044% (w\/v). The amount in the dose of this medicine is equivalent to less than 0.9 ml of beer or 0.4 ml of wine. Treatment should be reevaluated if symptoms worsen or new symptoms occur. If mouth irritation develops, treatment with flurbiprofen should be discontinued. \u003cu\u003eElderly population\u003c\/u\u003e Elderly people experience an increased frequency of adverse reactions to NSAIDs, especially bleeding and gastrointestinal perforation, which can be fatal.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eFlurbiprofen must \u003cu\u003ebe avoided\u003c\/u\u003e in association with:\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eOther NSAIDs including selective cyclooxygenase-2 inhibitors\u003c\/i\u003e | Avoid concomitant use of two or more NSAIDs, as this may increase the risk of adverse effects (especially gastrointestinal adverse events such as ulcers and bleeding) (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eAcetylsalicylic acid (at low doses)\u003c\/i\u003e | Unless taking low-dose aspirin (not exceeding 75 mg\/day) has been recommended by your doctor, as the potential risk of adverse events may increase (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e Flurbiprofen must be used with \u003cu\u003ecaution\u003c\/u\u003e in association with:\u003c\/b\u003e | \u003ci\u003eAnticoagulants\u003c\/i\u003e | NSAIDs may potentiate the effects of anticoagulants such as warfarin (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eAntiplatelet agents:\u003c\/i\u003e | There is an increased risk of gastrointestinal ulceration or bleeding (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eAntihypertensive drugs (Diuretics, ACE inhibitors, Angiotensin II antagonists)\u003c\/i\u003e | NSAIDs can reduce the effect of diuretics. Other antihypertensive drugs may potentiate nephrotoxicity caused by cyclooxygenase inhibition, especially in patients with impaired renal function.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eCardiac glycosides\u003c\/i\u003e | NSAIDs can exacerbate heart failure, reduce VGR (glomerular filtration rate) and increase plasma levels of glycosides, therefore adequate control and, if necessary, dose adjustment is recommended.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eCyclosporine\u003c\/i\u003e | There is an increased risk of nephrotoxicity.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eCorticosteroids\u003c\/i\u003e | There is an increased risk of gastrointestinal ulceration or bleeding (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eLithium\u003c\/i\u003e | There may be an increase in serum lithium levels - adequate monitoring and, if necessary, dose adjustment is recommended.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eMethotrexate\u003c\/i\u003e | The administration of NSAIDs within 24 hours before or after the administration of methotrexate can lead to high concentrations of methotrexate and an increase in its toxic effects.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eMifepristone\u003c\/i\u003e | NSAIDs should not be used for 8 - 12 days following administration of mifepristone, as they may reduce the effect of mifepristone.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eOral antidiabetics\u003c\/i\u003e | Alterations in blood glucose levels have been reported (increasing the frequency of checks is recommended).\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003ePhenytoin\u003c\/i\u003e | Serum levels of phenytoin may increase, therefore adequate monitoring and, if necessary, dose adjustment is recommended.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003ePotassium-sparing diuretics\u003c\/i\u003e | Concomitant use may cause hyperkalemia.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eProbenecid and Sulfinpyrazone\u003c\/i\u003e | Medicines containing probenecid and sulfinpyrazone may delay the excretion of flurbiprofen.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eQuinolone antibiotics\u003c\/i\u003e | Data obtained in animals indicate that NSAIDs may increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may be at increased risk of developing seizures.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eSelective serotonin reuptake inhibitors (SSRIs)\u003c\/i\u003e | There is an increased risk of gastrointestinal ulceration or bleeding (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eTacrolimus\u003c\/i\u003e | An increased risk of nephrotoxicity is possible when NSAIDs are administered concomitantly with tacrolimus.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eZidovudine\u003c\/i\u003e | There is an increased risk of haematological toxicity when NSAIDs are administered with zidovudine.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eAlcohol\u003c\/i\u003e | May increase the risk of adverse reactions, especially bleeding in the gastrointestinal tract.\u003c\/p\u003e\n\u003cp\u003eNo studies have yet found any interaction between flurbiprofen and tolbutamide or antacids. \u003cu\u003ePediatric population\u003c\/u\u003e No additional information is available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity reactions to NSAIDs have been reported and these may consist of: (a) non-specific allergic reactions and anaphylaxis; (b) respiratory tract reactivity, e.g. asthma, aggravated asthma, bronchospasm, dyspnoea; (c) various skin reactions, e.g. pruritus, urticaria, angioedema and, more rarely, exfoliative and bullous dermatosis (including epidermal necrolysis and erythema multiforme). Edema, hypertension and heart failure have been reported in association with treatment with NSAIDs. Data are insufficient to exclude this risk following the use of flurbiprofen oral mucosal spray, solution. The list of adverse effects reported below refers to what was experienced with flurbiprofen, used short term and at doses compatible with those reported in point 4.2. Very common (≥ 1\/10); Common (≥ 1\/100 to \u003c1\/10); Uncommon (≥1\/1,000 to \u003c1\/100); Rare (≥ 1\/10,000 to \u003c1\/1,000); Very rare (\u003c1\/10,000); Not known (frequency cannot be estimated from the available data). \u003ci\u003ePathologies of the blood and lymphatic system.\u003c\/i\u003e Not known: anemia, thrombocytopenia. \u003ci\u003eCardiovascular and cerebrovascular diseases.\u003c\/i\u003e Not known: edema, hypertension, heart failure. \u003ci\u003eNervous system disorders.\u003c\/i\u003e Common: dizziness, headache, paraesthesia. Uncommon: drowsiness. \u003ci\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/i\u003e Common: throat irritation; Uncommon: exacerbation of asthma and bronchospasm, dyspnoea, wheezing, oropharyngeal blistering, pharyngeal hypoesthesia. \u003ci\u003eGastrointestinal disorders.\u003c\/i\u003e Common: diarrhoea, mouth ulceration, nausea, oral pain, oral paraesthesia, oropharyngeal pain, oral discomfort (hot or burning sensation, tingling in the mouth); Uncommon: abdominal distension, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, glossodynia, dysgeusia, oral dysesthesia, vomiting. \u003ci\u003ePathologies of the skin and subcutaneous tissue.\u003c\/i\u003e Uncommon: various types of skin rashes, itching; Not known: severe skin reactions such as bullous reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. \u003ci\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/i\u003e Uncommon: pyrexia, pain. \u003ci\u003eImmune system disorders.\u003c\/i\u003e Rare: anaphylactic reaction. \u003ci\u003ePsychiatric disorders.\u003c\/i\u003e Uncommon: insomnia. \u003ci\u003eHepatobiliary disorders.\u003c\/i\u003e Not known: hepatitis \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e","brand":"Bayer","offers":[{"title":"Default Title","offer_id":51131202339143,"sku":"046444016","price":12.65,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/bayer-spa-aspi-gola-dolact-8-75mg-dose-spray-per-mucosa-orale-15ml-farmacia-dottor-tili-1213792392.jpg?v=1767132804"},{"product_id":"benagol-24-pastiglie-con-vitamina-c-gusto-arancia","title":"Benagol 24 tablets with vitamin C orange flavour","description":"\u003cp\u003e\u003cstrong\u003eBenagol with Vitamin C\u003c\/strong\u003e it's a \u003cstrong\u003eantiseptic for the throat\u003c\/strong\u003e formulated to relieve the \u003cstrong\u003esore throat\u003c\/strong\u003e and protect the oropharyngeal mucosa. Thanks to the combination of \u003cstrong\u003e2,4-dichlorobenzyl alcohol\u003c\/strong\u003e e \u003cstrong\u003eamylmetacresol\u003c\/strong\u003e, performs an action \u003cstrong\u003eantibacterial and disinfectant\u003c\/strong\u003e, helping to combat the microorganisms responsible for irritation.\u003c\/p\u003e\n\u003cp\u003eEnriched with \u003cstrong\u003eVitamin C\u003c\/strong\u003e, these tablets contribute to the normal functioning of the immune system, offering a \u003cstrong\u003edouble benefit\u003c\/strong\u003e against flu symptoms. The \u003cstrong\u003eorange flavour\u003c\/strong\u003e makes them pleasant to take, while the orosoluble formulation guarantees a gradual release for prolonged relief. The packaging from \u003cstrong\u003e16 tablets\u003c\/strong\u003e it is ideal for a practical and effective treatment.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy do you use Benagol 24 tablets with orange flavor vitamin C? What is it for?\u003c\/h3\u003e\u003cp\u003eAntiseptic of the oral cavity.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eACTIVE INGREDIENTS AND EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat is the composition of Benagol 24 orange flavored tablets with vitamin C?\u003c\/h3\u003e\u003cp\u003eBENAGOL Ginger and Spice flavored tablets Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch), spice flavoring and ginger flavoring (containing cinnamale, citral, citronellol, eugenol, farinasol, geraniol, isoeugenol and linalool). BENAGOL Honey and Lemon flavored tablets Active ingredients: 2,4-dichlorobenzil alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid glucose (containing sulphites and wheat starch), liquid sucrose, mint essence and lemon essence (containing citral, d-limonene, geraniol and linalool), honey (invert sugar). BENAGOL Sugar-Free Lemon Flavor Lozenges Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid maltitol, isomalt, lemon flavoring (containing benzyl alcohol, citral, citronellol, d-limonene, geraniol and linalool). BENAGOL Strawberry flavor tablets without sugar Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid maltitol, isomalt, strawberry flavor (containing propylene glycol and benzyl alcohol). BENAGOL Cold Mint flavor tablets Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch), mint flavor and eucalyptus essence (containing propylene glycol, benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool). BENAGOL Menthol-Eucalyptol flavor tablets Active ingredients: 2,4-dichlorobenzil alcohol 1.2 mg; amylmetacresol 0.6 mg; menthol 8.0 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch) and eucalyptus essence (containing d-limonene). BENAGOL Tablets with Vitamin C Orange flavor Active ingredients: 2,4-dichlorobenzil alcohol 1.2 mg; amylmetacresol 0.6 mg; sodium ascorbate 74.9 mg; ascorbic acid 33.5 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch), orange flavor (containing citral, citronellol, d-limonene, geraniol, linalool), propylene glycol. For the full list of excipients, see section 6.1.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003e\u003cu\u003eBENAGOL Ginger and Spice flavored tablets\u003c\/u\u003e: One tablet contains: liquid sucrose, liquid glucose (containing sulphites and wheat starch), tartaric acid, anthocyanins (E163) (containing sodium), plum flavour, cream flavour, spice flavor and ginger flavor (containing cinnamale, citral, citronellol, eugenol, farfalle, geraniol, isoeugenol and linalool), medium-chain saturated triglycerides. \u003cu\u003eBENAGOL Honey and Lemon flavored tablets\u003c\/u\u003e: One tablet contains: mint essence and lemon essence (containing citral, d-limonene, geraniol and linalool), tartaric acid, honey (invert sugar), liquid glucose (containing sulphites and wheat starch), liquid sucrose. \u003cu\u003eBENAGOL Menthol-Eucalyptol flavor tablets\u003c\/u\u003e: One tablet contains: indigo carmine (E 132) (containing sodium), eucalyptus essence (containing d-limonene), tartaric acid, liquid sucrose, liquid glucose (containing sulphites and wheat starch). \u003cu\u003eBENAGOL Orange flavored tablets with Vitamin C\u003c\/u\u003e: One tablet contains: liquid sucrose, liquid glucose (containing sulphites and wheat starch), tartaric acid, orange flavor (containing citral, citronellol, d-limonene, geraniol and linalool), levomenthol, propylene glycol. \u003cu\u003eBENAGOL Lemon flavored tablets without sugar\u003c\/u\u003e: One tablet contains: lemon flavoring (containing benzyl alcohol, citral, citronellol, dlimonene, geraniol and linalool), sodium saccharin, tartaric acid, liquid maltitol, isomalt. \u003cu\u003eBENAGOL Strawberry flavored tablets without sugar\u003c\/u\u003e: One tablet contains: strawberry flavor (containing propylene glycol and benzyl alcohol), anthocyanins (E163) (containing sodium), sodium saccharin, tartaric acid, liquid maltitol, isomalt. \u003cu\u003eBENAGOL Cold Mint flavor tablets\u003c\/u\u003e: One tablet contains: xylitol, levomenthol, mint flavor and eucalyptus essence (containing propylene glycol, benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool), liquid sucrose, liquid glucose (containing sulphites and wheat starch).\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eDOSAGE\u003c\/h2\u003e\n\u003ch3\u003eHow to take Benagol 24 tablets with orange flavor vitamin C?\u003c\/h3\u003e\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e The lowest effective dose for the shortest duration necessary to relieve symptoms should be used. \u003cb\u003eAdults and children over 6 years of age:\u003c\/b\u003e One tablet every 2 or 3 hours. In children over 6 years of age, consult your doctor for an appropriate dosage. Do not exceed the recommended doses and in particular, for BENAGOL with Vitamin C Orange flavor and BENAGOL Cold Mint flavor, do not exceed the daily maximum of 8 tablets. For all other flavors of BENAGOL, do not exceed the maximum daily dose of 12 tablets. \u003cu\u003eAdminister BENAGOL Cold Mint flavor and BENAGOL Ginger and Spice flavor to adults and children over the age of 12\u003c\/u\u003e. The duration of treatment with BENAGOL Menthol-Eucalyptol flavor must not exceed 3 days. BENAGOL Lemon flavor Without Sugar and BENAGOL Strawberry flavor Without Sugar are suitable for those patients who need to control their sugar and calorie intake. \u003ci\u003eElderly population\u003c\/i\u003e No data available. \u003cu\u003eMethod of administration\u003c\/u\u003e Oromucosal administration. The tablet should be dissolved slowly in the mouth.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003eWhen should Benagol 24 tablets with vitamin C orange flavor not be used and what side effects can it cause?\u003c\/h3\u003e\u003cp\u003eHypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. Do not administer to children under 6 years of age. BENAGOL Menthol-Eucalyptol flavor is contraindicated in children with a history of epilepsy or febrile convulsions. Do not administer BENAGOL Cold Mint flavor and BENAGOL Ginger and Spice flavor to children under 12 years of age.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003eBENAGOL Menthol - Eucalyptol flavour: due to the presence of menthol and in case of non-compliance with the recommended doses there may be a risk of convulsions in children and infants. Adverse reactions associated with the use of 2,4 dichlorobenzyl alcohol, amylmetacresol, levomenthol and ascorbic acid are listed below, divided by frequency and organ class. Frequencies are defined as: Very common (≥1\/10); Common (≥1\/100 and \u003c1\/10); Uncommon (≥1\/1000 and \u003c1\/100); Rare (≥1\/10000 and \u003c1\/1000); Very rare (\u003c1\/10000); Not known (frequency cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eClassification by systems and organs\u003c\/b\u003e \u003cb\u003eFrequency\u003c\/b\u003e \u003cb\u003eAdverse reactions\u003c\/b\u003e\u003cbr\u003eImmune system disorders Rare Hypersensitivity\u003cbr\u003eGastrointestinal disorders Rare Glossitis\u003cbr\u003eNot known Abdominal pain, nausea, gastrointestinal discomfort\u003cbr\u003eSkin and subcutaneous tissue disorders Not known Rash\u003c\/p\u003e\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003eWhich medicines or foods can modify the effect of Benagol 24 orange flavored tablets with vitamin C?\u003c\/h3\u003e\u003cp\u003eBENAGOL Menthol-Eucalyptol flavor must not be used in conjunction with other products (medicines or cosmetics) containing terpene derivatives, regardless of the route of administration (oral, rectal, cutaneous, nasal or inhalation).\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003eCan Benagol 24 tablets with vitamin C orange flavor be used during pregnancy and breastfeeding?\u003c\/h3\u003e\u003cp\u003eIn pregnant and breastfeeding women, the product should be administered only if clearly necessary. \u003cu\u003ePregnancy\u003c\/u\u003e There are no, or limited numbers, of data relating to the use of the active ingredients of BENAGOL in pregnant women. BENAGOL Menthol-Eucalyptol flavor is not recommended during pregnancy and in women of childbearing age who do not use contraceptive measures. \u003cu\u003eBreastfeeding\u003c\/u\u003e It is not known whether the active substances or their metabolites are excreted in breast milk. The risk to newborns and infants cannot be excluded. Ascorbic acid or its metabolites are excreted in breast milk. \u003cu\u003eFertility\u003c\/u\u003e No data are available regarding the effect on fertility. BENAGOL Menthol-Eucalyptol flavor is not recommended in women of childbearing age who are not using contraceptive measures.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Benagol 24 orange flavored tablets with vitamin C?\u003c\/h3\u003e\u003cp\u003eBe careful with pre-school children as if the tablets are swallowed whole they may cause choking. In the event of the appearance of sensitization or irritation phenomena, administration should be discontinued and suitable treatment instituted. BENAGOL Menthol-Eucalyptol flavor contains terpene derivatives which, in excessive doses, can cause neurological disorders such as convulsions in infants and children. Treatment with BENAGOL Menthol-Eucalyptol flavor must not be prolonged for more than 3 days due to the risks associated with the accumulation of terpene derivatives, such as \u003ci\u003eexample camphor, cineol, niaouli, wild thyme, terpineol, terpine, citral, menthol and essential oils of pine needles, eucalyptus and turpentine\u003c\/i\u003e (due to their lipophilic properties the rate of metabolism and disposal is not known) in tissues and the brain, in particular neuropsychological disorders. A higher than recommended dose should not be used to avoid an increased risk of adverse drug reactions and disorders associated with overdose (see section 4.9). BENAGOL Menthol-Eucalyptol flavor is flammable, it should not be brought near flames. \u003ci\u003eImportant information about some excipients\u003c\/i\u003e \u003cu\u003eBENAGOL Ginger and Spice flavored tablets, BENAGOL Honey and Lemon flavored tablets\u003c\/u\u003e, \u003cu\u003eBENAGOL Menthol-Eucalyptol flavor tablets, BENAGOL Orange flavor tablets with Vitamin C, BENAGOL Cold Mint flavor tablets contain\u003c\/u\u003e Liquid glucose: - Patients suffering from rare hereditary problems of glucose-galactose malabsorption should not take this medicine. - To be taken into consideration in people suffering from diabetes mellitus: BENAGOL Ginger and Spice flavored tablets contains 1.10 g of glucose per tablet. BENAGOL Honey and Lemon flavored tablets contains 0.98 g of glucose per tablet. BENAGOL Menthol-Eucalyptol flavor tablets contains 1.01 g of glucose per tablet. BENAGOL Tablets with Vitamin C Orange flavor contains 0.97 g of glucose per tablet. BENAGOL Cold Mint flavor tablets contains 1.10 g of glucose per tablet. - Liquid glucose contains sulphites. These medicines can rarely cause serious hypersensitivity reactions and bronchospasm. - Liquid glucose contains wheat starch. These medicines contain only a very small amount of gluten (from wheat starch). These medicines are considered “gluten-free” and are very unlikely to cause problems if the patient has celiac disease. One tablet of BENAGOL Ginger and Spice flavored tablets contains no more than 22.04 micrograms of gluten. One tablet of BENAGOL Honey and Lemon flavored tablets contains no more than 19.52 micrograms of gluten. One tablet of BENAGOL Menthol-Eucalyptol flavor contains no more than 20.26 micrograms of gluten. One tablet of BENAGOL Tablets with Vitamin C Orange flavor contains no more than 19.38 micrograms of gluten. One tablet of BENAGOL Cold Mint flavor tablets contains no more than 22.04 micrograms of gluten. If the patient is allergic to wheat (a condition other than celiac disease) he should not take these medicines. Liquid sucrose: - Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine. - To be taken into consideration in people suffering from diabetes mellitus: BENAGOL Ginger and Spice flavored tablets contains 1.38 g of sucrose per tablet. BENAGOL Honey and Lemon flavored tablets contains 1.44 g of sucrose per tablet. BENAGOL Menthol-Eucalyptol flavor tablets contains 1.50 g of sucrose per tablet. BENAGOL Tablets with Vitamin C Orange flavor contains 1.44 g of sucrose per tablet. BENAGOL Cold Mint flavor tablets contains 1.38 g of sucrose per tablet. \u003cu\u003eBENAGOL Ginger and Spice flavored tablets, BENAGOL Menthol-Eucalyptol flavored tablets\u003c\/u\u003e, \u003cu\u003eBENAGOL Tablets with Vitamin C Orange flavor, BENAGOL Tablets Lemon flavor Without Sugar, BENAGOL Tablets Strawberry flavor Without Sugar\u003c\/u\u003e These medicines contain less than 1 mmol (23 mg) sodium per dose, i.e. essentially 'sodium-free'. \u003cu\u003eBENAGOL Lemon Flavor Tablets Without Sugar and BENAGOL Strawberry Flavor Tablets Without Sugar\u003c\/u\u003e These medicines contain liquid maltitol and isomalt. Patients with rare hereditary problems of fructose intolerance should not take this medicine. They may have a mild laxative effect. The caloric value of maltitol and isomalt is 2.3 kcal\/g. \u003cu\u003eBENAGOL Ginger and Spice flavored tablets\u003c\/u\u003e This medicine contains a flavoring which contains cinnamale, citral, citronellol, eugenol, farfalle, geraniol, isoeugenol and linalool. Cinnamale, citral, citronellol, eugenol, farfalle, geraniol, isoeugenol and linalool can cause allergic reactions. This medicine contains excipients that can cause a warm sensation in the mouth and throat when you suck the lozenge. \u003cu\u003eBENAGOL Honey and Lemon flavored tablets\u003c\/u\u003e This medicine contains a flavoring which contains citral, d-limonene, geraniol and linalool. Citral, d-limonene, geraniol and linalool can cause allergic reactions. This medicine contains honey (invert sugar). Patients suffering from rare hereditary problems of fructose intolerance, or glucose-galactose malabsorption, should not take this medicine. \u003cu\u003eBENAGOL Menthol-Eucalyptol flavor tablets\u003c\/u\u003e This medicine contains a flavoring which contains d-limonene. D-limonene can cause allergic reactions. \u003cu\u003eBENAGOL Orange flavored tablets with Vitamin C\u003c\/u\u003e This medicine contains a flavoring which contains citral, citronellol, d-limonene, geraniol and linalool. Citral, citronellol, d-limonene, geraniol and linalool can cause allergic reactions. This medicine contains 3 mg of propylene glycol per tablet. \u003cu\u003eBENAGOL Lemon flavored tablets without sugar\u003c\/u\u003e This medicine contains a flavoring which contains benzyl alcohol, citral, citronellol, d-limonene, geraniol and linalool. Benzyl alcohol, citral, citronellol, d-limonene, geraniol and linalool can cause allergic reactions. \u003cu\u003eBENAGOL Strawberry flavored tablets without sugar\u003c\/u\u003e This medicine contains a flavoring which contains benzyl alcohol. Benzyl alcohol can cause allergic reactions. This medicine contains 7.30 mg of propylene glycol in each tablet. \u003cu\u003eBENAGOL Cold Mint flavor tablets\u003c\/u\u003e This medicine contains a flavoring which contains benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool. Benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool can cause allergic reactions. This medicine contains 1.89 mg of propylene glycol in each tablet.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003eA possible overdose could only cause gastrointestinal disorders, for which appropriate symptomatic treatments must be adopted. BENAGOL Menthol-Eucalyptol flavour: in case of accidental oral intake or incorrect administration in infants and children there may be a risk of neurological disorders. If necessary, administer appropriate symptomatic treatment in specialized treatment centers.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003eNo effects on the ability to drive or use machines are reported.\u003c\/p\u003e\n\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow do you store Benagol 24 orange flavored tablets with vitamin C?\u003c\/h3\u003e\u003cp\u003eDo not store above 25°C.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Benagol 24 tablets with orange flavor vitamin C?\u003c\/h3\u003e\u003cp\u003e24 tablets\u003c\/p\u003e\n\u003ch2\u003eDRUG LEGAL TEXT\u003c\/h2\u003e\n\u003cp\u003eContent responsibility\u003c\/p\u003e\u003cp\u003eThis sheet contains information that is not intended to replace a doctor's diagnosis or advice, as only the doctor can draw up any prescription and give therapeutic indications. All contents must be understood and are of an exclusively informative nature and aimed exclusively at bringing to the attention of customers or potential customers in the pre-purchase phase of the products sold through this site. In case of pathologies, disorders or allergies it is always best to consult your doctor first.\u003c\/p\u003e\u003cp\u003ePlease note\u003c\/p\u003e\u003cp\u003eThe product names, ingredients and percentages indicated in the descriptions are purely indicative and may be subject to changes or updates by the manufacturing companies. Due to the impossibility of adapting to these updates in real time, the photos and technical information of the products included on Dottortili.com may differ from those shown on the label or otherwise disseminated by the manufacturing companies. The only identification element appears to be the ministerial code MINSAN. The online pharmacy Dottortili.com does not guarantee the truthfulness and timeliness of the information published and declines any responsibility for any errors, omissions or failure to update the same. Dottortili.com assumes no responsibility for damages of any nature that may arise from access to the information published.\u003c\/p\u003e\u003cp\u003eData source: Farmadati Italia\u003c\/p\u003e\u003cp\u003eWebsite: www.farmadati.it\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia database is used by almost all pharmacies, parapharmacies, herbalist shops, health shops, large-scale retail trade, computerized doctors, etc. thanks to the guarantee of historical reliability, seriousness and professionalism of the company on the national territory.\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia S.r.l management system complies with the requirements of the UNI EN ISO 9001:2015 standards for quality management systems and UNI CEI ISO\/IEC 27001:2017 for information security management systems.\u003c\/p\u003e","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":51131202470215,"sku":"016242075","price":12.28,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/reckitt-benckiser-h-it-spa-benagol-24-pastiglie-con-vitamina-c-gusto-arancia-farmacia-dottor-tili-1213792390.webp?v=1767132831"},{"product_id":"benagol-24-pastiglie-gusto-miele-e-limone","title":"Benagol 24 tablets honey and lemon flavour","description":"\u003cp\u003e\u003cstrong\u003eBenagol Honey and Lemon\u003c\/strong\u003e it's a \u003cstrong\u003eantiseptic for the throat\u003c\/strong\u003e in tablets, indicated for the treatment of \u003cstrong\u003eoropharyngeal irritation\u003c\/strong\u003e and of \u003cstrong\u003esore throat\u003c\/strong\u003e mild or moderate. Thanks to the combination of \u003cstrong\u003e2,4-dichlorobenzyl alcohol\u003c\/strong\u003e e \u003cstrong\u003eamylmetacresol\u003c\/strong\u003e, performs an action \u003cstrong\u003eantibacterial and disinfectant\u003c\/strong\u003e, helping to combat the microorganisms responsible for infections.\u003c\/p\u003e\n\u003cp\u003eThe \u003cstrong\u003ehoney and lemon flavour\u003c\/strong\u003e makes the intake more pleasant, while the formulation in \u003cstrong\u003eorosoluble tablets\u003c\/strong\u003e guarantees immediate and prolonged relief. Ideal for \u003cstrong\u003erelieve burning, pain and discomfort in the throat\u003c\/strong\u003e, Benagol is a practical and effective remedy to always keep on hand. The package contains \u003cstrong\u003e16 tablets\u003c\/strong\u003e, perfect for prolonged treatment.\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy do you use Benagol 24 honey and lemon flavored tablets? What is it for?\u003c\/h3\u003e\u003cp\u003eAntiseptic of the oral cavity.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eACTIVE INGREDIENTS AND EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat is the composition of Benagol 24 honey and lemon flavored tablets?\u003c\/h3\u003e\u003cp\u003eBENAGOL Ginger and Spice flavored tablets Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch), spice flavoring and ginger flavoring (containing cinnamale, citral, citronellol, eugenol, farinasol, geraniol, isoeugenol and linalool). BENAGOL Honey and Lemon flavored tablets Active ingredients: 2,4-dichlorobenzil alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid glucose (containing sulphites and wheat starch), liquid sucrose, mint essence and lemon essence (containing citral, d-limonene, geraniol and linalool), honey (invert sugar). BENAGOL Sugar-Free Lemon Flavor Lozenges Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid maltitol, isomalt, lemon flavoring (containing benzyl alcohol, citral, citronellol, d-limonene, geraniol and linalool). BENAGOL Strawberry flavor tablets without sugar Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid maltitol, isomalt, strawberry flavor (containing propylene glycol and benzyl alcohol). BENAGOL Cold Mint flavor tablets Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch), mint flavor and eucalyptus essence (containing propylene glycol, benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool). BENAGOL Menthol-Eucalyptol flavor tablets Active ingredients: 2,4-dichlorobenzil alcohol 1.2 mg; amylmetacresol 0.6 mg; menthol 8.0 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch) and eucalyptus essence (containing d-limonene). BENAGOL Tablets with Vitamin C Orange flavor Active ingredients: 2,4-dichlorobenzil alcohol 1.2 mg; amylmetacresol 0.6 mg; sodium ascorbate 74.9 mg; ascorbic acid 33.5 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch), orange flavor (containing citral, citronellol, d-limonene, geraniol, linalool), propylene glycol. For the full list of excipients, see section 6.1.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003e\u003cu\u003eBENAGOL Ginger and Spice flavored tablets\u003c\/u\u003e: One tablet contains: liquid sucrose, liquid glucose (containing sulphites and wheat starch), tartaric acid, anthocyanins (E163) (containing sodium), plum flavour, cream flavour, spice flavor and ginger flavor (containing cinnamale, citral, citronellol, eugenol, farfalle, geraniol, isoeugenol and linalool), medium-chain saturated triglycerides. \u003cu\u003eBENAGOL Honey and Lemon flavored tablets\u003c\/u\u003e: One tablet contains: mint essence and lemon essence (containing citral, d-limonene, geraniol and linalool), tartaric acid, honey (invert sugar), liquid glucose (containing sulphites and wheat starch), liquid sucrose. \u003cu\u003eBENAGOL Menthol-Eucalyptol flavor tablets\u003c\/u\u003e: One tablet contains: indigo carmine (E 132) (containing sodium), eucalyptus essence (containing d-limonene), tartaric acid, liquid sucrose, liquid glucose (containing sulphites and wheat starch). \u003cu\u003eBENAGOL Orange flavored tablets with Vitamin C\u003c\/u\u003e: One tablet contains: liquid sucrose, liquid glucose (containing sulphites and wheat starch), tartaric acid, orange flavor (containing citral, citronellol, d-limonene, geraniol and linalool), levomenthol, propylene glycol. \u003cu\u003eBENAGOL Lemon flavored tablets without sugar\u003c\/u\u003e: One tablet contains: lemon flavoring (containing benzyl alcohol, citral, citronellol, dlimonene, geraniol and linalool), sodium saccharin, tartaric acid, liquid maltitol, isomalt. \u003cu\u003eBENAGOL Strawberry flavored tablets without sugar\u003c\/u\u003e: One tablet contains: strawberry flavor (containing propylene glycol and benzyl alcohol), anthocyanins (E163) (containing sodium), sodium saccharin, tartaric acid, liquid maltitol, isomalt. \u003cu\u003eBENAGOL Cold Mint flavor tablets\u003c\/u\u003e: One tablet contains: xylitol, levomenthol, mint flavor and eucalyptus essence (containing propylene glycol, benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool), liquid sucrose, liquid glucose (containing sulphites and wheat starch).\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eDOSAGE\u003c\/h2\u003e\n\u003ch3\u003eHow to take Benagol 24 honey and lemon flavored tablets?\u003c\/h3\u003e\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e The lowest effective dose for the shortest duration necessary to relieve symptoms should be used. \u003cb\u003eAdults and children over 6 years of age:\u003c\/b\u003e One tablet every 2 or 3 hours. In children over 6 years of age, consult your doctor for an appropriate dosage. Do not exceed the recommended doses and in particular, for BENAGOL with Vitamin C Orange flavor and BENAGOL Cold Mint flavor, do not exceed the daily maximum of 8 tablets. For all other flavors of BENAGOL, do not exceed the maximum daily dose of 12 tablets. \u003cu\u003eAdminister BENAGOL Cold Mint flavor and BENAGOL Ginger and Spice flavor to adults and children over the age of 12\u003c\/u\u003e. The duration of treatment with BENAGOL Menthol-Eucalyptol flavor must not exceed 3 days. BENAGOL Lemon flavor Without Sugar and BENAGOL Strawberry flavor Without Sugar are suitable for those patients who need to control their sugar and calorie intake. \u003ci\u003eElderly population\u003c\/i\u003e No data available. \u003cu\u003eMethod of administration\u003c\/u\u003e Oromucosal administration. The tablet should be dissolved slowly in the mouth.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003eWhen should Benagol 24 honey and lemon flavored tablets not be used and what side effects can it cause?\u003c\/h3\u003e\u003cp\u003eHypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. Do not administer to children under 6 years of age. BENAGOL Menthol-Eucalyptol flavor is contraindicated in children with a history of epilepsy or febrile convulsions. Do not administer BENAGOL Cold Mint flavor and BENAGOL Ginger and Spice flavor to children under 12 years of age.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003eBENAGOL Menthol - Eucalyptol flavour: due to the presence of menthol and in case of non-compliance with the recommended doses there may be a risk of convulsions in children and infants. Adverse reactions associated with the use of 2,4 dichlorobenzyl alcohol, amylmetacresol, levomenthol and ascorbic acid are listed below, divided by frequency and organ class. Frequencies are defined as: Very common (≥1\/10); Common (≥1\/100 and \u003c1\/10); Uncommon (≥1\/1000 and \u003c1\/100); Rare (≥1\/10000 and \u003c1\/1000); Very rare (\u003c1\/10000); Not known (frequency cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.\u003c\/p\u003e\u003cb\u003eClassification by systems and organs\u003c\/b\u003e \u003cb\u003eFrequency\u003c\/b\u003e \u003cb\u003eAdverse reactions\u003c\/b\u003e\u003cbr\u003eImmune system disorders Rare Hypersensitivity\u003cbr\u003eGastrointestinal disorders Rare Glossitis\u003cbr\u003eNot known Abdominal pain, nausea, gastrointestinal discomfort\u003cbr\u003eSkin and subcutaneous tissue disorders Not known Rash\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003eWhich medicines or foods can modify the effect of Benagol 24 honey and lemon flavored tablets?\u003c\/h3\u003e\u003cp\u003eBENAGOL Menthol-Eucalyptol flavor must not be used in conjunction with other products (medicines or cosmetics) containing terpene derivatives, regardless of the route of administration (oral, rectal, cutaneous, nasal or inhalation).\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003eCan Benagol 24 honey and lemon flavored tablets be used during pregnancy and breastfeeding?\u003c\/h3\u003e\u003cp\u003eIn pregnant and breastfeeding women, the product should be administered only if clearly necessary. \u003cu\u003ePregnancy\u003c\/u\u003e There are no, or limited numbers, of data relating to the use of the active ingredients of BENAGOL in pregnant women. BENAGOL Menthol-Eucalyptol flavor is not recommended during pregnancy and in women of childbearing age who do not use contraceptive measures. \u003cu\u003eBreastfeeding\u003c\/u\u003e It is not known whether the active substances or their metabolites are excreted in breast milk. The risk to newborns and infants cannot be excluded. Ascorbic acid or its metabolites are excreted in breast milk. \u003cu\u003eFertility\u003c\/u\u003e No data are available regarding the effect on fertility. BENAGOL Menthol-Eucalyptol flavor is not recommended in women of childbearing age who are not using contraceptive measures.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Benagol 24 honey and lemon flavored tablets?\u003c\/h3\u003e\u003cp\u003eBe careful with pre-school children as if the tablets are swallowed whole they may cause choking. In the event of the appearance of sensitization or irritation phenomena, administration should be discontinued and suitable treatment instituted. BENAGOL Menthol-Eucalyptol flavor contains terpene derivatives which, in excessive doses, can cause neurological disorders such as convulsions in infants and children. Treatment with BENAGOL Menthol-Eucalyptol flavor must not be prolonged for more than 3 days due to the risks associated with the accumulation of terpene derivatives, such as \u003ci\u003eexample camphor, cineol, niaouli, wild thyme, terpineol, terpine, citral, menthol and essential oils of pine needles, eucalyptus and turpentine\u003c\/i\u003e (due to their lipophilic properties the rate of metabolism and disposal is not known) in tissues and the brain, in particular neuropsychological disorders. A higher than recommended dose should not be used to avoid an increased risk of adverse drug reactions and disorders associated with overdose (see section 4.9). BENAGOL Menthol-Eucalyptol flavor is flammable, it should not be brought near flames. \u003ci\u003eImportant information about some excipients\u003c\/i\u003e \u003cu\u003eBENAGOL Ginger and Spice flavored tablets, BENAGOL Honey and Lemon flavored tablets\u003c\/u\u003e, \u003cu\u003eBENAGOL Menthol-Eucalyptol flavor tablets, BENAGOL Orange flavor tablets with Vitamin C, BENAGOL Cold Mint flavor tablets contain\u003c\/u\u003e Liquid glucose: - Patients suffering from rare hereditary problems of glucose-galactose malabsorption should not take this medicine. - To be taken into consideration in people suffering from diabetes mellitus: BENAGOL Ginger and Spice flavored tablets contains 1.10 g of glucose per tablet. BENAGOL Honey and Lemon flavored tablets contains 0.98 g of glucose per tablet. BENAGOL Menthol-Eucalyptol flavor tablets contains 1.01 g of glucose per tablet. BENAGOL Tablets with Vitamin C Orange flavor contains 0.97 g of glucose per tablet. BENAGOL Cold Mint flavor tablets contains 1.10 g of glucose per tablet. - Liquid glucose contains sulphites. These medicines can rarely cause serious hypersensitivity reactions and bronchospasm. - Liquid glucose contains wheat starch. These medicines contain only a very small amount of gluten (from wheat starch). These medicines are considered “gluten-free” and are very unlikely to cause problems if the patient has celiac disease. One tablet of BENAGOL Ginger and Spice flavored tablets contains no more than 22.04 micrograms of gluten. One tablet of BENAGOL Honey and Lemon flavored tablets contains no more than 19.52 micrograms of gluten. One tablet of BENAGOL Menthol-Eucalyptol flavor contains no more than 20.26 micrograms of gluten. One tablet of BENAGOL Tablets with Vitamin C Orange flavor contains no more than 19.38 micrograms of gluten. One tablet of BENAGOL Cold Mint flavor tablets contains no more than 22.04 micrograms of gluten. If the patient is allergic to wheat (a condition other than celiac disease) he should not take these medicines. Liquid sucrose: - Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine. - To be taken into consideration in people suffering from diabetes mellitus: BENAGOL Ginger and Spice flavored tablets contains 1.38 g of sucrose per tablet. BENAGOL Honey and Lemon flavored tablets contains 1.44 g of sucrose per tablet. BENAGOL Menthol-Eucalyptol flavor tablets contains 1.50 g of sucrose per tablet. BENAGOL Tablets with Vitamin C Orange flavor contains 1.44 g of sucrose per tablet. BENAGOL Cold Mint flavor tablets contains 1.38 g of sucrose per tablet. \u003cu\u003eBENAGOL Ginger and Spice flavored tablets, BENAGOL Menthol-Eucalyptol flavored tablets\u003c\/u\u003e, \u003cu\u003eBENAGOL Tablets with Vitamin C Orange flavor, BENAGOL Tablets Lemon flavor Without Sugar, BENAGOL Tablets Strawberry flavor Without Sugar\u003c\/u\u003e These medicines contain less than 1 mmol (23 mg) sodium per dose, i.e. essentially 'sodium-free'. \u003cu\u003eBENAGOL Lemon Flavor Tablets Without Sugar and BENAGOL Strawberry Flavor Tablets Without Sugar\u003c\/u\u003e These medicines contain liquid maltitol and isomalt. Patients with rare hereditary problems of fructose intolerance should not take this medicine. They may have a mild laxative effect. The caloric value of maltitol and isomalt is 2.3 kcal\/g. \u003cu\u003eBENAGOL Ginger and Spice flavored tablets\u003c\/u\u003e This medicine contains a flavoring which contains cinnamale, citral, citronellol, eugenol, farfalle, geraniol, isoeugenol and linalool. Cinnamale, citral, citronellol, eugenol, farfalle, geraniol, isoeugenol and linalool can cause allergic reactions. This medicine contains excipients that can cause a warm sensation in the mouth and throat when you suck the lozenge. \u003cu\u003eBENAGOL Honey and Lemon flavored tablets\u003c\/u\u003e This medicine contains a flavoring which contains citral, d-limonene, geraniol and linalool. Citral, d-limonene, geraniol and linalool can cause allergic reactions. This medicine contains honey (invert sugar). Patients suffering from rare hereditary problems of fructose intolerance, or glucose-galactose malabsorption, should not take this medicine. \u003cu\u003eBENAGOL Menthol-Eucalyptol flavor tablets\u003c\/u\u003e This medicine contains a flavoring which contains d-limonene. D-limonene can cause allergic reactions. \u003cu\u003eBENAGOL Orange flavored tablets with Vitamin C\u003c\/u\u003e This medicine contains a flavoring which contains citral, citronellol, d-limonene, geraniol and linalool. Citral, citronellol, d-limonene, geraniol and linalool can cause allergic reactions. This medicine contains 3 mg of propylene glycol per tablet. \u003cu\u003eBENAGOL Lemon flavored tablets without sugar\u003c\/u\u003e This medicine contains a flavoring which contains benzyl alcohol, citral, citronellol, d-limonene, geraniol and linalool. Benzyl alcohol, citral, citronellol, d-limonene, geraniol and linalool can cause allergic reactions. \u003cu\u003eBENAGOL Strawberry flavored tablets without sugar\u003c\/u\u003e This medicine contains a flavoring which contains benzyl alcohol. Benzyl alcohol can cause allergic reactions. This medicine contains 7.30 mg of propylene glycol in each tablet. \u003cu\u003eBENAGOL Cold Mint flavor tablets\u003c\/u\u003e This medicine contains a flavoring which contains benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool. Benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool can cause allergic reactions. This medicine contains 1.89 mg of propylene glycol in each tablet.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003eA possible overdose could only cause gastrointestinal disorders, for which appropriate symptomatic treatments must be adopted. BENAGOL Menthol-Eucalyptol flavour: in case of accidental oral intake or incorrect administration in infants and children there may be a risk of neurological disorders. If necessary, administer appropriate symptomatic treatment in specialized treatment centers.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003eNo effects on the ability to drive or use machines are reported.\u003c\/p\u003e\n\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow do you store Benagol 24 honey and lemon flavored tablets?\u003c\/h3\u003e\u003cp\u003eDo not store above 25°C.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Benagol 24 honey and lemon flavored tablets?\u003c\/h3\u003e\u003cp\u003e24 tablets\u003c\/p\u003e\n\u003ch2\u003eDRUG LEGAL TEXT\u003c\/h2\u003e\n\u003cp\u003eContent responsibility\u003c\/p\u003e\u003cp\u003eThis sheet contains information that is not intended to replace a doctor's diagnosis or advice, as only the doctor can draw up any prescription and give therapeutic indications. All contents must be understood and are of an exclusively informative nature and aimed exclusively at bringing to the attention of customers or potential customers in the pre-purchase phase of the products sold through this site. In case of pathologies, disorders or allergies it is always best to consult your doctor first.\u003c\/p\u003e\u003cp\u003ePlease note\u003c\/p\u003e\u003cp\u003eThe product names, ingredients and percentages indicated in the descriptions are purely indicative and may be subject to changes or updates by the manufacturing companies. Due to the impossibility of adapting to these updates in real time, the photos and technical information of the products included on Dottortili.com may differ from those shown on the label or otherwise disseminated by the manufacturing companies. The only identification element appears to be the ministerial code MINSAN. The online pharmacy Dottortili.com does not guarantee the truthfulness and timeliness of the information published and declines any responsibility for any errors, omissions or failure to update the same. Dottortili.com assumes no responsibility for damages of any nature that may arise from access to the information published.\u003c\/p\u003e\u003cp\u003eData source: Farmadati Italia\u003c\/p\u003e\u003cp\u003eWebsite: www.farmadati.it\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia database is used by almost all pharmacies, parapharmacies, herbalist shops, health shops, large-scale retail trade, computerized doctors, etc. thanks to the guarantee of historical reliability, seriousness and professionalism of the company on the national territory.\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia S.r.l management system complies with the requirements of the UNI EN ISO 9001:2015 standards for quality management systems and UNI CEI ISO\/IEC 27001:2017 for information security management systems.\u003c\/p\u003e","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":51131220459847,"sku":"016242063","price":12.28,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/reckitt-benckiser-h-it-spa-benagol-24-pastiglie-gusto-miele-e-limone-farmacia-dottor-tili-1213792353.jpg?v=1767142726"},{"product_id":"benagol-24-pastiglie-gusto-limone-senza-zucchero","title":"Benagol 24 lemon flavoured tablets without sugar","description":"\u003cp\u003eBenagol 24 sugar-free lemon flavored tablets is a product formulated to offer an action \u003cstrong\u003eantiseptic of the oral cavity\u003c\/strong\u003e. Each tablet contains the active ingredients \u003cstrong\u003e2,4-dichlorobenzyl alcohol\u003c\/strong\u003e e \u003cstrong\u003eamylmetacresol\u003c\/strong\u003e, known for their antibacterial properties. This product is ideal for those looking for a sugar-free option, thanks to the use of \u003cstrong\u003eliquid maltitol\u003c\/strong\u003e e \u003cstrong\u003eisomalt\u003c\/strong\u003e as sweeteners. The lemon aroma, enriched with components such as \u003cstrong\u003ebenzyl alcohol\u003c\/strong\u003e, \u003cstrong\u003ecitral\u003c\/strong\u003e, \u003cstrong\u003ecitronellol\u003c\/strong\u003e, \u003cstrong\u003ed-limonene\u003c\/strong\u003e, \u003cstrong\u003egeraniol\u003c\/strong\u003e e \u003cstrong\u003elinalool\u003c\/strong\u003e, gives a fresh and pleasant taste. The tablets are designed to dissolve slowly in the mouth, ensuring a gradual release of the active ingredients. Benagol is an effective choice for maintaining oral health by reducing the growth of bacteria in the throat and mouth.\u003c\/p\u003e\n\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy do I use Benagol 24 sugar-free lemon flavored tablets? What is it for?\u003c\/h3\u003e\u003cp\u003eAntiseptic of the oral cavity.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eACTIVE INGREDIENTS AND EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat is the composition of Benagol 24 sugar-free lemon flavored tablets?\u003c\/h3\u003e\u003cp\u003eBENAGOL Ginger and Spice flavored tablets Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch), spice flavoring and ginger flavoring (containing cinnamale, citral, citronellol, eugenol, farinasol, geraniol, isoeugenol and linalool). BENAGOL Honey and Lemon flavored tablets Active ingredients: 2,4-dichlorobenzil alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid glucose (containing sulphites and wheat starch), liquid sucrose, mint essence and lemon essence (containing citral, d-limonene, geraniol and linalool), honey (invert sugar). BENAGOL Sugar-Free Lemon Flavor Lozenges Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid maltitol, isomalt, lemon flavoring (containing benzyl alcohol, citral, citronellol, d-limonene, geraniol and linalool). BENAGOL Strawberry flavor tablets without sugar Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid maltitol, isomalt, strawberry flavor (containing propylene glycol and benzyl alcohol). BENAGOL Cold Mint flavor tablets Active ingredients: 2,4-dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch), mint flavor and eucalyptus essence (containing propylene glycol, benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool). BENAGOL Menthol-Eucalyptol flavor tablets Active ingredients: 2,4-dichlorobenzil alcohol 1.2 mg; amylmetacresol 0.6 mg; menthol 8.0 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch) and eucalyptus essence (containing d-limonene). BENAGOL Tablets with Vitamin C Orange flavor Active ingredients: 2,4-dichlorobenzil alcohol 1.2 mg; amylmetacresol 0.6 mg; sodium ascorbate 74.9 mg; ascorbic acid 33.5 mg. Excipients with known effects: liquid sucrose, liquid glucose (containing sulphites and wheat starch), orange flavor (containing citral, citronellol, d-limonene, geraniol, linalool), propylene glycol. For the full list of excipients, see section 6.1.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cp\u003e\u003cu\u003eBENAGOL Ginger and Spice flavored tablets\u003c\/u\u003e: One tablet contains: liquid sucrose, liquid glucose (containing sulphites and wheat starch), tartaric acid, anthocyanins (E163) (containing sodium), plum flavour, cream flavour, spice flavor and ginger flavor (containing cinnamale, citral, citronellol, eugenol, farfalle, geraniol, isoeugenol and linalool), medium-chain saturated triglycerides. \u003cu\u003eBENAGOL Honey and Lemon flavored tablets\u003c\/u\u003e: One tablet contains: mint essence and lemon essence (containing citral, d-limonene, geraniol and linalool), tartaric acid, honey (invert sugar), liquid glucose (containing sulphites and wheat starch), liquid sucrose. \u003cu\u003eBENAGOL Menthol-Eucalyptol flavor tablets\u003c\/u\u003e: One tablet contains: indigo carmine (E 132) (containing sodium), eucalyptus essence (containing d-limonene), tartaric acid, liquid sucrose, liquid glucose (containing sulphites and wheat starch). \u003cu\u003eBENAGOL Orange flavored tablets with Vitamin C\u003c\/u\u003e: One tablet contains: liquid sucrose, liquid glucose (containing sulphites and wheat starch), tartaric acid, orange flavor (containing citral, citronellol, d-limonene, geraniol and linalool), levomenthol, propylene glycol. \u003cu\u003eBENAGOL Lemon flavored tablets without sugar\u003c\/u\u003e: One tablet contains: lemon flavoring (containing benzyl alcohol, citral, citronellol, dlimonene, geraniol and linalool), sodium saccharin, tartaric acid, liquid maltitol, isomalt. \u003cu\u003eBENAGOL Strawberry flavored tablets without sugar\u003c\/u\u003e: One tablet contains: strawberry flavor (containing propylene glycol and benzyl alcohol), anthocyanins (E163) (containing sodium), sodium saccharin, tartaric acid, liquid maltitol, isomalt. \u003cu\u003eBENAGOL Cold Mint flavor tablets\u003c\/u\u003e: One tablet contains: xylitol, levomenthol, mint flavor and eucalyptus essence (containing propylene glycol, benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool), liquid sucrose, liquid glucose (containing sulphites and wheat starch).\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eDOSAGE\u003c\/h2\u003e\n\u003ch3\u003eHow to take Benagol 24 sugar-free lemon flavored tablets?\u003c\/h3\u003e\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e The lowest effective dose for the shortest duration necessary to relieve symptoms should be used. \u003cb\u003eAdults and children over 6 years of age:\u003c\/b\u003e One tablet every 2 or 3 hours. In children over 6 years of age, consult your doctor for an appropriate dosage. Do not exceed the recommended doses and in particular, for BENAGOL with Vitamin C Orange flavor and BENAGOL Cold Mint flavor, do not exceed the daily maximum of 8 tablets. For all other flavors of BENAGOL, do not exceed the maximum daily dose of 12 tablets. \u003cu\u003eAdminister BENAGOL Cold Mint flavor and BENAGOL Ginger and Spice flavor to adults and children over the age of 12\u003c\/u\u003e. The duration of treatment with BENAGOL Menthol-Eucalyptol flavor must not exceed 3 days. BENAGOL Lemon flavor Without Sugar and BENAGOL Strawberry flavor Without Sugar are suitable for those patients who need to control their sugar and calorie intake. \u003ci\u003eElderly population\u003c\/i\u003e No data available. \u003cu\u003eMethod of administration\u003c\/u\u003e Oromucosal administration. The tablet should be dissolved slowly in the mouth.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003eWhen should Benagol 24 sugar-free lemon flavored tablets not be used and what side effects can it cause?\u003c\/h3\u003e\u003cp\u003eHypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. Do not administer to children under 6 years of age. BENAGOL Menthol-Eucalyptol flavor is contraindicated in children with a history of epilepsy or febrile convulsions. Do not administer BENAGOL Cold Mint flavor and BENAGOL Ginger and Spice flavor to children under 12 years of age.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cp\u003eBENAGOL Menthol - Eucalyptol flavour: due to the presence of menthol and in case of non-compliance with the recommended doses there may be a risk of convulsions in children and infants. Adverse reactions associated with the use of 2,4 dichlorobenzyl alcohol, amylmetacresol, levomenthol and ascorbic acid are listed below, divided by frequency and organ class. Frequencies are defined as: Very common (≥1\/10); Common (≥1\/100 and \u003c1\/10); Uncommon (≥1\/1000 and \u003c1\/100); Rare (≥1\/10000 and \u003c1\/1000); Very rare (\u003c1\/10000); Not known (frequency cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.\u003c\/p\u003eSystem organ classification Frequency Adverse reactions\u003cbr\u003eImmune system disorders Rare Hypersensitivity\u003cbr\u003eGastrointestinal disorders Rare Glossitis\u003cbr\u003eNot known Abdominal pain, nausea, gastrointestinal discomfort\u003cbr\u003eSkin and subcutaneous tissue disorders Not known Rash\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003eWhich medicines or foods can change the effect of Benagol 24 sugar-free lemon flavored lozenges?\u003c\/h3\u003e\u003cp\u003eBENAGOL Menthol-Eucalyptol flavor must not be used in conjunction with other products (medicines or cosmetics) containing terpene derivatives, regardless of the route of administration (oral, rectal, cutaneous, nasal or inhalation).\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003eCan Benagol 24 sugar-free lemon flavored tablets be used during pregnancy and breastfeeding?\u003c\/h3\u003e\u003cp\u003eIn pregnant and breastfeeding women, the product should be administered only if clearly necessary. \u003cu\u003ePregnancy\u003c\/u\u003e There are no, or limited numbers, of data relating to the use of the active ingredients of BENAGOL in pregnant women. BENAGOL Menthol-Eucalyptol flavor is not recommended during pregnancy and in women of childbearing age who do not use contraceptive measures. \u003cu\u003eBreastfeeding\u003c\/u\u003e It is not known whether the active substances or their metabolites are excreted in breast milk. The risk to newborns and infants cannot be excluded. Ascorbic acid or its metabolites are excreted in breast milk. \u003cu\u003eFertility\u003c\/u\u003e No data are available regarding the effect on fertility. BENAGOL Menthol-Eucalyptol flavor is not recommended in women of childbearing age who are not using contraceptive measures.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Benagol 24 sugar-free lemon flavored tablets?\u003c\/h3\u003e\u003cp\u003eBe careful with pre-school children as if the tablets are swallowed whole they may cause choking. In the event of the appearance of sensitization or irritation phenomena, administration should be discontinued and suitable treatment instituted. BENAGOL Menthol-Eucalyptol flavor contains terpene derivatives which, in excessive doses, can cause neurological disorders such as convulsions in infants and children. Treatment with BENAGOL Menthol-Eucalyptol flavor must not be prolonged for more than 3 days due to the risks associated with the accumulation of terpene derivatives, such as \u003ci\u003eexample camphor, cineol, niaouli, wild thyme, terpineol, terpine, citral, menthol and essential oils of pine needles, eucalyptus and turpentine\u003c\/i\u003e (due to their lipophilic properties the rate of metabolism and disposal is not known) in tissues and the brain, in particular neuropsychological disorders. A higher than recommended dose should not be used to avoid an increased risk of adverse drug reactions and disorders associated with overdose (see section 4.9). BENAGOL Menthol-Eucalyptol flavor is flammable, it should not be brought near flames. \u003ci\u003eImportant information about some excipients\u003c\/i\u003e \u003cu\u003eBENAGOL Ginger and Spice flavored tablets, BENAGOL Honey and Lemon flavored tablets\u003c\/u\u003e, \u003cu\u003eBENAGOL Menthol-Eucalyptol flavor tablets, BENAGOL Orange flavor tablets with Vitamin C, BENAGOL Cold Mint flavor tablets contain\u003c\/u\u003e Liquid glucose: - Patients suffering from rare hereditary problems of glucose-galactose malabsorption should not take this medicine. - To be taken into consideration in people suffering from diabetes mellitus: BENAGOL Ginger and Spice flavored tablets contains 1.10 g of glucose per tablet. BENAGOL Honey and Lemon flavored tablets contains 0.98 g of glucose per tablet. BENAGOL Menthol-Eucalyptol flavor tablets contains 1.01 g of glucose per tablet. BENAGOL Tablets with Vitamin C Orange flavor contains 0.97 g of glucose per tablet. BENAGOL Cold Mint flavor tablets contains 1.10 g of glucose per tablet. - Liquid glucose contains sulphites. These medicines can rarely cause serious hypersensitivity reactions and bronchospasm. - Liquid glucose contains wheat starch. These medicines contain only a very small amount of gluten (from wheat starch). These medicines are considered “gluten-free” and are very unlikely to cause problems if the patient has celiac disease. One tablet of BENAGOL Ginger and Spice flavored tablets contains no more than 22.04 micrograms of gluten. One tablet of BENAGOL Honey and Lemon flavored tablets contains no more than 19.52 micrograms of gluten. One tablet of BENAGOL Menthol-Eucalyptol flavor contains no more than 20.26 micrograms of gluten. One tablet of BENAGOL Tablets with Vitamin C Orange flavor contains no more than 19.38 micrograms of gluten. One tablet of BENAGOL Cold Mint flavor tablets contains no more than 22.04 micrograms of gluten. If the patient is allergic to wheat (a condition other than celiac disease) he should not take these medicines. Liquid sucrose: - Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine. - To be taken into consideration in people suffering from diabetes mellitus: BENAGOL Ginger and Spice flavored tablets contains 1.38 g of sucrose per tablet. BENAGOL Honey and Lemon flavored tablets contains 1.44 g of sucrose per tablet. BENAGOL Menthol-Eucalyptol flavor tablets contains 1.50 g of sucrose per tablet. BENAGOL Tablets with Vitamin C Orange flavor contains 1.44 g of sucrose per tablet. BENAGOL Cold Mint flavor tablets contains 1.38 g of sucrose per tablet. \u003cu\u003eBENAGOL Ginger and Spice flavored tablets, BENAGOL Menthol-Eucalyptol flavored tablets\u003c\/u\u003e, \u003cu\u003eBENAGOL Tablets with Vitamin C Orange flavor, BENAGOL Tablets Lemon flavor Without Sugar, BENAGOL Tablets Strawberry flavor Without Sugar\u003c\/u\u003e These medicines contain less than 1 mmol (23 mg) sodium per dose, i.e. essentially 'sodium-free'. \u003cu\u003eBENAGOL Lemon Flavor Tablets Without Sugar and BENAGOL Strawberry Flavor Tablets Without Sugar\u003c\/u\u003e These medicines contain liquid maltitol and isomalt. Patients with rare hereditary problems of fructose intolerance should not take this medicine. They may have a mild laxative effect. The caloric value of maltitol and isomalt is 2.3 kcal\/g. \u003cu\u003eBENAGOL Ginger and Spice flavored tablets\u003c\/u\u003e This medicine contains a flavoring which contains cinnamale, citral, citronellol, eugenol, farfalle, geraniol, isoeugenol and linalool. Cinnamale, citral, citronellol, eugenol, farfalle, geraniol, isoeugenol and linalool can cause allergic reactions. This medicine contains excipients that can cause a warm sensation in the mouth and throat when you suck the lozenge. \u003cu\u003eBENAGOL Honey and Lemon flavored tablets\u003c\/u\u003e This medicine contains a flavoring which contains citral, d-limonene, geraniol and linalool. Citral, d-limonene, geraniol and linalool can cause allergic reactions. This medicine contains honey (invert sugar). Patients suffering from rare hereditary problems of fructose intolerance, or glucose-galactose malabsorption, should not take this medicine. \u003cu\u003eBENAGOL Menthol-Eucalyptol flavor tablets\u003c\/u\u003e This medicine contains a flavoring which contains d-limonene. D-limonene can cause allergic reactions. \u003cu\u003eBENAGOL Orange flavored tablets with Vitamin C\u003c\/u\u003e This medicine contains a flavoring which contains citral, citronellol, d-limonene, geraniol and linalool. Citral, citronellol, d-limonene, geraniol and linalool can cause allergic reactions. This medicine contains 3 mg of propylene glycol per tablet. \u003cu\u003eBENAGOL Lemon flavored tablets without sugar\u003c\/u\u003e This medicine contains a flavoring which contains benzyl alcohol, citral, citronellol, d-limonene, geraniol and linalool. Benzyl alcohol, citral, citronellol, d-limonene, geraniol and linalool can cause allergic reactions. \u003cu\u003eBENAGOL Strawberry flavored tablets without sugar\u003c\/u\u003e This medicine contains a flavoring which contains benzyl alcohol. Benzyl alcohol can cause allergic reactions. This medicine contains 7.30 mg of propylene glycol in each tablet. \u003cu\u003eBENAGOL Cold Mint flavor tablets\u003c\/u\u003e This medicine contains a flavoring which contains benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool. Benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool can cause allergic reactions. This medicine contains 1.89 mg of propylene glycol in each tablet.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cp\u003eA possible overdose could only cause gastrointestinal disorders, for which appropriate symptomatic treatments must be adopted. BENAGOL Menthol-Eucalyptol flavour: in case of accidental oral intake or incorrect administration in infants and children there may be a risk of neurological disorders. If necessary, administer appropriate symptomatic treatment in specialized treatment centers.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cp\u003eNo effects on the ability to drive or use machines are reported.\u003c\/p\u003e\n\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow do you store Benagol 24 sugar-free lemon flavored tablets?\u003c\/h3\u003e\u003cp\u003eDo not store above 25°C.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Benagol 24 sugar-free lemon flavored tablets?\u003c\/h3\u003e\u003cp\u003e24 tablets\u003c\/p\u003e\n\u003ch2\u003eDRUG LEGAL TEXT\u003c\/h2\u003e\n\u003cp\u003eContent responsibility\u003c\/p\u003e\u003cp\u003eThis sheet contains information that is not intended to replace a doctor's diagnosis or advice, as only the doctor can draw up any prescription and give therapeutic indications. All contents must be understood and are of an exclusively informative nature and aimed exclusively at bringing to the attention of customers or potential customers in the pre-purchase phase of the products sold through this site. In case of pathologies, disorders or allergies it is always best to consult your doctor first.\u003c\/p\u003e\u003cp\u003ePlease note\u003c\/p\u003e\u003cp\u003eThe product names, ingredients and percentages indicated in the descriptions are purely indicative and may be subject to changes or updates by the manufacturing companies. Due to the impossibility of adapting to these updates in real time, the photos and technical information of the products included on Dottortili.com may differ from those shown on the label or otherwise disseminated by the manufacturing companies. The only identification element appears to be the ministerial code MINSAN. The online pharmacy Dottortili.com does not guarantee the truthfulness and timeliness of the information published and declines any responsibility for any errors, omissions or failure to update the same. Dottortili.com assumes no responsibility for damages of any nature that may arise from access to the information published.\u003c\/p\u003e\u003cp\u003eData source: Farmadati Italia\u003c\/p\u003e\u003cp\u003eWebsite: www.farmadati.it\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia database is used by almost all pharmacies, parapharmacies, herbalist shops, health shops, large-scale retail trade, computerized doctors, etc. thanks to the guarantee of historical reliability, seriousness and professionalism of the company on the national territory.\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia S.r.l management system complies with the requirements of the UNI EN ISO 9001:2015 standards for quality management systems and UNI CEI ISO\/IEC 27001:2017 for information security management systems.\u003c\/p\u003e","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":51131224326471,"sku":"016242087","price":12.28,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/reckitt-benckiser-h-it-spa-benagol-24-pastiglie-gusto-limone-senza-zucchero-farmacia-dottor-tili-1213792345.jpg?v=1767142809"},{"product_id":"curasept-ads-gel-parodontale-1-30ml","title":"Curasept ADS periodontal gel 1% 30ml","description":"\u003cp\u003eChoose the \u003cstrong\u003eCuraprox CS 1560 Soft Toothbrush\u003c\/strong\u003e for a gentle but effective brushing experience, which respects the health of your gums and helps you maintain a healthy and shining smile every day.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Curasept ADS periodontal gel 1% 30ml contain?\u003c\/h3\u003e\u003cp\u003eAqua, Propylene Glycol, Hydroxypropylcellulose, PVP-VA, PEG-40 Hydrogenated Castor Oil, Chlorhexidine Digluconate, Sodium Acetate, Mentha Piperita Oil, Acetic Acid, Sodium Metabisulfite, Ascorbic Acid.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Curasept ADS periodontal gel 1% 30ml?\u003c\/h3\u003e\u003cp\u003eWash your hands before and after use.\u003cbr\u003eApply a small amount of gel twice a day, for 7-10 days, with a finger or toothbrush. To introduce it into the interdental spaces, soak a brush with gel. In periodontopathic subjects, application in the pockets is recommended.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Curasept ADS periodontal gel 1% 30ml?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWarnings\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003e- keep out of reach of children.\u003cbr\u003e- wash your hands before and after use.\u003cbr\u003e- do not ingest.\u003cbr\u003e- do not use the product after the expiry date indicated on the packaging or if the packaging is not intact.\u003cbr\u003e- store at room temperature.\u003cbr\u003e- do not dispose of the case and\/or contents in the environment.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Curasept ADS periodontal gel 1% 30ml stored?\u003c\/h3\u003e\u003cp\u003eStore at room temperature.\u003cbr\u003eValidity in unopened package: 36 months.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Curasept ADS periodontal gel 1% 30ml?\u003c\/h3\u003e\u003cp\u003e30ml tube.\u003c\/p\u003e","brand":"Curasept","offers":[{"title":"Default Title","offer_id":51131231011143,"sku":"939917795","price":8.93,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/curasept-spa-curasept-ads-gel-parodontale-1-30ml-farmacia-dottor-tili-1213792331.jpg?v=1767143128"},{"product_id":"alovex-protezione-attiva-gel-8ml","title":"Alovex Active Protection Gel 8ml","description":"\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy use Alovex Active Protection gel 8ml? What is it for?\u003c\/h3\u003e\u003cp\u003eGel for oral use that forms a protective film on the lesion, indicated for the protection of canker sores and small abrasions of the oral cavity, even in difficult to reach areas such as the tongue.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Alovex Active Protection gel 8ml contain?\u003c\/h3\u003e\u003cp\u003eWater, polyvinylpyrrolidone, maltodextrin, propylene glycol, ethoxylated hydrogenated castor oil 40 EO, xanthan gum, potassium sorbate, sodium benzoate, hyaluronic acid (sodium salt) *, aroma, benzalkonium chloride, EDTA sodium salt, sodium saccharin, dipotassium glycyrate, aloe vera.\u003c\/p\u003e\u003cp\u003e*hyaluronic acid (sodium salt) with high molecular weight.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Alovex Active Protection gel 8ml?\u003c\/h3\u003e\u003cp\u003eIt is easy to use even in children because it can be applied with one or two drops of gel, in order to cover the entire lesion, avoiding direct contact with the applicator.\u003cbr\u003eIf the lesion is difficult to reach. As in the case of a canker sore on the tongue, the product can be applied with the help of a clean finger or gauze, making sure that the protective film covers the entire surface of the abrasion.\u003cbr\u003eRemember to close the cap after each application and apply the product 3-4 times a day or more as needed.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Alovex Active Protection gel 8ml?\u003c\/h3\u003e\u003cp\u003eValidity with intact packaging: 24 months.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Alovex Active Protection gel 8ml stored?\u003c\/h3\u003e\u003cp\u003eValidity with intact packaging: 24 months.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Alovex Active Protection gel 8ml?\u003c\/h3\u003e\u003cp\u003e8 ml tube.\u003c\/p\u003e","brand":"Recordati","offers":[{"title":"Default Title","offer_id":51131231076679,"sku":"930625203","price":12.65,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/recordati-spa-alovex-protezione-attiva-gel-8ml-farmacia-dottor-tili-1213792330.jpg?v=1767143110"},{"product_id":"aspi-gola-8-75mg-16-pastiglie-gusto-miele-limone","title":"Aspi Gola 8.75mg 16 Honey Lemon Flavored Lozenges","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSymptomatic treatment of irritative-inflammatory conditions also associated with oropharyngeal pain (e.g. gingivitis, stomatitis, pharyngitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not use the medicine in children under 12 years of age. Flurbiprofen is contraindicated in patients with known hypersensitivity to flurbiprofen or to any of the excipients listed in section 6.1. Patients who have previously shown hypersensitivity reactions (e.g. asthma, urticaria, allergy, rhinitis, angioedema, bronchospasm) towards ibuprofen, acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). Flurbiprofen is also contraindicated in patients with a history of gastrointestinal bleeding or perforation related to previous NSAID treatment. Flurbiprofen should not be taken by patients with active or anamnestic ulcerative colitis, Crohn's disease, recurrent peptic ulcer or gastrointestinal haemorrhage (defined as two or more distinct episodes of demonstrated ulceration or bleeding). Flurbiprofen is contraindicated in patients with severe heart failure, severe hepatic failure and renal failure (see section 4.4). Third trimester of pregnancy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAt the recommended doses, when using the medicine in its various pharmaceutical forms, any swallowing does not cause any harm to the patient, as the dose of flurbiprofen is significantly lower than that commonly used in systemic treatments. \u003ci\u003eElderly\u003c\/i\u003e: Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal. \u003ci\u003eRespiratory disorders\u003c\/i\u003e Cases of bronchospasm have been reported with flurbiprofen in patients with a history of bronchial asthma or allergies. Flurbiprofen should be used with caution in these patients. \u003ci\u003eOther NSAIDs\u003c\/i\u003e It is advisable not to combine the medicine with other NSAIDs (see section 4.5). \u003ci\u003eSystemic lupus erythematosus (SLE) and mixed connective tissue disease\u003c\/i\u003e Patients with systemic lupus erythematosus and mixed connective tissue disease may have an increased risk of aseptic meningitis (see section 4.8), however this effect is not usually seen with products intended for limited and short-term use such as flurbiprofen. \u003ci\u003eCardiac, hepatic and renal impairment\u003c\/i\u003e The medicine should be used with caution in patients with cardiac, renal or hepatic insufficiency. NSAIDs have been reported to cause various forms of nephrotoxicity, including interstitial nephritis, nephrotic syndrome, and renal failure. The administration of an NSAID can cause a dose-dependent reduction in the formation of prostaglandins and precipitate renal failure. Patients at highest risk of developing this reaction are those with impaired renal function, cardiac impairment, liver dysfunction, those on diuretic therapy and the elderly; however, this effect is not usually observed with products intended for limited and short-term use such as flurbiprofen. \u003ci\u003eCardiovascular and cerebrovascular effects\u003c\/i\u003e Before starting treatment in patients with a positive history of hypertension and\/or heart failure, caution is required (discuss with your doctor or pharmacist), since fluid retention, hypertension and edema have been reported in association with treatment with NSAIDs. Clinical studies and epidemiological data suggest that the use of some NSAIDs, especially at high doses and for long-term treatments, may be associated with a modest increase in the risk of arterial thrombotic events such as myocardial infarction or stroke. There are insufficient data to exclude a similar risk for flurbiprofen. Patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should be treated with flurbiprofen only after careful consideration. Similar considerations must be made before starting long-term treatment in patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidemia, diabetes mellitus, smoking). \u003ci\u003eEffects on the central nervous system\u003c\/i\u003e Analgesic-induced headache. In case of prolonged or irregular use of analgesics, headache may occur, which must not be treated by increasing the dose of the medicine. \u003ci\u003e \u003cu\u003eGastrointestinal effects\u003c\/u\u003e \u003c\/i\u003e Flurbiprofen should be administered with caution to patients with a history of peptic ulcers and other gastrointestinal diseases as these conditions may be exacerbated. The risk of gastrointestinal bleeding, ulcer or perforation is higher with increasing dosage of flurbiprofen in patients with a history of ulcer, particularly if complicated by bleeding and perforation, and in the elderly. These patients should start treatment with the lowest available dose. Gastrointestinal bleeding, ulcer or perforation have been reported with all NSAIDs at any time during treatment. These adverse reactions can be fatal and can occur with or without warning symptoms or in case of a previous history of serious gastrointestinal reactions. Patients with a history of gastrointestinal disease, especially if elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) in the initial stages of treatment. Undesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.2). Caution should be advised in patients receiving concomitant medicinal products that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking flurbiprofen, treatment should be discontinued. \u003ci\u003eDermatological effects\u003c\/i\u003e The use of the medicine, especially if prolonged, can give rise to sensitization or local irritation phenomena. In such cases it is necessary to interrupt treatment and consult a doctor to institute, if necessary, suitable therapy. Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). Flurbiprofen should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. \u003ci\u003eInfections\u003c\/i\u003e Since isolated cases of exacerbation of inflammation related to infections (e.g. development of necrotizing fasciitis) have been described in temporal association with the systemic use of drugs belonging to the NSAID class, patients are recommended to immediately consult a doctor in case of appearance or worsening of signs of a bacterial infection during flurbiprofen-based therapy. A possible indication for starting antibiotic therapy must be taken into consideration. If mouth irritation develops, treatment should be discontinued. \u003cb\u003eImportant information about some excipients\u003c\/b\u003e ASPI GOLA Lemon and Honey flavored lozenges contain glucose. Patients suffering from rare problems of glucose-galactose malabsorption should not take this medicine. ASPI GOLA Lemon and Honey flavored lozenges contain sucrose. Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine. Do not use for prolonged treatments beyond 7 days. If you do not notice appreciable results after 3 days of treatment, the cause could be a different pathological condition. In these cases it is advisable to consult your doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCaution should be exercised in patients treated with any of the medicines listed below, as interactions have been reported in some patients. However, inform your doctor if you are taking other medicines. Flurbiprofen should be avoided in association with: - \u003ci\u003eAcetylsalicylic acid\u003c\/i\u003e: unless the intake of acetylsalicylic acid in low doses (not exceeding 100 mg\/day or local prophylactic doses for cardiovascular protection) has been recommended by the doctor; As with other medicinal products containing NSAIDs, concomitant administration of flurbiprofen and acetylsalicylic acid is generally not recommended due to the potential for increased side effects (see section 4.4). - \u003ci\u003eCox-2 inhibitors and other NSAIDs\u003c\/i\u003e: Concomitant use of other NSAIDs, including selective cyclooxygenase-2 inhibitors, should be avoided due to potential additive effects and an increased risk of adverse reactions (see section 4.4)\u003ci\u003e.\u003c\/i\u003e Flurbiprofen should be used with caution in association with: - \u003ci\u003eAnticoagulants:\u003c\/i\u003e NSAIDs may potentiate the effects of anticoagulants such as warfarin (see section 4.4). - \u003ci\u003eAntiplatelet agents\u003c\/i\u003e: increased risk of gastrointestinal bleeding. - \u003ci\u003eSelective serotonin reuptake inhibitors (SSRIs)\u003c\/i\u003e: increased risk of gastrointestinal bleeding. - \u003ci\u003eAntihypertensives (diuretics, ACE inhibitors and angiotensin II antagonists)\u003c\/i\u003e: NSAIDs can reduce the effect of diuretics. Other antihypertensive drugs may potentiate nephrotoxicity caused by cyclooxygenase inhibition, especially in patients with impaired renal function (these patients must be adequately hydrated). - \u003ci\u003eAlcohol\u003c\/i\u003e: may increase the risk of adverse reactions, especially bleeding in the gastrointestinal tract. - \u003ci\u003eCardiac glycosides\u003c\/i\u003e: NSAIDs can exacerbate heart failure, reduce VGR (glomerular filtration rate) and increase plasma levels of glycosides. - \u003ci\u003eCyclosporine\u003c\/i\u003e: increased risk of nephrotoxicity. - \u003ci\u003eCorticosteroids\u003c\/i\u003e: increased risk of gastrointestinal ulcer or haemorrhage with NSAIDs (see section 4.4). - \u003ci\u003eLithium:\u003c\/i\u003e there is evidence for a possible increase in plasma lithium levels. - \u003ci\u003eMethotrexate\u003c\/i\u003e: There may be an increase in plasma levels of methotrexate. - \u003ci\u003eMifepristone\u003c\/i\u003e: NSAIDs should not be used for 8-12 days after administration of mifepristone, as NSAIDs may reduce the effect of mifepristone. - \u003ci\u003eQuinolone antibiotics\u003c\/i\u003e: Animal data indicate that NSAIDs may increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing seizures. - \u003ci\u003eTacrolimus\u003c\/i\u003e: possible increased risk of nephrotoxicity when NSAIDs are administered together with tacrolimus. - \u003ci\u003eZidovudine\u003c\/i\u003e: Increased risk of haematological toxicity when NSAIDs are administered with zidovudine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity reactions to NSAIDs have been reported and these may consist of: (a) non-specific allergic reactions and anaphylaxis (b) respiratory tract reactivity, e.g. asthma, aggravated asthma, bronchospasm, dyspnoea (c) various skin disorders, including for example skin rashes of different types, pruritus, urticaria, purpura, angioedema and, more rarely, exfoliative and bullous dermatosis (including necrolysis epidermal and erythema multiforme). The most commonly observed adverse reactions are gastrointestinal in nature. Local use of the medicine, especially if prolonged, can give rise to local sensitization or irritation phenomena. The dissolution of the medicine in tablet form in the oral cavity may be accompanied by sensations of heat or tingling in the oropharynx. In such cases it is necessary to interrupt treatment and institute, if necessary, suitable therapy. The following side effects have been reported, particularly after the administration of formulations for systemic use. They refer to those detected with the use of flurbiprofen used short term and at doses compatible with the classification of self-medication medicines. When treating chronic conditions and for long periods of time, additional side effects may occur. The side effects associated with the use of flurbiprofen are divided below based on system organ classification and frequency. Frequency is defined as: very common (≥ 1\/10), common (≥1\/100, \u003c1\/10), uncommon (≥1\/1,000, \u003c1\/100), rare (≥1\/10,000, \u003c1\/1,000), very rare (\u003c1\/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eClassification by systems and organs\u003c\/b\u003e | \u003cb\u003eFrequency\u003c\/b\u003e | \u003cb\u003eAdverse reactions\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003ePathologies of the blood and lymphatic system | Not known | Anemia, thrombocytopenia, aplastic anemia and agranulocytosis\u003c\/p\u003e\n\u003cp\u003eNervous system disorders | Municipality | Dizziness, headache, paraesthesia\u003c\/p\u003e\n\u003cp\u003eUncommon | Drowsiness\u003c\/p\u003e\n\u003cp\u003eNot known | Cerebrovascular accidents, optic neuritis, migraine, confusional states, dizziness\u003c\/p\u003e\n\u003cp\u003eImmune system disorders | Rare | Anaphylactic reactions\u003c\/p\u003e\n\u003cp\u003eNot known | Angioedema, hypersensitivity\u003c\/p\u003e\n\u003cp\u003eEye diseases | Not known | Visual disturbances\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders | Not known | Tinnitus\u003c\/p\u003e\n\u003cp\u003eCardiac disorders | Not known | Heart failure, edema\u003c\/p\u003e\n\u003cp\u003eVascular pathologies | Not known | Hypertension\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders | Municipality | Throat irritation\u003c\/p\u003e\n\u003cp\u003eUncommon | Asthma, bronchospasm and dyspnea, blisters in the oropharynx, oropharyngeal hypoesthesia\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders | Municipality | Diarrhoea, mouth ulcers, nausea, oral pain, oral paraesthesia, oropharyngeal pain, oral discomfort (hot or burning sensation, tingling in the mouth)\u003c\/p\u003e\n\u003cp\u003eUncommon | Abdominal distension, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, glossodynia, dysgeusia, oral dysesthesia, vomiting\u003c\/p\u003e\n\u003cp\u003eNot known | Melena, haematemesis, gastrointestinal haemorrhage, colitis, exacerbation of Crohn's disease, gastritis, peptic ulcer, gastric perforation, ulcer haemorrhage\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders | Uncommon | Rash, itching\u003c\/p\u003e\n\u003cp\u003eNot known | Urticaria, purpura, bullous dermatitis (including Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis and Erythema multiforme)\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders | Not known | Nephrotoxicity, tubulointerstitial nephritis and nephrotic syndrome, renal failure (as with other NSAIDs)\u003c\/p\u003e\n\u003cp\u003eSystemic disorders and conditions relating to the administration site | Uncommon | Pyrexia, pain\u003c\/p\u003e\n\u003cp\u003eNot known | Discomfort, fatigue\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders | Not known | Hepatitis\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders | Uncommon | Insomnia\u003c\/p\u003e\n\u003cp\u003eNot known | Depression, hallucination\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eReporting of suspected adverse reactions. \u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetti-reazione-avversa.\u003c\/p\u003e","brand":"Bayer","offers":[{"title":"Default Title","offer_id":51131266040135,"sku":"041513033","price":9.63,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/bayer-spa-aspi-gola-8-75mg-16-pastiglie-gusto-miele-limone-farmacia-dottor-tili-1213792279.jpg?v=1767133110"},{"product_id":"benactiv-gola-0-25-spray-per-mucosa-orale-15ml","title":"Benactiv Gola 0.25% spray for oral mucosa 15ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e Symptomatic treatment of irritative-inflammatory states also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy. \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e Symptomatic treatment of irritative-inflammatory conditions also associated with oropharyngeal pain (e.g. gingivitis, stomatitis, pharyngitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not use the medicine in children under 12 years of age. Flurbiprofen is contraindicated in patients with known hypersensitivity to flurbiprofen or to any of the excipients listed in section 6.1. Patients who have previously shown hypersensitivity reactions (e.g. asthma, urticaria, allergy, rhinitis, angioedema, bronchospasm) towards ibuprofen, acetylsalicylic acid (aspirin) or other non-steroidal anti-inflammatory drugs (NSAIDs). Flurbiprofen is also contraindicated in patients with a history of gastrointestinal bleeding or perforation related to previous NSAID treatment. Flurbiprofen should not be taken by patients with active or anamnestic ulcerative colitis, Crohn's disease, recurrent peptic ulcer or gastrointestinal haemorrhage (defined as two or more distinct episodes of demonstrated ulceration or bleeding). Flurbiprofen is contraindicated in patients with severe heart failure, severe hepatic failure and renal failure (see section 4.4). Third trimester of pregnancy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAt the recommended doses, when using the medicine in its various pharmaceutical forms, any swallowing does not cause any harm to the patient, as the dose of flurbiprofen is significantly lower than that commonly used in systemic treatments. Elderly: Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal haemorrhage and perforation, which may be fatal. \u003ci\u003eRespiratory disorders \u003c\/i\u003e Cases of bronchospasm have been reported with flurbiprofen in patients with a history of bronchial asthma or allergies. Flurbiprofen should be used with caution in these patients. \u003ci\u003eOther NSAIDs \u003c\/i\u003e It is advisable not to combine the medicine with other NSAIDs (see section 4.5). \u003ci\u003eSystemic lupus erythematosus (SLE) and mixed connective tissue disease \u003c\/i\u003e Patients with systemic lupus erythematosus and mixed connective tissue disease may have an increased risk of aseptic meningitis (see section 4.8), however this effect is not usually seen with products intended for limited and short-term use such as flurbiprofen. \u003ci\u003eCardiac, hepatic and renal impairment \u003c\/i\u003e The medicine should be used with caution in patients with cardiac, renal or hepatic insufficiency. NSAIDs have been reported to cause various forms of nephrotoxicity, including interstitial nephritis, nephrotic syndrome, and renal failure. The administration of an NSAID can cause a dose-dependent reduction in the formation of prostaglandins and precipitate renal failure. Patients at highest risk of developing this reaction are those with impaired renal function, cardiac impairment, liver dysfunction, those on diuretic therapy and the elderly; however, this effect is not usually observed with products intended for limited and short-term use such as flurbiprofen. \u003ci\u003eCardiovascular and cerebrovascular effects \u003c\/i\u003e Before starting treatment in patients with a positive history of hypertension and\/or heart failure, caution is required (discuss with your doctor or pharmacist), since fluid retention, hypertension and edema have been reported in association with treatment with NSAIDs. Clinical studies and epidemiological data suggest that the use of some NSAIDs, especially at high doses and for long-term treatments, may be associated with a modest increase in the risk of arterial thrombotic events such as myocardial infarction or stroke. There are insufficient data to exclude a similar risk for flurbiprofen. Patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should be treated with flurbiprofen only after careful consideration. Similar considerations must be made before starting long-term treatment in patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidemia, diabetes mellitus, smoking). \u003ci\u003eEffects on the central nervous system \u003c\/i\u003e Analgesic-induced headache. In case of prolonged or irregular use of analgesics, headache may occur, which must not be treated by increasing the dose of the medicine. \u003ci\u003eGastrointestinal effects\u003c\/i\u003e Flurbiprofen should be administered with caution to patients with a history of peptic ulcers and other gastrointestinal diseases as these conditions may be exacerbated. The risk of gastrointestinal haemorrhage, ulcer or perforation is higher with increasing dosage of flurbiprofen in patients with a history of ulcer, particularly if complicated by haemorrhage and perforation, and in the elderly. These patients should start treatment with the lowest available dose. Gastrointestinal bleeding, ulcer or perforation have been reported with all NSAIDs at any time during treatment. These adverse reactions can be fatal and can occur with or without warning symptoms or in case of a previous history of serious gastrointestinal reactions. Patients with a history of gastrointestinal disease, especially if elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) in the initial stages of treatment. Undesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.2). Caution should be advised in patients receiving concomitant medicinal products that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking flurbiprofen, treatment should be discontinued. \u003ci\u003eDermatological effects\u003c\/i\u003e The use of the medicine, especially if prolonged, can give rise to sensitization or local irritation phenomena. In such cases it is necessary to interrupt treatment and consult a doctor to institute, if necessary, suitable therapy. Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). Flurbiprofen should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. \u003ci\u003eInfections\u003c\/i\u003e Since isolated cases of exacerbation of inflammation related to infections (e.g. development of necrotizing fasciitis) have been described in temporal association with the systemic use of drugs belonging to the NSAID class, patients are recommended to immediately consult a doctor in case of appearance or worsening of signs of a bacterial infection during flurbiprofen-based therapy. A possible indication for starting antibiotic therapy must be taken into consideration. If mouth irritation develops, treatment should be discontinued. BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain para-hydroxybenzoates which can cause allergic reactions (even delayed). BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain hydrogenated 40-polyoxyethylene castor oil which may cause localized skin reactions. BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain an aroma which in turn contains d-limonene. D-limonene can cause allergic reactions. BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain less than 1 mmol (23mg) sodium per 10 ml dose, i.e. essentially \"sodium-free\". BENACTIV GOLA Lemon and Honey flavored lozenges contain liquid glucose, liquid sucrose and honey (invert sugar). Patients suffering from rare problems of fructose intolerance, glucose-galactose malabsorption or sucrase isomaltase insufficiency should not take this medicine. To be taken into consideration in people with diabetes mellitus: this medicine contains 1.07 g of glucose and 1.41 g of sucrose per tablet. BENACTIV GOLA Lemon and Honey flavored lozenges contain sulphites. Rarely it can cause serious hypersensitivity reactions and bronchospasm. BENACTIV GOLA Lemon and Honey flavored lozenges contain only a very small amount of gluten (from wheat starch). This medicine is considered “gluten-free” and is very unlikely to cause problems for a celiac patient. One tablet contains no more than 21.38 micrograms of gluten. If a patient is allergic to wheat (condition other than celiac disease) he or she should not take this medicine. BENACTIV THROAT Lemon and Honey flavored lozenges contain an aroma which in turn contains citral, citronellol, d-limonene, farfalle, geraniol and linalool. Citral, citronellol, d-limonene, farinasol, geraniol and linalool can cause allergic reactions. BENACTIV THROAT Lemon and Honey flavored lozenges contain an aroma which in turn contains butylated hydroxyanisole which can cause localized skin reactions (e.g. contact dermatitis) or irritation to the eyes and mucous membranes. BENACTIV GOLA Sugar-Free Lozenges Orange flavor is instead indicated for those patients who need to control their intake of sugars and calories. BENACTIV GOLA Orange flavored sugar-free lozenges contain an aroma which in turn contains citral, citronellol, d-limonene, geraniol and linalool. Citral, citronellol, d-limonene, geraniol and linalool can cause allergic reactions. BENACTIV GOLA Orange flavored sugar-free lozenges contain liquid maltitol and isomalt. Patients with rare hereditary problems of fructose intolerance should not take this medicine. May have a mild laxative effect. The caloric value of maltitol and isomalt is 2.3 kcal\/g. Do not use for prolonged treatments beyond 7 days. If you do not notice appreciable results after 3 days of treatment, the cause could be a different pathological condition. In these cases it is advisable to consult your doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCaution should be exercised in patients treated with any of the medicines listed below, as interactions have been reported in some patients. However, inform your doctor if you are taking other medicines. Flurbiprofen should be avoided in association with: - Aspirin: unless the intake of low-dose aspirin (not exceeding 100 mg\/day or local prophylactic doses for cardiovascular protection) has been recommended by the doctor; As with other NSAID-containing medicinal products, concomitant administration of flurbiprofen and aspirin is generally not recommended due to the potential for increased side effects (see section 4.4). - Cox-2 inhibitors and other NSAIDs: concomitant use of other NSAIDs, including selective cyclooxygenase-2 inhibitors, should be avoided due to potential additive effects and an increased risk of adverse reactions (see section 4.4). Flurbiprofen should be used with caution in association with: - Anticoagulants: NSAIDs can potentiate the effects of anticoagulants such as warfarin (see section 4.4) - Antiaggregating agents: increased risk of gastrointestinal bleeding - Selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding - Antihypertensives (diuretics, ACE inhibitors and angiotensin II antagonists): i NSAIDs can reduce the effect of diuretics. Other antihypertensive drugs may potentiate nephrotoxicity caused by inhibition of cyclooxygenase, especially in patients with impaired renal function (these patients must be adequately hydrated) - Alcohol: may increase the risk of adverse reactions, especially bleeding in the gastrointestinal tract - Cardiac glycosides: NSAIDs may exacerbate heart failure, reduce GFR (glomerular filtration rate) and increase plasma levels of glycosides - Cyclosporine: increased risk of nephrotoxicity - Corticosteroids: increased risk of gastrointestinal ulcer or haemorrhage with NSAIDs (see section 4.4) - Lithium: there is evidence for a possible increase in plasma lithium levels - Methotrexate: there may be an increase in plasma levels of methotrexate - Mifepristone: NSAIDs should not be used for 8-12 days after administration of mifepristone, as NSAIDs may reduce the effect of mifepristone - Quinolone antibiotics: data obtained in animals indicate that NSAIDs may increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing seizures - Tacrolimus: possible increased risk of nephrotoxicity when NSAIDs are administered together with tacrolimus - Zidovudine: increased risk of haematological toxicity when NSAIDs are administered with zidovudine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity reactions to NSAIDs have been reported and these may consist of: (a) non-specific allergic reactions and anaphylaxis (b) respiratory tract reactivity, e.g. asthma, aggravated asthma, bronchospasm, dyspnoea (c) various skin disorders, including for example skin rashes of different types, pruritus, urticaria, purpura, angioedema and, more rarely, exfoliative and bullous dermatosis (including necrolysis epidermal and erythema multiforme). The most commonly observed adverse reactions are gastrointestinal in nature. Local use of the medicine, especially if prolonged, can give rise to local sensitization or irritation phenomena. The dissolution of the medicine in tablet form in the oral cavity may be accompanied by sensations of heat or tingling in the oropharynx. In such cases it is necessary to interrupt treatment and institute, if necessary, suitable therapy. The following side effects have been reported, particularly after the administration of formulations for systemic use. They refer to those detected with the use of flurbiprofen used short term and at doses compatible with the classification of self-medication medicines. When treating chronic conditions and for long periods of time, additional side effects may occur. The side effects associated with the use of flurbiprofen are divided below based on system organ classification and frequency. Frequency is defined as: very common (≥ 1\/10), common (≥1\/100, \u003c1\/10), uncommon (≥1\/1,000, \u003c1\/100), rare (≥1\/10,000, \u003c1\/1,000), very rare (\u003c1\/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eClassification by systems and organs\u003c\/b\u003e | \u003cb\u003eFrequency\u003c\/b\u003e | \u003cb\u003eAdverse reactions\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003ePathologies of the blood and lymphatic system | Not known | Anemia, thrombocytopenia, aplastic anemia and agranulocytosis\u003c\/p\u003e\n\u003cp\u003ePathologies of the nervous system | Municipality | Dizziness, headache, paraesthesia\u003c\/p\u003e\n\u003cp\u003eUncommon | Drowsiness\u003c\/p\u003e\n\u003cp\u003eNot known | Cerebrovascular accident, optic neuritis, migraine, confusional states, dizziness\u003c\/p\u003e\n\u003cp\u003eDisorders of the immune system | Rare | Anaphylactic reaction\u003c\/p\u003e\n\u003cp\u003eNot known | Angioedema, hypersensitivity\u003c\/p\u003e\n\u003cp\u003eEye diseases | Not known | Vision impairment\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders | Not known | Tinnitus\u003c\/p\u003e\n\u003cp\u003eCardiac disorders | Not known | Heart failure, edema\u003c\/p\u003e\n\u003cp\u003eVascular pathologies | Not known | Hypertension\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders | Municipality | Throat irritation\u003c\/p\u003e\n\u003cp\u003eUncommon | Asthma, bronchospasm and dyspnea, oropharyngeal vesicular rash, oropharyngeal hypoesthesia\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders | Municipality | Diarrhoea, mouth ulceration, nausea, oral pain, oral paraesthesia, oropharyngeal pain, oral discomfort (hot or burning sensation, tingling in the mouth)\u003c\/p\u003e\n\u003cp\u003eUncommon | Abdominal distension, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, glossodynia, dysgeusia, oral dysesthesia, vomiting\u003c\/p\u003e\n\u003cp\u003eNot known | Melena, haematemesis, gastrointestinal haemorrhage, colitis, exacerbation of Crohn's disease, gastritis, peptic ulcer, gastric perforation, ulcer haemorrhage\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders | Uncommon | Skin rash, itching\u003c\/p\u003e\n\u003cp\u003eNot known | Urticaria, purpura, bullous dermatitis (including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme)\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders | Not known | Toxic nephropathy, tubulointerstitial nephritis and nephrotic syndrome, renal failure (as with other NSAIDs)\u003c\/p\u003e\n\u003cp\u003eSystemic disorders and conditions relating to the administration site | Uncommon | Pyrexia, pain\u003c\/p\u003e\n\u003cp\u003eNot known | Discomfort, tiredness\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders | Not known | Hepatitis\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders | Uncommon | Insomnia\u003c\/p\u003e\n\u003cp\u003eNot known | Depression, hallucination\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":51131271971143,"sku":"033262041","price":11.63,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/reckitt-benckiser-h-it-spa-benactiv-gola-0-25-spray-per-mucosa-orale-15ml-farmacia-dottor-tili-1213792265.jpg?v=1767133307"},{"product_id":"corsodyl-1g-100g-gel-dentale-30g","title":"Corsodyl 1g\/100g dental gel 30g","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDisinfectant action of the oral cavity, even before and after tooth extractions or minor operations. Anti-plaque action, adjuvant in the prevention of gingivitis and periodontitis secondary to the formation of dental plaque. Protective action against infections in wearers of fixed or removable prostheses, for its antiseptic activity on teeth and gums.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not exceed the indicated doses. Avoid contact with eyes and ears. If the product comes into contact with your eyes or ears, wash promptly with water. The product is for external oral use only; do not ingest. If you experience pain, swelling or irritation in your mouth, stop treatment and consult your doctor or dentist. If you experience a rash, swelling or difficulty breathing, discontinue use of the product and contact a doctor immediately. Initially, transient changes in taste and transient sensations of numbness, tingling or burning of the tongue may occur. These effects usually diminish with continued use. If they persist, consult your doctor or dentist. The use, especially prolonged, of products for topical use can give rise to sensitization phenomena; in this case, stop treatment and consult your doctor to institute suitable therapy. Do not use for prolonged treatments; after a short period of treatment without appreciable results, consult your doctor. Chlorhexidine gluconate can cause surface discoloration of the tongue, teeth and some materials used for fillings and dentures. The stains are not permanent and can largely be prevented by reducing the consumption of food chromogens, such as tea, coffee and red wine. As regards teeth and orthodontic material, this staining can be prevented with the daily use of a common toothpaste or before the use of Corsodyl solution, spray for oral mucosa and dental gel, taking care to rinse the mouth with water in the interval between the two treatments, or at another time of the day. These precautions are necessary as chlorhexidine gluconate is incompatible with anionic compounds generally found in common toothpastes. In some cases, the coloring can be eliminated by resorting to professional cleaning. In the case of anterior prostheses and fillings that have infiltrated edges and\/or rough surfaces, the pigmentation could remain even after professional cleaning. A professional cleaning intervention may be required following treatments such as jaw fixation or application of orthodontic appliances which have not made it possible to carry out normal mechanical oral hygiene (e.g. brushing). \u003cb\u003eImportant information about some excipients\u003c\/b\u003e CORSODYL oral mucosa solution, oral mucosa spray and dental gel contain hydrogenated polyoxyethylene-castor oil which may cause localized skin reactions. CORSODYL solution and spray for oral mucosa contain mint essence, an aroma which in turn contains d-limonene, eugenol and linalool, which may cause allergic reactions. CORSODYL dental gel contains mint essence, an aroma which itself contains d-limonene which can cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known clinically significant interactions with other drugs. Avoid the simultaneous use of other antiseptics.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUndesirable effects arising from clinical trial data and post-marketing data are listed below by system organ class and frequency. Frequencies are defined as: very common (≥1\/10), common (≥1\/100, \u003c1\/10), uncommon (≥1\/1000, \u003c1\/100), rare (≥1\/10000, \u003c1\/1000), very rare (\u003c1\/10000), frequency not known (cannot be estimated from the available data). \u003ci\u003eData from clinical studies\u003c\/i\u003e \u003cu\u003eGastrointestinal disorders\u003c\/u\u003e. Very common: coated tongue; Common: dry mouth. \u003cu\u003eNervous system disorders\u003c\/u\u003e. Common: ageusia\/dysgeusia, glossodynia, paraesthesia\/hypoesthesia of the oral cavity. \u003ci\u003ePost-marketing data\u003c\/i\u003e \u003cu\u003eGastrointestinal disorders\u003c\/u\u003e. Frequency not known: superficial discoloration of the tongue and teeth (see “Special warnings and precautions for use”), pain\/irritation of the mouth, scaling\/pain\/swelling of the oral mucosa (see “Special warnings and precautions for use”), swelling of the parotid glands. \u003cu\u003ePathologies of the skin and subcutaneous tissue\u003c\/u\u003e. Frequency not known: idiosyncratic skin reactions. \u003cu\u003eImmune system disorders\u003c\/u\u003e. Frequency not known: hypersensitivity, allergic reactions and anaphylaxis (see “Contraindications”, “Special warnings and precautions for use”). The side effects noted are generally mild and local in nature. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at \u003cb\u003eError! Hyperlink reference not valid.\u003c\/b\u003e https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e","brand":"Haleon","offers":[{"title":"Default Title","offer_id":51131278721351,"sku":"014371088","price":13.5,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/haleon-italy-srl-corsodyl-1g-100g-gel-dentale-30g-farmacia-dottor-tili-1213792252.jpg?v=1767133650"},{"product_id":"froben-gola-0-25-collutorio-160ml","title":"Froben Throat 0.25% mouthwash 160ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFroben Gola is indicated for the symptomatic treatment of irritative-inflammatory conditions also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to flurbiprofen or to any of the excipients listed in section 6.1. Froben Gola is also contraindicated in: • patients who have previously experienced hypersensitivity reactions (e.g. asthma, urticaria) after taking aspirin or other NSAIDs. • patients with a history of gastrointestinal bleeding or perforation related to previous treatment with NSAIDs. • patients with active or anamnestic ulcerative colitis, Crohn's disease, recurrent peptic ulcer or gastrointestinal bleeding (defined as two or more distinct episodes of demonstrated ulceration or bleeding). • patients with severe cardiac, renal or hepatic insufficiency (see section 4.4). Froben Gola is contraindicated during the third trimester of pregnancy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eGeneral precautions \u003c\/b\u003e Undesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.2 and the sections below on gastrointestinal and cardiovascular risks). \u003cb\u003eUse in elderly patients \u003c\/b\u003e Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal. \u003cb\u003e \u003ci\u003e \u003cu\u003eGastrointestinal effects \u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Flurbiprofen should be administered with caution to patients with a history of peptic ulcers and other gastrointestinal diseases as these conditions may be exacerbated. Gastrointestinal bleeding, ulcer or perforation have been reported with all NSAIDs at any time during treatment. These adverse events can be fatal and can occur with or without warning symptoms or in case of a previous history of serious gastrointestinal events. The risk of gastrointestinal haemorrhage, ulcer or perforation is higher with increasing dosage of flurbiprofen in patients with a history of ulcer, particularly if complicated by haemorrhage and perforation, and in the elderly. These patients should start treatment with the lowest available dose. Concomitant use of protective agents (misoprostol or proton pump inhibitors) should be considered for these patients and also for patients taking low doses of aspirin or other drugs that may increase the risk of gastrointestinal events (see section below and section 4.5). Patients with a history of gastrointestinal disease, especially if elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) in the initial stages of treatment. When gastrointestinal bleeding or ulceration occurs in patients taking Froben Gola, treatment should be suspended. \u003cb\u003e \u003ci\u003e \u003cu\u003eRespiratory Disorders\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Cases of bronchospasm have been reported with flurbiprofen in patients with a history of bronchial asthma. \u003cb\u003e \u003ci\u003e \u003cu\u003eCardiac, renal and hepatic impairment \u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Particular caution must be taken when treating patients with severely compromised renal, cardiac or hepatic function, as the use of NSAIDs can lead to deterioration of renal function. In such patients the dosage should be kept as low as possible and renal function should be monitored. The administration of an NSAID can cause a dose-dependent reduction in the formation of prostaglandins, accelerating renal failure. Patients at highest risk of developing this reaction are those with impaired kidney function, heart failure and liver dysfunction, those taking diuretics and elderly people. Renal function should be monitored in these patients (see also section 4.3). Flurbiprofen should be administered with caution in patients with a history of heart failure or hypertension as cases of edema have been reported in association with the administration of flurbiprofen. \u003cb\u003e \u003ci\u003e \u003cu\u003eCardiovascular and cerebrovascular effects\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Adequate monitoring and appropriate instructions are necessary in patients with a history of hypertension and\/or mild to moderate congestive heart failure since, in association with the administration of flurbiprofen and treatment with NSAIDs, fluid retention and edema have been found. In these patients Froben Gola should be taken with caution. Clinical studies and epidemiological data suggest that the use of some NSAIDs, especially at high doses and for long-term treatments, may be associated with a modest increase in the risk of arterial thrombotic events such as myocardial infarction or stroke. There are insufficient data to exclude a similar risk for flurbiprofen. Patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should be treated with flurbiprofen only after careful consideration. Similar considerations must be made before starting long-term treatment in patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidemia, diabetes mellitus, smoking). \u003cb\u003e \u003cu\u003eSkin reactions\u003c\/u\u003e \u003c\/b\u003e Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs. In the early stages of therapy, patients appear to be at higher risk: the onset of the reaction occurs in most cases within the first month of treatment. Flurbiprofen should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. \u003cb\u003e \u003ci\u003e \u003cu\u003eRenal effects\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Caution should be used when initiating treatment with NSAIDs such as flurbiprofen in patients with considerable dehydration. \u003cb\u003e \u003ci\u003e \u003cu\u003eHematological effects\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e Flurbiprofen, like other NSAIDs, can inhibit platelet aggregation and prolong bleeding time. \u003cb\u003e \u003ci\u003e \u003cu\u003eSystemic lupus erythematosus (SLE) and connective system diseases\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e An increased risk of aseptic meningitis may occur in patients with Systemic Lupus Erythematosus (SLE) and connective system disorders (see section 4.8). The effects reported above have been reported in particular after the administration of formulations based on Flurbiprofen for systemic use. At the recommended doses, swallowing FROBEN GOLA does not cause any harm to the patient as these doses are significantly lower than those of the single dosage of the product systemically. The use of FROBEN GOLA, especially if prolonged, can give rise to local sensitization or irritation phenomena; in such cases it is necessary to interrupt the treatment and consult the doctor to institute, if necessary, a suitable therapy. Flurbiprofen should not be used for prolonged treatments. It is necessary to inform patients to seek medical advice if after short periods of treatment without appreciable results. \u003cb\u003eImpairment of fertility\u003c\/b\u003e The use of flurbiprofen may impair female fertility and is not recommended in women trying to become pregnant. In women who have difficulty conceiving or who are undergoing infertility investigations, discontinuation of treatment with flurbiprofen should be considered. \u003cb\u003e \u003ci\u003e \u003cu\u003eImportant information about some excipients\u003c\/u\u003e \u003c\/i\u003e \u003c\/b\u003e \u003cu\u003eFROBEN THROAT 250mg\/100ml Mouthwash\u003c\/u\u003e contains: • \u003ci\u003eSorbitol (E420)\u003c\/i\u003e. Patients with hereditary fructose intolerance should not be given this medicine. • \u003ci\u003eEthanol\u003c\/i\u003e. This medicine contains 12 vol% ethanol (alcohol), e.g. up to 1 g per dose, equivalent to 24 ml of beer, 10 ml of wine per dose. It can be harmful to alcoholics. To be taken into consideration in pregnant or breastfeeding women, children and high-risk groups such as people with liver disease or epilepsy. For those who carry out sporting activities, the use of medicines containing ethyl alcohol can lead to positive anti-doping tests in relation to the blood alcohol concentration limits indicated by some sports federations. • \u003ci\u003ePatent blue dye V(E131)\u003c\/i\u003e which can cause allergic reactions. \u003cu\u003eFROBEN THROAT 250mg\/100ml Spray for oral mucosa\u003c\/u\u003e contains: • \u003ci\u003eSorbitol\u003c\/i\u003e. The additive effect of co-administration of medicinal products containing sorbitol (or fructose) and daily dietary intake of sorbitol (or fructose) should be considered. The sorbitol content in oral medicinal products may modify the bioavailability of other co-administered oral medicinal products. • \u003ci\u003eEthanol\u003c\/i\u003e. This medicine contains 12 vol% ethanol (alcohol), e.g. up to 40 mg per dose, equivalent to 1 ml of beer, 0.4 ml of wine per dose. For those who carry out sporting activities, the use of medicines containing ethyl alcohol can lead to positive anti-doping tests in relation to the blood alcohol concentration limits indicated by some sports federations. • \u003ci\u003ePatent blue dye V(E131)\u003c\/i\u003e which can cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCaution should be exercised in patients treated with any of the medicines listed below, as interactions have been reported in some patients. \u003cb\u003eDiuretics, ACE inhibitors and angiotensin II antagonists\u003c\/b\u003e: NSAIDs can reduce the effect of diuretics and other antihypertensive drugs. Diuretics may also increase the risk of NSAID nephrotoxicity. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit the cyclo-oxygenase system may lead to further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking Flurbiprofen concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in elderly patients. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy and on a periodic basis thereafter. \u003cb\u003eLithium salts:\u003c\/b\u003e decrease in lithium elimination. \u003cb\u003eMethotrexate: \u003c\/b\u003ecaution is advised in case of concomitant administration of flurbiprofen and methotrexate as NSAIDs can increase the levels of methotrexate and therefore its toxic effects). \u003cb\u003eAnticoagulants, such as warfarin: \u003c\/b\u003eincreased anticoagulant effect. \u003cb\u003eAnti-aggregating agents:\u003c\/b\u003e increased risk of gastrointestinal bleeding \u003cb\u003eSelective serotonin reuptake inhibitors (SSRIs):\u003c\/b\u003e increased risk of gastrointestinal bleeding. \u003cb\u003eAspirin:\u003c\/b\u003e As with other NSAID-containing medicines, concomitant administration of flurbiprofen and aspirin is generally not recommended due to the potential for increased side effects. \u003cb\u003eCardiac glycosides\u003c\/b\u003e: NSAIDs can exacerbate heart failure, reduce glomerular filtration rate and increase plasma levels of cardiac glycosides. \u003cb\u003eCyclosporins:\u003c\/b\u003e increased risk of nephrotoxicity with NSAIDs. \u003cb\u003eCorticosteroids:\u003c\/b\u003e increased risk of gastrointestinal ulcer or bleeding with NSAIDs. \u003cb\u003eCox-2 inhibitors and other NSAIDs:\u003c\/b\u003e Concomitant use of other NSAIDs, including selective cyclooxygenase-2 inhibitors, should be avoided due to potential additive effects. \u003cb\u003eMifepristone\u003c\/b\u003e: NSAIDs should not be taken for 8-12 days after administration of mifepristone as NSAIDs may reduce the effects of mifepristone. \u003cb\u003eQuinolone Antibiotics: \u003c\/b\u003eResults from animal studies suggest that NSAIDs may increase the risk of seizures associated with the use of quinolone antibiotics. Patients taking NSAIDs and Quinolones may have an increased risk of developing seizures. \u003cb\u003eTacrolimus\u003c\/b\u003e: possible increased risk of nephrotoxicity in case of co-administration with NSAIDs. \u003cb\u003eZidovudine\u003c\/b\u003e: increased risk of blood toxicity in case of co-administration with NSAIDs. There is evidence of an increased risk of haemarthrosis and haematoma in haemophilia patients affected by HIV in simultaneous treatment with Zidovudine and other NSAIDs. The interactions reported above have been reported in particular after the administration of Flurbiprofen-based formulations for systemic use. At the recommended doses of FROBEN GOLA, no interactions with other medicinal products or of any other nature have been reported. However, inform your doctor if you are taking other medicines.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe following adverse reactions, reported in particular after the administration of formulations for systemic use, are reported according to the MedDRA classification. Frequency groupings are classified according to the following convention: very common (≥ 1\/10), Common (≥1\/100 to \u003c1\/10), Uncommon (≥1\/1000 to \u003c1\/100), Rare (≥ 1\/10,000 to \u003c1\/1000), Very rare (\u003c1\/10,000) and Not Known (frequency cannot be estimated).\u003c\/p\u003e\n\u003cp\u003eSystem organ class according to MedDRA | Frequency | Adverse Reaction\u003c\/p\u003e\n\u003cp\u003ePathologies of the blood and lymphatic system | Uncommon | Anemia\u003c\/p\u003e\n\u003cp\u003eVery rare | Leukopenia, agranulocytosis, aplastic anemia, neutropenia, thrombocytopenia, hemolytic anemia.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders | Uncommon | Hypersensitivity\u003c\/p\u003e\n\u003cp\u003eRare | Anaphylactic reaction\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders | Rare | Depression, confusional state\u003c\/p\u003e\n\u003cp\u003eVery rare | Hallucination\u003c\/p\u003e\n\u003cp\u003eNervous System Pathologies | Municipality | Migraine, dizziness\u003c\/p\u003e\n\u003cp\u003eUncommon | Paresthesia\u003c\/p\u003e\n\u003cp\u003eRare | Drowsiness, Insomnia\u003c\/p\u003e\n\u003cp\u003eNot known | Optic neuritis, cerebrovascular accident, headache.\u003c\/p\u003e\n\u003cp\u003eEye diseases | Uncommon | Vision disorders\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders | Uncommon | Tinnitus, vertigo\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders | Uncommon | Asthma, dyspnea\u003c\/p\u003e\n\u003cp\u003eRare | Bronchospasm\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders | Municipality | Dyspepsia, diarrhoea, nausea, vomiting, abdominal pain, flatulence, constipation, melena, haematemesis, gastrointestinal haemorrhage\u003c\/p\u003e\n\u003cp\u003eUncommon | Gastritis, duodenal ulcer, gastric ulcer, mouth ulcer, gastrointestinal perforation\u003c\/p\u003e\n\u003cp\u003eVery rare | Pancreatitis\u003c\/p\u003e\n\u003cp\u003eNot Known | Colitis and Crohn's disease\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders | Very rare | Jaundice, cholestatic jaundice, abnormal liver function\u003c\/p\u003e\n\u003cp\u003eNot known | Hepatitis\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders | Uncommon | Rash, urticaria, pruritus, purpura, angioedema, photosensitivity reactions\u003c\/p\u003e\n\u003cp\u003eVery rare | Severe forms of bullous skin reactions (e.g. Erythema Multiforme, Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis)\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders | Rare | Nephrotoxicity in various forms i.e. interstitial nephritis, nephrotic syndrome, renal failure and acute renal failure. (see paragraph 4.4)\u003c\/p\u003e\n\u003cp\u003eNot known | Glomerulonephritis\u003c\/p\u003e\n\u003cp\u003eSystemic disorders and conditions relating to the administration site | Municipality | Fatigue, malaise, edema\u003c\/p\u003e\n\u003cp\u003eCardiac disorders | Uncommon | Heart failure\u003c\/p\u003e\n\u003cp\u003eVascular pathologies | Uncommon | Hypertension\u003c\/p\u003e\n\u003cp\u003eDiagnostic tests | Municipality | Abnormal liver function test, prolonged bleeding time\u003c\/p\u003e\n\u003cp\u003eMetabolism and nutrition disorders | Municipality | Fluid retention\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eImmune system disorders\u003c\/b\u003e Hypersensitivity reactions have been reported following treatment with NSAIDs. These consist of: a) non-specific allergic reactions and anaphylaxis; b) reactions affecting the respiratory tract including asthma, even severe, bronchospasm or dyspnoea, or c) various skin disorders, such as various types of skin rashes, itching, urticaria, purpura, angioedema and, very rarely, exfoliative and bullous dermatitis (including Toxic Epidermal Necrolysis and erythema multiforme). \u003cb\u003eCardiac and vascular pathologies\u003c\/b\u003e Cases of edema, hypertension and heart failure have been reported in association with treatment with NSAIDs. Clinical studies and epidemiological data suggest that the intake of some NSAIDs (especially if at high doses and in case of long-term treatment) may be associated with an increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4).\u003cb\u003eNervous System Pathologies \u003c\/b\u003e Aseptic meningitis (especially in patients with existing autoimmune disorders such as Systemic Lupus Erythematosus and connective tissue disorders) with symptoms such as stiff neck, headache, nausea, vomiting, fever or disorientation (see section 4.4). \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetti-reazione-avversa.\u003c\/p\u003e","brand":"Viatris Healthcare","offers":[{"title":"Default Title","offer_id":51131281670471,"sku":"042822015","price":12.56,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/viatris-italia-srl-froben-gola-0-25-collutorio-160ml-farmacia-dottor-tili-1213792246.jpg?v=1767133769"},{"product_id":"oki-gola-1-6-collutorio-150ml","title":"Oki Gola 1.6% mouthwash 150ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSymptomatic treatment of irritative-inflammatory conditions also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients, listed in paragraph 6.1. Individual hypersensitivity in subjects in whom the use of other non-steroidal anti-inflammatory drugs has caused allergic reactions such as asthma, urticaria or rhinitis. During pregnancy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use of topical drugs, especially if prolonged, could give rise to sensitization phenomena, in which case it is necessary to suspend the treatment and adopt suitable therapeutic measures. In prolonged and high-dose therapies, keep in mind the possibility of competition between absorbed ketoprofen and other drugs with high binding to plasma proteins. This medicine contains methyl parahydroxybenzoate, known to cause allergic reactions (including delayed reactions). This medicine contains mint flavouring, which in turn contains d-Limonene and linalool which may cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAt present, no negative interactions with other drugs have emerged.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal irritation phenomena and angioneurotic edema have been reported, especially in subjects with hypersensitivity to NSAIDs, with very rare frequency. There are no known systemic side effects. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e","brand":"Dompé","offers":[{"title":"Default Title","offer_id":51131293991239,"sku":"041797010","price":11.44,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/dompe-farmaceutici-spa-oki-gola-1-6-collutorio-150ml-farmacia-dottor-tili-1213792218.jpg?v=1767134290"},{"product_id":"alovex-protezione-attiva-collutorio-120ml","title":"Alovex Active Protection Mouthwash 120ml","description":"\u003cp\u003eThe \u003cstrong\u003eAlovex Active Protection mouthwash 120ml\u003c\/strong\u003e is a medical device designed to offer immediate relief and protection in case of canker sores, aphthous stomatitis and other irritations of the oral cavity. Thanks to its advanced formulation, this mouthwash forms a \u003cstrong\u003eprotective film\u003c\/strong\u003e which isolates the lesions from contact with external agents, reducing pain and promoting healing. It is particularly suitable for those suffering from injuries caused by orthodontic braces, dental prosthetics or accidental bites.\u003c\/p\u003e\n\n\u003cp\u003eThe presence of \u003cstrong\u003eAloe Vera\u003c\/strong\u003e and high molecular weight hyaluronic acid helps to soothe and hydrate the oral mucosa, while its mechanical action guarantees effective protection without burning. The product is alcohol-free, making it also suitable for children and those with particular sensitivities. Its pleasant aroma and ease of use make it an ideal ally for daily oral hygiene, improving comfort during meals and conversation.\u003c\/p\u003e\n\n\u003cp\u003eThe \u003cstrong\u003eAlovex Active Protection mouthwash 120ml\u003c\/strong\u003e it is harmless if accidentally ingested, offering additional safety for the whole family. Its formulation was developed to guarantee an effective and delicate treatment, ideal for those looking for a quick and safe remedy against annoying mouth lesions.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy use Alovex Active Protection mouthwash 120ml? What is it for?\u003c\/h3\u003e\u003cp\u003eMouthwash, medical device indicated for the relief and protection in case of canker sores, aphthous stomatitis and other irritations of the oral cavity; it forms a protective film that isolates the lesions, reducing pain and promoting healing, also being useful in the case of injuries from orthodontic appliances or dental prostheses.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Alovex Active Protection mouthwash 120ml contain?\u003c\/h3\u003e\u003cp\u003eWater, polyvinylpyrrolidone, maltodextrin, propylene glycol, aloe vera, potassium sorbate, sodium benzoate, hydroxycellulose, ethoxylated hydrogenated castor oil 40 EO, EDTA sodium salt, benzalkonium chloride, hyaluronic acid (sodium salt) *, flavouring, sodium saccharin, dipotassium glycyrrhizate.\u003c\/p\u003e\u003cp\u003e*hyaluronic acid (sodium salt) with high molecular weight.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Alovex Active Protection mouthwash 120ml?\u003c\/h3\u003e\u003cp\u003eIt is a ready-to-use remedy, to be used 10 ml 3-4 times a day, or more as needed, using the special glass contained in the package. Rinse for at least one minute.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Alovex Active Protection mouthwash 120ml?\u003c\/h3\u003e\u003cp\u003eValidity with intact packaging: 24 months.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Alovex Active Protection mouthwash 120ml stored?\u003c\/h3\u003e\u003cp\u003eValidity with intact packaging: 24 months.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Alovex Active Protection mouthwash 120ml?\u003c\/h3\u003e\u003cp\u003e120 ml bottle with measuring cup.\u003c\/p\u003e","brand":"Recordati","offers":[{"title":"Default Title","offer_id":51131303821639,"sku":"930624301","price":12.65,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/recordati-spa-alovex-protezione-attiva-collutorio-120ml-farmacia-dottor-tili-1213792165.jpg?v=1767134748"},{"product_id":"neo-borocillina-gola-dolore-8-75mg-16-pastiglie-senza-zucchero-gusto-menta","title":"Neo Borocillina Gola Dolore 8.75mg 16 sugar-free mint-flavored tablets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNEO BOROCILLINA THROAT PAIN mouthwash \/ NEO BOROCILLINA THROAT PAIN spray for oral mucosa is used in the symptomatic treatment of irritative-inflammatory conditions also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy. NEO BOROCILLINA THROAT PAIN tablets are used in the symptomatic treatment of irritative-inflammatory states also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFlurbiprofen is contraindicated in patients with hypersensitivity (asthma, bronchospasm, urticaria or allergic type) towards flurbiprofen or to any of the excipients, and towards acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). Third trimester of pregnancy. The administration of flurbiprofen is not recommended in breastfeeding mothers. Do not use in patients who have peptic ulcers or who have had them in the past. \u003ci\u003e \u003cu\u003eDo not give the tablets to children under the age of 12\u003c\/u\u003e \u003c\/i\u003e \u003ci\u003e \u003cu\u003eyears.\u003c\/u\u003e \u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAt the recommended doses, when using the medicine in its various pharmaceutical forms, any swallowing does not, in itself, cause any harm to the patient, as these doses are widely lower than those commonly used in treatments with flurbiprofen systemically. In patients with renal, cardiac or hepatic insufficiency, the medicine NEO BOROCILLINA THROAT PAIN should be used with caution. It is recommended not to combine the medicine with NSAIDs. Use of the product, especially if prolonged, can give rise to local sensitization or irritation phenomena; in such cases it is necessary to interrupt the treatment and consult the doctor to institute, if necessary, a suitable therapy. Do not use for prolonged treatments. After a short period of treatment without appreciable results, consult your doctor. \u003cb\u003eNEO BOROCILLINA THROAT PAIN mouthwash and NEO BOROCILLINA THROAT PAIN spray for oral mucosa (all presentations) contain:\u003c\/b\u003e - 960 mg of ethanol per 10 ml of mouthwash. May cause burning sensation on damaged skin. - hydrogenated polyoxide castor oil which may cause localized skin reactions. - parahydroxy benzoates which can cause allergic reactions (even delayed). NEO BOROCILLINA THROAT PAIN 0.25% spray for oral mucosa orange and honey flavor and NEO BOROCILLINA THROAT PAIN 0.25% spray for oral mucosa lemon and honey flavor also contain the coloring sunset yellow (E110), which can cause allergic reactions.NEO BOROCILLINA THROAT PAIN 8.75 mg lozenges (all presentations) contains isomalt: patients suffering from rare hereditary problems of intolerance to fructose, you should not take this medicine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHowever, inform your doctor if you are taking other medicines. As demonstrated in some clinical studies, flurbiprofen may occasionally reduce the diuretic activity of furosemide. Furthermore, flurbiprofen may occasionally interfere with the action of anticoagulant drugs. However, no interaction of flurbiprofen with digoxin, tolbutamide and antacids has been demonstrated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use of NEO BOROCILLINA THROAT PAIN, especially if prolonged, can give rise to sensitization or local irritation phenomena; in such cases it is necessary to interrupt the treatment and institute, if necessary, a suitable therapy. The following side effects have been reported, particularly after the administration of higher doses systemically: \u003ci\u003e \u003cu\u003ePathologies of the blood and lymphatic system\u003c\/u\u003e \u003c\/i\u003e Thrombocytopenia, aplastic anemia and agranulocytosis. \u003ci\u003e \u003cu\u003eImmune system disorders\u003c\/u\u003e \u003c\/i\u003e Anaphylaxis, angioedema, allergic reaction. \u003ci\u003e \u003cu\u003eNervous system disorders\u003c\/u\u003e \u003c\/i\u003e Dizziness, cerebrovascular accident, visual disturbances, optic neuritis, migraine, paraesthesia, depression, confusion, hallucination, vertigo, discomfort, fatigue and drowsiness. \u003ci\u003e \u003cu\u003eEar and labyrinth disorders\u003c\/u\u003e \u003c\/i\u003e Tinnitus. \u003ci\u003e \u003cu\u003eRespiratory, thoracic and mediastinal disorders\u003c\/u\u003e \u003c\/i\u003e Reactivity of the respiratory tract (asthma, bronchospasm and dyspnea). \u003ci\u003e \u003cu\u003eGastrointestinal disorders\u003c\/u\u003e \u003c\/i\u003e The most commonly observed adverse events are gastrointestinal in nature. The following have been reported after administration of flurbiprofen: nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melena, haematemesis, ulcerative stomatitis, gastrointestinal haemorrhage and exacerbation of colitis and Crohn's disease. Less frequently, gastritis, peptic ulcer, perforation and ulcer bleeding have been observed. \u003ci\u003e \u003cu\u003ePathologies of the skin and subcutaneous tissue\u003c\/u\u003e \u003c\/i\u003e Skin disorders including rash, pruritus, urticaria, purpura and very rarely bullous dermatoses (including Stevens-Johnson syndrome, Toxic Epidermal Necrolysis and Erythema multiforme). \u003ci\u003e \u003cu\u003eRenal and urinary disorders\u003c\/u\u003e \u003c\/i\u003e Nephrotoxicity in various forms, including interstitial nephritis and nephrotic syndrome. As with other NSAIDs, rare cases of renal failure have been reported. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/p\u003e","brand":"Alfasigma","offers":[{"title":"Default Title","offer_id":51131307360583,"sku":"035760040","price":10.42,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/alfasigma-spa-neo-borocillina-gola-dolore-8-75mg-16-pastiglie-senza-zucchero-gusto-menta-farmacia-dottor-tili-1213792156.jpg?v=1767135047"},{"product_id":"curasept-gel-parodontale-0-5-ads-dna-30mlo","title":"Curasept periodontal gel 0.5% ADS + DNA 30ml","description":"\u003cp\u003eThe \u003cstrong\u003eCurasept periodontal gel 0.5% ADS + DNA 30ml\u003c\/strong\u003e is an advanced topical gum treatment, designed to offer effective protection against plaque and support gum health. Formulated with \u003cstrong\u003eChlorhexidine Digluconate 0.5%\u003c\/strong\u003e, this anti-plaque gel is ideal for use before and after dental treatments, ensuring optimal protection of the gingival sulcus. It is particularly suitable for those who use prostheses or orthodontic appliances, as well as for periodontopathic subjects and those with dental implants.\u003c\/p\u003e\n\n\u003cp\u003eThanks to his \u003cstrong\u003eantibacterial action\u003c\/strong\u003e, Curasept periodontal gel helps prevent and manage oral diseases such as gingivitis and peri-implantitis, offering essential support during dental treatment. The A.D.S. system (Anti Discoloration System) integrated into the formula reduces the risk of tooth pigmentation, maintaining a bright and healthy smile.\u003c\/p\u003e\n\n\u003cp\u003eThe gel is enriched with \u003cstrong\u003esodium DNA\u003c\/strong\u003e, a component that contributes to the regeneration of gum tissue, promoting faster and more effective healing. Its formulation is designed for localized applications, making it a precious ally even following surgery or post-extractions.\u003c\/p\u003e\n\n\u003cp\u003eAvailable in a practical format of \u003cstrong\u003e30ml\u003c\/strong\u003e, Curasept periodontal gel is easy to apply and integrates perfectly into your daily oral hygiene routine, offering long-lasting protection and superior comfort for your gums.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Curasept periodontal gel 0.5% ADS + DNA 30ml used? What is it for?\u003c\/h3\u003e\u003cp\u003eGingival gel based on chlorhexidine digluconate 0.5% with A.D.S. system, indicated for the hygiene of the gingival sulcus before and after dental treatments and for those who wear prostheses or orthodontic appliances; useful as a support in the management of gingivitis and peri-implantitis.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Curasept periodontal gel 0.5% ADS + DNA 30ml contain?\u003c\/h3\u003e\u003cp\u003ePurified Water, Propylene Glycol, Hydroxyethylcellulose, PVP-VA Copolymer, Cremofor RH40, Chlorhexidine Digluconate 0.5%, Sodium Acetate, Aroma, Acetic Acid, Sodium Metabisulfite, Ascorbic Acid, Sodium DNA.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Curasept periodontal gel 0.5% ADS + DNA 30ml?\u003c\/h3\u003e\u003cp\u003eApply a small amount of gel, with a finger or toothbrush, to the gums, 3 times a day for 2 weeks. Wash your hands after use.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Curasept periodontal gel 0.5% ADS + DNA 30ml?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWarnings\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eKeep out of reach of children. Wash your hands before and after use. Do not ingest. Do not use the product after the expiry date indicated on the package or if the package is not intact. Store at room temperature\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Curasept periodontal gel 0.5% ADS + DNA 30ml stored?\u003c\/h3\u003e\u003cp\u003eStore at room temperature.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Curasept periodontal gel 0.5% ADS + DNA 30ml?\u003c\/h3\u003e\u003cp\u003e30ml tube.\u003c\/p\u003e","brand":"Curasept","offers":[{"title":"Default Title","offer_id":51131327021383,"sku":"980299832","price":8.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/curasept-spa-curasept-gel-parodontale-0-5-ads-dna-30mlo-farmacia-dottor-tili-1213792063.jpg?v=1767136839"},{"product_id":"dequadin-0-25mg-20-compresse","title":"Dequadin 0.25mg 20 tablets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTablets: Topical treatment in angina, stomatitis, pharyngitis and tonsillitis. After tooth extractions DEQUADIN tablets are useful for the prophylaxis of infections. Spray for oral mucosa and solution for oral mucosa: Topical treatment in gingivitis, stomatitis, tonsillitis, pharyngitis. After tooth extractions DEQUADIN spray and solution for oral mucosa are useful for the prophylaxis of infections.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. In children under three years of age, especially if predisposed to laryngospasm or convulsions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use, especially if prolonged, of products for topical use can give rise to sensitization phenomena; if this occurs, treatment must be suspended and suitable therapy instituted. The same applies in the event of the development of resistant microorganisms. Spray for oral mucosa and solution for oral mucosa: use should be limited to lesions of the mouth and throat.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAvoid the simultaneous use of other antiseptics and detergents.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use of the medicine may cause local irritation\u003cb\u003e.\u003c\/b\u003e Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/it\/responsabili.\u003c\/p\u003e","brand":"Eurospital","offers":[{"title":"Default Title","offer_id":51131334066503,"sku":"012235040","price":8.28,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/eurospital-spa-dequadin-0-25mg-20-compresse-farmacia-dottor-tili-1213792052.jpg?v=1767137387"},{"product_id":"benactivdol-gola-8-75mg-dose-spray-15ml","title":"Benactivdol Throat 8.75mg\/dose spray 15ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBenactivdol Throat is indicated for the short-term symptomatic treatment of acute pain in sore throat in adults.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. • Patients who have previously experienced hypersensitivity reactions (e.g. asthma, bronchospasm, rhinitis, angioedema or urticaria) in response to acetylsalicylic acid or other NSAIDs. • Patients with current or previous recurrent peptic ulcers\/haemorrhages (two or more distinct episodes of demonstrated ulceration) and intestinal ulceration. • Patients with a history of gastrointestinal bleeding or perforation, severe colitis, bleeding or haematopoietic disorders related to previous therapy with NSAIDs. • Last trimester of pregnancy (see section 4.6). • Severe heart failure, renal failure or hepatic failure (see section 4.4). • Children and adolescents under the age of 18.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects can be minimized by using the lowest effective dose for the shortest duration of treatment needed to control symptoms. \u003cb\u003eInfections \u003c\/b\u003e Since isolated cases of exacerbation of inflammation related to infections (e.g. development of necrotizing fasciitis) have been described in temporal association with the systemic use of drugs belonging to the NSAID class, patients are recommended to immediately consult a doctor in case of appearance or worsening of signs of a bacterial infection during therapy based on flurbiprofen spray. A possible indication for starting antibiotic therapy must be taken into consideration. In case of purulent bacterial pharyngitis\/tonsillitis, the patient should consult the doctor for a re-evaluation of the treatment. Treatment should not be administered for more than 3 days. Treatment should be reevaluated if symptoms worsen or new symptoms occur. If mouth irritation develops, treatment with flurbirprofen should be discontinued. \u003cb\u003eElderly population \u003c\/b\u003e Elderly people experience an increased frequency of adverse reactions to NSAIDs, especially bleeding and gastrointestinal perforation, which can be fatal. \u003cb\u003eRespiratory disorders \u003c\/b\u003e Bronchospasm can be precipitated in patients suffering from or with a history of bronchial asthma or allergic disease, Flurbiprofen spray should be used with caution in these patients. \u003cb\u003eOther NSAIDs \u003c\/b\u003e The use of flurbiprofen spray should be avoided concomitantly with other NSAIDs, including selective cyclooxygenase-2 inhibitors (see section 4.5). \u003cb\u003eSystemic lupus erythematosus (SLE) and mixed connective tissue disease \u003c\/b\u003e Patients with systemic lupus erythematosus (SLE) and mixed connective tissue disease may be at increased risk of aseptic meningitis (see section 4.8), however this effect is not usually seen with products intended for short-term use such as flurbiprofen spray. \u003cb\u003eCardiovascular, renal and hepatic impairment \u003c\/b\u003e NSAIDs have been reported to cause various forms of nephrotoxicity, including interstitial nephritis, nephrotic syndrome, and renal failure. The administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and precipitate renal failure. Patients at highest risk of developing this reaction are those with impaired renal function, cardiac impairment, liver dysfunction, those on diuretic therapy and the elderly; this effect is not usually observed with products intended for short-term use such as flurbiprofen spray. \u003cb\u003eHepatic effects\u003c\/b\u003e Mild to moderate hepatic dysfunction (see sections 4.3 and 4.8). \u003cb\u003eCardiovascular and cerebrovascular effects \u003c\/b\u003e Before starting treatment in patients with a positive history of hypertension and\/or heart failure, caution is required (contact your doctor or pharmacist) since fluid retention, hypertension and edema have been reported in association with treatment with NSAIDs. Data from clinical and epidemiological studies suggest that the use of some NSAIDs (particularly at high doses and in long-term treatments) may be associated with a slight increase in the risk of arterial thrombotic events (for example myocardial infarction or stroke). There are insufficient data to exclude this risk with flurbiprofen when administered at a daily dosage of less than 5 times (3 actuations for each dose). \u003cb\u003eEffects on the central nervous system \u003c\/b\u003e Headache induced by analgesics - In case of prolonged or irregular use of analgesics, headache may occur, which must not be treated by increasing the dose of the medicine. \u003cb\u003eGastrointestinal disorders \u003c\/b\u003e NSAIDs should be administered with caution to patients with a history of gastrointestinal disorders (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). Gastrointestinal bleeding, ulceration or perforation, which may be fatal, have been reported with all NSAIDs at any time during treatment, in the presence or absence of warning symptoms or a history of serious gastrointestinal events. The risk of gastrointestinal bleeding, ulceration or perforation is higher with increasing doses of NSAIDs, in patients with a history of ulcer, especially if complicated with the presence of haemorrhage or perforation (see section 4.3) and in the elderly; this effect is not usually observed with products intended for short-term use such as flurbiprofen spray. Patients with a history of gastrointestinal toxicity, particularly the elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) to their healthcare provider. Caution should be advised in patients receiving concomitant medicinal products that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking flurbiprofen, treatment should be discontinued. \u003cb\u003eHematological effects \u003c\/b\u003e Flurbiprofen, like other NSAIDs, can inhibit platelet aggregation and prolong bleeding time. Flurbiprofen spray should be used with caution in patients with potential bleeding abnormalities. \u003cb\u003eDermatological effects \u003c\/b\u003e Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported very rarely in association with the use of NSAIDs (see section 4.8). Flurbiprofen spray should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. This product contains methyl parahydroxybenzoate and propyl parahydroxybenzoate which may cause allergic reactions (sometimes even delayed). This medicine contains flavors containing citral, d-limonene, eugenol and linalool. Citral, d-limonene, eugenol and linalool can cause allergic reactions. This medicinal product contains less than 1 mmol sodium (23mg) per dose, i.e. essentially 'sodium-free'.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e \u003cu\u003eFlurbiprofen should be avoided in association with\u003c\/u\u003e:\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eOther NSAIDs including selective cyclooxygenase-2 inhibitors:\u003c\/i\u003e | Avoid concomitant use of two or more NSAIDs, as this may increase the risk of adverse effects (especially gastrointestinal adverse events such as ulcers and bleeding) (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eAcetylsalicylic acid (at low doses):\u003c\/i\u003e | Unless the intake of acetylsalicylic acid at low doses (not exceeding 75 mg\/day) has been recommended by the doctor (see section 4.4), since the potential risk of adverse events may increase.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e \u003cu\u003eFlurbiprofen should be used with caution in association with\u003c\/u\u003e:\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eAnticoagulants:\u003c\/i\u003e | NSAIDs may potentiate the effects of anticoagulants such as warfarin (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eAntiplatelet agents:\u003c\/i\u003e | There is an increased risk of gastrointestinal ulceration or bleeding (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eAntihypertensive drugs (Diuretics, ACE inhibitors, Angiotensin II antagonists):\u003c\/i\u003e | NSAIDs can reduce the effect of diuretics. Other antihypertensive drugs may potentiate nephrotoxicity caused by cyclooxygenase inhibition, especially in patients with impaired renal function.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eAlcohol:\u003c\/i\u003e | May increase the risk of adverse reactions, especially bleeding in the gastrointestinal tract.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eCardiac glycosides:\u003c\/i\u003e | NSAIDs can exacerbate heart failure, reduce VGR (glomerular filtration rate) and increase plasma glycoside levels - adequate monitoring and, if necessary, dose adjustment is recommended.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eCyclosporine:\u003c\/i\u003e | There is an increased risk of nephrotoxicity.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eCorticosteroids:\u003c\/i\u003e | There is an increased risk of gastrointestinal ulceration or bleeding (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eLithium:\u003c\/i\u003e | There may be an increase in serum lithium levels - adequate monitoring and, if necessary, dose adjustment is recommended.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eMethotrexate:\u003c\/i\u003e | The administration of NSAIDs within 24 hours before or after the administration of methotrexate can lead to high concentrations of methotrexate and an increase in its toxic effects.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eMifepristone:\u003c\/i\u003e | NSAIDs should not be used for 8 - 12 days following administration of mifepristone, as NSAIDs may reduce the effect of mifepristone.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eOral antidiabetics:\u003c\/i\u003e | Alterations in blood glucose levels have been reported (increasing the frequency of checks is recommended).\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003ePhenytoin:\u003c\/i\u003e | Serum levels of phenytoin may increase - adequate monitoring and, if necessary, dose adjustment is recommended.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003ePotassium-sparing diuretics:\u003c\/i\u003e | Concomitant use may cause hyperkalemia.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eProbenecid and Sulfinpyrazone:\u003c\/i\u003e | Medicines containing probenecid and sulfinpyrazone may delay the excretion of flurbiprofen.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eQuinolone antibiotics:\u003c\/i\u003e | Data obtained in animals indicate that NSAIDs may increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may be at increased risk of developing seizures.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eSelective serotonin reuptake inhibitors (SSRIs):\u003c\/i\u003e | There is an increased risk of gastrointestinal ulceration or bleeding (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eTacrolimus:\u003c\/i\u003e | An increased risk of nephrotoxicity is possible when NSAIDs are administered concomitantly with tacrolimus.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eZidovudine:\u003c\/i\u003e | There is an increased risk of haematological toxicity when NSAIDs are administered with zidovudine.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePediatric population \u003c\/b\u003e No additional information is available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity reactions to NSAIDs have been reported and these may consist of: (a) non-specific allergic reactions and anaphylaxis (b) respiratory tract reactivity, e.g. asthma, asthma aggravated, bronchospasm, dyspnoea (c) various skin reactions, e.g. pruritus, urticaria, angioedema and, more rarely, exfoliative and bullous dermatosis (including epidermal necrolysis and erythema multiforme). Edema, hypertension and heart failure have been reported in association with treatment with NSAIDs. Data are insufficient to exclude this risk following the use of flurbiprofen oral mucosal spray, solution. \u003cb\u003eThe list of adverse effects reported below refers to the clinical evaluation carried out with flurbiprofen, used short term and at doses compatible with the OTC classification.\u003c\/b\u003e (Very common (≥1\/10), Common (≥1\/100 to \u003c1\/10), Uncommon (≥1\/1000 to \u003c1\/100), Rare (≥1\/10000 to \u003c1\/1000), Very rare (\u003c1\/10000), not known (frequency cannot be estimated from the available data)). \u003ci\u003ePathologies of the blood and lymphatic system\u003c\/i\u003e Not known: Anemia, Thrombocytopenia. \u003ci\u003eCardiac and vascular pathologies\u003c\/i\u003e Not known: Edema, Hypertension, Heart failure. \u003ci\u003eNervous system disorders\u003c\/i\u003e Common: Dizziness, Headache, Paraesthesia. Uncommon: Drowsiness. \u003ci\u003eRespiratory, thoracic and mediastinal disorders\u003c\/i\u003e Common: Throat irritation. Uncommon: exacerbation of asthma and bronchospasm, dyspnoea, wheezing, formation of blisters at the oropharyngeal level, pharyngeal hypoesthesia. \u003ci\u003eGastrointestinal disorders\u003c\/i\u003e Common: Diarrhoea, Mouth ulceration, Nausea, Oral pain, Oral paraesthesia, Oropharyngeal pain, Oral discomfort (hot or burning sensation, tingling in the mouth). Uncommon: Abdominal distension, Abdominal pain, Constipation, Dry mouth, Dyspepsia, Flatulence, Glossodynia, Dysgeusia, Oral dysesthesia, Vomiting. \u003ci\u003ePathologies of the skin and subcutaneous tissue\u003c\/i\u003e Uncommon: Skin rashes of various types, Itching. Not known: Severe skin reactions such as bullous reactions, including Stevens-Johnson Syndrome and Toxic Epidermal Necrosis. \u003ci\u003eSystemic pathologies and conditions relating to the administration site\u003c\/i\u003e Uncommon: Pyrexia, Pain. \u003ci\u003eImmune system disorders\u003c\/i\u003e Rare: Anaphylactic reaction. \u003ci\u003ePsychiatric disorders\u003c\/i\u003e Uncommon: Insomnia. \u003ci\u003eHepatobiliary disorders\u003c\/i\u003e Not known: Hepatitis \u003cb\u003eReporting of suspected adverse reactions \u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioniavverse\u003c\/p\u003e","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":51131346420039,"sku":"043050018","price":13.49,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/reckitt-benckiser-h-it-spa-benactivdol-gola-8-75mg-dose-spray-15ml-farmacia-dottor-tili-1213791987.jpg?v=1767149609"},{"product_id":"aftamed-collutorio-150ml-menarini","title":"Aftamed Mouthwash 150ml Menarini","description":"\u003cp\u003e\u003cstrong\u003eAftamed Mouthwash\u003c\/strong\u003e it is a specific treatment for \u003cstrong\u003ecanker sores and lesions of the oral mucosa\u003c\/strong\u003e, formulated to relieve pain and promote rapid healing.\nThanks to its soothing and protective action, it helps restore the well-being of the oral cavity by reducing inflammation and discomfort.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Aftamed Mouthwash 150ml Menarini used? What is it for?\u003c\/h3\u003e\u003cp\u003eMouthwash, medical device indicated for the treatment of canker sores and lesions of the oral mucosa; thanks to hyaluronic acid and xylitol it exerts a soothing and protective action which helps reduce inflammation and discomfort, promoting healing.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Aftamed Mouthwash 150ml Menarini contain?\u003c\/h3\u003e\u003cp\u003eFormulation enriched with:\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHyaluronic acid\u003c\/strong\u003e: promotes tissue regeneration and protects the oral mucosa. \u003cstrong\u003eXylitol\u003c\/strong\u003e: antibacterial and refreshing action. \u003cstrong\u003eNatural extracts\u003c\/strong\u003e: they soothe irritation and promote healing.\u003c\/p\u003e\u003cp\u003eFormula \u003cstrong\u003ewithout alcohol\u003c\/strong\u003e, gentle on the gums.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Aftamed Mouthwash 150ml Menarini?\u003c\/h3\u003e\u003cp\u003ePour a small amount of mouthwash (approximately 10 ml) into the measuring cup. Perform a rinse lasting 1.5 seconds \u003cstrong\u003eat least 1 minute\u003c\/strong\u003e, distributing the product throughout the oral cavity. Do not rinse with water after use. Repeat the application \u003cstrong\u003e2-3 times a day\u003c\/strong\u003e, preferably after meals.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Aftamed Collutorio 150ml Menarini?\u003c\/h3\u003e\u003cp\u003eDo not ingest. Keep out of reach of children. Do not use in case of hypersensitivity to the components. If symptoms persist, consult a doctor. Store in a cool, dry place, away from heat sources.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Aftamed Collutorio 150ml Menarini?\u003c\/h3\u003e\u003cp\u003eBottle of \u003cstrong\u003e150ml\u003c\/strong\u003e with measuring cup.\u003c\/p\u003e","brand":"Menarini","offers":[{"title":"Default Title","offer_id":51131360510279,"sku":"904733363","price":12.93,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/a-menarini-ind-farm-riun-srl-aftamed-collutorio-150ml-menarini-farmacia-dottor-tili-1213791933.jpg?v=1767141646"},{"product_id":"neo-borocillina-gola-dolore-8-75mg-32-pastiglie-senza-zucchero-gusto-menta","title":"Neo Borocillina Gola Dolore 8.75mg 32 sugar-free mint-flavored tablets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNEO BOROCILLINA THROAT PAIN mouthwash \/ NEO BOROCILLINA THROAT PAIN spray for oral mucosa is used in the symptomatic treatment of irritative-inflammatory conditions also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy. NEO BOROCILLINA THROAT PAIN tablets are used in the symptomatic treatment of irritative-inflammatory states also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFlurbiprofen is contraindicated in patients with hypersensitivity (asthma, bronchospasm, urticaria or allergic type) towards flurbiprofen or to any of the excipients, and towards acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). Third trimester of pregnancy. The administration of flurbiprofen is not recommended in breastfeeding mothers. Do not use in patients who have peptic ulcers or who have had them in the past. \u003ci\u003e \u003cu\u003eDo not give the tablets to children under the age of 12\u003c\/u\u003e \u003c\/i\u003e \u003ci\u003e \u003cu\u003eyears.\u003c\/u\u003e \u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAt the recommended doses, when using the medicine in its various pharmaceutical forms, any swallowing does not, in itself, cause any harm to the patient, as these doses are widely lower than those commonly used in treatments with flurbiprofen systemically. In patients with renal, cardiac or hepatic insufficiency, the medicine NEO BOROCILLINA THROAT PAIN should be used with caution. It is recommended not to combine the medicine with NSAIDs. Use of the product, especially if prolonged, can give rise to local sensitization or irritation phenomena; in such cases it is necessary to interrupt the treatment and consult the doctor to institute, if necessary, a suitable therapy. Do not use for prolonged treatments. After a short period of treatment without appreciable results, consult your doctor. \u003cb\u003eNEO BOROCILLINA THROAT PAIN mouthwash and NEO BOROCILLINA THROAT PAIN spray for oral mucosa (all presentations) contain:\u003c\/b\u003e - 960 mg of ethanol per 10 ml of mouthwash. May cause burning sensation on damaged skin. - hydrogenated polyoxide castor oil which may cause localized skin reactions. - parahydroxy benzoates which can cause allergic reactions (even delayed). NEO BOROCILLINA THROAT PAIN 0.25% spray for oral mucosa orange and honey flavor and NEO BOROCILLINA THROAT PAIN 0.25% spray for oral mucosa lemon and honey flavor also contain the coloring sunset yellow (E110), which can cause allergic reactions.NEO BOROCILLINA THROAT PAIN 8.75 mg lozenges (all presentations) contains isomalt: patients suffering from rare hereditary problems of intolerance to fructose, you should not take this medicine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHowever, inform your doctor if you are taking other medicines. As demonstrated in some clinical studies, flurbiprofen may occasionally reduce the diuretic activity of furosemide. Furthermore, flurbiprofen may occasionally interfere with the action of anticoagulant drugs. However, no interaction of flurbiprofen with digoxin, tolbutamide and antacids has been demonstrated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use of NEO BOROCILLINA THROAT PAIN, especially if prolonged, can give rise to sensitization or local irritation phenomena; in such cases it is necessary to interrupt the treatment and institute, if necessary, a suitable therapy. The following side effects have been reported, particularly after the administration of higher doses systemically: \u003ci\u003e \u003cu\u003ePathologies of the blood and lymphatic system\u003c\/u\u003e \u003c\/i\u003e Thrombocytopenia, aplastic anemia and agranulocytosis. \u003ci\u003e \u003cu\u003eImmune system disorders\u003c\/u\u003e \u003c\/i\u003e Anaphylaxis, angioedema, allergic reaction. \u003ci\u003e \u003cu\u003eNervous system disorders\u003c\/u\u003e \u003c\/i\u003e Dizziness, cerebrovascular accident, visual disturbances, optic neuritis, migraine, paraesthesia, depression, confusion, hallucination, vertigo, discomfort, fatigue and drowsiness. \u003ci\u003e \u003cu\u003eEar and labyrinth disorders\u003c\/u\u003e \u003c\/i\u003e Tinnitus. \u003ci\u003e \u003cu\u003eRespiratory, thoracic and mediastinal disorders\u003c\/u\u003e \u003c\/i\u003e Reactivity of the respiratory tract (asthma, bronchospasm and dyspnea). \u003ci\u003e \u003cu\u003eGastrointestinal disorders\u003c\/u\u003e \u003c\/i\u003e The most commonly observed adverse events are gastrointestinal in nature. The following have been reported after administration of flurbiprofen: nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melena, haematemesis, ulcerative stomatitis, gastrointestinal haemorrhage and exacerbation of colitis and Crohn's disease. Less frequently, gastritis, peptic ulcer, perforation and ulcer bleeding have been observed. \u003ci\u003e \u003cu\u003ePathologies of the skin and subcutaneous tissue\u003c\/u\u003e \u003c\/i\u003e Skin disorders including rash, pruritus, urticaria, purpura and very rarely bullous dermatoses (including Stevens-Johnson syndrome, Toxic Epidermal Necrolysis and Erythema multiforme). \u003ci\u003e \u003cu\u003eRenal and urinary disorders\u003c\/u\u003e \u003c\/i\u003e Nephrotoxicity in various forms, including interstitial nephritis and nephrotic syndrome. As with other NSAIDs, rare cases of renal failure have been reported. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/p\u003e","brand":"Alfasigma","offers":[{"title":"Default Title","offer_id":51131368603975,"sku":"035760065","price":13.86,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/alfasigma-spa-neo-borocillina-gola-dolore-8-75mg-32-pastiglie-senza-zucchero-gusto-menta-farmacia-dottor-tili-1213791892.jpg?v=1767150251"},{"product_id":"pyralvex-50mg-ml-10mg-ml-soluzione-gengivale-10ml","title":"Pyralvex 50mg\/ml + 10mg\/ml gingival solution 10ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGingivitis, stomatitis, oropharyngitis, adjuvant in the treatment of alveolar pyorrhea.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. Not to be used in children under 12 years of age. With the topical application of salicylic acid there is a hypothetical risk of inducing Reye's syndrome. Reye's syndrome has been observed after oral administration of higher doses of salicylic acid or acetylsalicylic acid in children. There have been no confirmed cases of Reye's Syndrome associated with the use of Pyralvex. Due to the ethanol content the medicine is not suitable for patients with alcoholism.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not exceed the recommended application frequency. Salicylate toxicity may occur if the suggested frequency of application is exceeded. Coloring of teeth, dentures and dentures (see section 4.8). Products for topical use, especially if applied for repeated and prolonged periods of time, can give rise to hypersensitivity phenomena. In this case, stop treatment and consult your doctor in order to establish suitable therapy. After a short period of treatment without appreciable results, consult your doctor. \u003cu\u003eInformation on excipients\u003c\/u\u003e This medicine contains 476 mg of ethanol alcohol (alcohol) in each ml, which is equivalent to 59.5% v\/v. May cause burning sensation on damaged skin. PYRALVEX is flammable.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSalicylates are highly bound to plasma proteins and can displace other drugs from binding sites. Clinically important interactions may occur with heparin and oral anticoagulants, but these are primarily due to an effect on platelet function, rather than on pharmacokinetic parameters.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn the system organ class, undesirable effects are listed in order of frequency (number of patients expected to experience the reaction), using the following convention: Very common (≥1\/10); Common (≥1\/100, \u003c1\/10); Uncommon (≥1\/1,000, \u003c1\/100); Rare (≥1\/10,000, \u003c1\/1,000); Very Rare (\u003c1\/10,000); Not known (frequency cannot be estimated from the available data). \u003cb\u003eImmune system disorders.\u003c\/b\u003e \u003cb\u003eNot known: \u003c\/b\u003eAllergic reactions. \u003cb\u003eGastrointestinal disorders.\u003c\/b\u003e Common: Temporary discoloration of the teeth or oral mucosa. \u003cb\u003eDisorders of the skin and subcutaneous tissue.\u003c\/b\u003e Not known: skin rash and urticaria. \u003cb\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/b\u003e Very common: Transient local burning sensation at the application site. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e","brand":"Viatris Healthcare","offers":[{"title":"Default Title","offer_id":51131382497607,"sku":"005268038","price":11.9,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/viatris-healthcare-pyralvex-50mg-ml-10mg-ml-soluzione-gengivale-10ml-farmacia-dottor-tili-1254211107.jpg?v=1786730500"},{"product_id":"tantum-verde-0-30-spray-15ml","title":"Tantum Verde 0.30% spray 15ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSymptomatic treatment of irritative-inflammatory conditions also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to benzydamine or to any of the excipients.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUse of the product, especially if prolonged, may give rise to sensitization phenomena. In this case, stop treatment and consult your doctor to institute suitable therapy. In a limited number of patients, oropharyngeal ulcerations can be a sign of more serious pathologies. Therefore, if the symptoms persist for more than three days, the patient should contact his doctor or dentist as necessary. The use of benzydamine is not recommended in patients with hypersensitivity to acetylsalicylic acid or other NSAIDs. Tantum Verde solution for oral mucosa must be administered with caution in subjects who have had episodes of bronchial asthma in the past, as bronchospasm phenomena could occur in this type of patient. Tantum Verde contains parahydroxybenzoates which may cause allergic reactions (even delayed). For those who carry out sporting activities: the use of medicines containing ethyl alcohol can result in positive anti-doping tests in relation to the blood alcohol concentration limits indicated by some sports federations.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo interaction studies with other drugs have been conducted.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eWithin each frequency class, undesirable effects are reported in order of decreasing severity. The following value scales were used: very common (≥1\/10); common (≥1\/100, \u003c1\/10); uncommon (≥ 1\/1000, \u003c 1\/100); rare ≥ 1\/10,000, \u003c 1\/1000); very rare (\u003c1\/10,000); not known (frequency cannot be estimated from the available data). \u003cu\u003eGastrointestinal disorders \u003c\/u\u003e– \u003ci\u003eRare\u003c\/i\u003e: burning and dry mouth. \u003cu\u003eImmune system disorders \u003c\/u\u003e– \u003ci\u003eRare\u003c\/i\u003e: hypersensitivity reactions – \u003ci\u003eNot known\u003c\/i\u003e: anaphylactic reactions. \u003cu\u003eRespiratory, thoracic, mediastinal disorders \u003c\/u\u003e– \u003ci\u003eVery rare\u003c\/i\u003e: laryngospasm. \u003cu\u003ePathologies of the skin and subcutaneous tissue\u003c\/u\u003e – \u003ci\u003eUncommon\u003c\/i\u003e: photosensitivity – \u003ci\u003eVery rare\u003c\/i\u003e: angioedema.\u003c\/p\u003e","brand":"Angelini Pharma","offers":[{"title":"Default Title","offer_id":51131382530375,"sku":"022088088","price":11.63,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-pharma-italia-spa-tantum-verde-0-30-spray-15ml-farmacia-dottor-tili-1213791705.jpg?v=1767144310"},{"product_id":"aftamed-spray-orale-20ml-menarini","title":"Aftamed Oral Spray 20ml Menarini","description":"\u003cp\u003e\u003cstrong\u003eAftamed Oral Spray\u003c\/strong\u003e it is a specific treatment for \u003cstrong\u003ecanker sores, lesions of the oral mucosa and irritated gums\u003c\/strong\u003e.\nThanks to its formula with hyaluronic acid, it promotes tissue regeneration and provides rapid pain relief.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy should Aftamed Oral Spray 20ml Menarini be used? What is it for?\u003c\/h3\u003e\u003cp\u003eOral spray (medical device) based on hyaluronic acid and xylitol, indicated for the treatment of canker sores, lesions of the oral mucosa and irritated gums; promotes tissue regeneration and rapid pain relief.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Aftamed Oral Spray 20ml Menarini contain?\u003c\/h3\u003e\u003cp\u003eFormula enriched with:\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eHyaluronic acid\u003c\/strong\u003e: promotes the regeneration of the oral mucosa. \u003cstrong\u003eXylitol\u003c\/strong\u003e: antibacterial and refreshing action. \u003cstrong\u003eNatural extracts\u003c\/strong\u003e: soothe irritation and reduce discomfort.\u003c\/p\u003e\u003cp\u003eFormula \u003cstrong\u003ewithout alcohol\u003c\/strong\u003e, gentle on sensitive gums and mucous membranes.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Aftamed Oral Spray 20ml Menarini?\u003c\/h3\u003e\u003cp\u003eShake the bottle well before use. Apply 1-2 sprays directly to the affected area. Repeat the application \u003cstrong\u003e2-3 times a day\u003c\/strong\u003e or as needed. Avoid drinking or eating for at least 30 minutes after use to maximize the effect.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Aftamed Oral Spray 20ml Menarini?\u003c\/h3\u003e\u003cp\u003eFor oral use only. Do not ingest. Keep out of reach of children. Do not use in case of hypersensitivity to the components. Store in a cool, dry place.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Aftamed Oral Spray 20ml Menarini?\u003c\/h3\u003e\u003cp\u003eSpray bottle from \u003cstrong\u003e20ml\u003c\/strong\u003e.\u003c\/p\u003e","brand":"Menarini","offers":[{"title":"Default Title","offer_id":51131383021895,"sku":"904733413","price":13.86,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/a-menarini-ind-farm-riun-srl-aftamed-spray-orale-20ml-menarini-farmacia-dottor-tili-1213791700.jpg?v=1767144452"},{"product_id":"golamixin-10-ml-spray-mucosa-orale","title":"Golamixin 10 ml spray oral mucosa","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTopical therapy of bacterial stomatitis sensitive to thyrothricin.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSubjects with known hypersensitivity to the individual components, especially thyrothricin. Subjects for whom a marked predisposition to allergies is known.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn very early childhood the product should be administered in cases of actual need and under the direct supervision of the doctor. If there is no response within two days of starting administration, interrupt treatment due to possible colonization of strains or fungi (especially Candida) resistant to thyrothricin. The use, especially if prolonged, of products for topical use can give rise to sensitization phenomena. In this case it is necessary to interrupt therapy and institute suitable therapy. Similar behavior must be observed in the event of the development of non-susceptible microorganisms. Keep out of reach of children.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGiven the low doses administered, no serious interactions with other drugs are expected.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBlackening of the tongue, rarely glossitis and sensitization reactions have been reported with the use of thyrothricin which, however, regress upon discontinuation of treatment. More relevant may be the symptoms of sensitization of anesthetics, including muscular disorders and convulsions.\u003c\/p\u003e","brand":"Teofarma","offers":[{"title":"Default Title","offer_id":51730202558791,"sku":"016703035","price":12.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/teofarma-golamixin-10-ml-spray-mucosa-orale-farmacia-dottor-tili-1258975919.jpg?v=1790944399"},{"product_id":"broxodin-gel-30-ml-gel","title":"Broxodin gel 30 ml gel","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBROXO Din is indicated for the disinfection of the oral mucosa.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe product is for external use only: it must not be ingested and contact with eyes and ears must be avoided. In case of contact with eyes and\/or ears, wash immediately with water. The patient must be informed that, in the event of the onset of symptoms such as pain, edema or irritation of the oral cavity, skin rash, respiratory tract edema, difficulty breathing, he must discontinue the product and immediately contact a doctor. The recommended doses should not be exceeded. The product must not be used for prolonged treatments: after a short period of treatment without appreciable results, medical evaluation is necessary. The use, especially prolonged, of products for topical use can give rise to sensitization phenomena: in this case the treatment must be interrupted and a medical evaluation must be carried out. In the initial stages of treatment, the onset of taste alteration, numbness or burning of the tongue is possible. Usually, these are transient events that reduce with use. If these effects persist, the patient should be referred to a doctor or dentist. The product may cause staining of oral surfaces such as teeth and tongue. It is possible that the coloring also affects any dental material. The coloring can be removed by professional cleaning, which however may not be effective in the presence of damaged surfaces. To prevent staining, the patient should be recommended to reduce the consumption of chromogenic foods (such as tea, coffee and red wine), take care of oral hygiene with brushing, use of common toothpaste and dental floss, especially in the areas where the first signs of staining appear. It is useful to recommend rinsing with water between the two treatments with Broxo Din or at other times of the day. \u003cb\u003eImportant information about some excipients \u003c\/b\u003e Broxo Din 200 mg\/100 g mouthwash contains ethoxylated hydrogenated castor oil (Macrogolglycerol hydroxystearate). May cause local skin reactions. Broxo Din 200 mg\/100 g gingival gel contains nipagin (methyl parahydroxybenzoate). May cause allergic reactions (even delayed).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAvoid the simultaneous use of other antiseptics and detergents.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFrom the data available in the literature and post-marketing, it emerges that the use of chlorhexidine-based products for the oral cavity can lead to the onset of adverse events such as allergic reactions (both local and systemic), burning, irritation, coated tongue, dry mouth, alterations in taste, alterations in sensitivity of the oral cavity, glossodynia, coloration of the tongue and teeth, pain, edema and\/or desquamation of the oral mucosa. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e","brand":"Sit Laboratorio Farmaceutico","offers":[{"title":"Default Title","offer_id":51730204721479,"sku":"032036030","price":7.13,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/sit-laboratorio-farmac-srl-broxodin-gel-30-ml-gel-farmacia-dottor-tili-1213791395.jpg?v=1767139247"},{"product_id":"corsodyl-200-mg-100-ml-150-ml-soluzione-per-mucosa-orale","title":"Corsodyl 200 mg\/100 ml 150 ml oral mucosal solution","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDisinfectant action of the oral cavity, even before and after tooth extractions or minor operations. Anti-plaque action, adjuvant in the prevention of gingivitis and periodontitis secondary to the formation of dental plaque. Protective action against infections in wearers of fixed or removable prostheses, for its antiseptic activity on teeth and gums.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not exceed the indicated doses. Avoid contact with eyes and ears. If the product comes into contact with your eyes or ears, wash promptly with water. The product is for external oral use only; do not ingest. If you experience pain, swelling or irritation in your mouth, stop treatment and consult your doctor or dentist. If you experience a rash, swelling or difficulty breathing, discontinue use of the product and contact a doctor immediately. Initially, transient changes in taste and transient sensations of numbness, tingling or burning of the tongue may occur. These effects usually diminish with continued use. If they persist, consult your doctor or dentist. The use, especially prolonged, of products for topical use can give rise to sensitization phenomena; in this case, stop treatment and consult your doctor to institute suitable therapy. Do not use for prolonged treatments; after a short period of treatment without appreciable results, consult your doctor. Chlorhexidine gluconate can cause surface discoloration of the tongue, teeth and some materials used for fillings and dentures. The stains are not permanent and can largely be prevented by reducing the consumption of food chromogens, such as tea, coffee and red wine. As regards teeth and orthodontic material, this staining can be prevented with the daily use of a common toothpaste or before the use of Corsodyl solution, spray for oral mucosa and dental gel, taking care to rinse the mouth with water in the interval between the two treatments, or at another time of the day. These precautions are necessary as chlorhexidine gluconate is incompatible with anionic compounds generally found in common toothpastes. In some cases, the coloring can be eliminated by resorting to professional cleaning. In the case of anterior prostheses and fillings that have infiltrated edges and\/or rough surfaces, the pigmentation could remain even after professional cleaning. A professional cleaning intervention may be required following treatments such as jaw fixation or application of orthodontic appliances which have not made it possible to carry out normal mechanical oral hygiene (e.g. brushing). \u003cb\u003eImportant information about some excipients\u003c\/b\u003e CORSODYL oral mucosa solution, oral mucosa spray and dental gel contain hydrogenated polyoxyethylene-castor oil which may cause localized skin reactions. CORSODYL solution and spray for oral mucosa contain mint essence, an aroma which in turn contains d-limonene, eugenol and linalool, which may cause allergic reactions. CORSODYL dental gel contains mint essence, an aroma which itself contains d-limonene which can cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known clinically significant interactions with other drugs. Avoid the simultaneous use of other antiseptics.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUndesirable effects arising from clinical trial data and post-marketing data are listed below by system organ class and frequency. Frequencies are defined as: very common (≥1\/10), common (≥1\/100, \u003c1\/10), uncommon (≥1\/1000, \u003c1\/100), rare (≥1\/10000, \u003c1\/1000), very rare (\u003c1\/10000), frequency not known (cannot be estimated from the available data). \u003ci\u003eData from clinical studies\u003c\/i\u003e \u003cu\u003eGastrointestinal disorders\u003c\/u\u003e. Very common: coated tongue; Common: dry mouth. \u003cu\u003eNervous system disorders\u003c\/u\u003e. Common: ageusia\/dysgeusia, glossodynia, paraesthesia\/hypoesthesia of the oral cavity. \u003ci\u003ePost-marketing data\u003c\/i\u003e \u003cu\u003eGastrointestinal disorders\u003c\/u\u003e. Frequency not known: superficial discoloration of the tongue and teeth (see “Special warnings and precautions for use”), pain\/irritation of the mouth, scaling\/pain\/swelling of the oral mucosa (see “Special warnings and precautions for use”), swelling of the parotid glands. \u003cu\u003ePathologies of the skin and subcutaneous tissue\u003c\/u\u003e. Frequency not known: idiosyncratic skin reactions. \u003cu\u003eImmune system disorders\u003c\/u\u003e. Frequency not known: hypersensitivity, allergic reactions and anaphylaxis (see “Contraindications”, “Special warnings and precautions for use”). The side effects noted are generally mild and local in nature. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at \u003cb\u003eError! Hyperlink reference not valid.\u003c\/b\u003e https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e","brand":"Haleon","offers":[{"title":"Default Title","offer_id":51730205933895,"sku":"014371037","price":12.56,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/haleon-italy-srl-corsodyl-200-mg-100-ml-150-ml-soluzione-per-mucosa-orale-farmacia-dottor-tili-1213791366.jpg?v=1767139750"},{"product_id":"dentinale-0-5-0-5-25-g-pasta-gengivale","title":"Dentinal 0.5% + 0.5% 25 g gingival paste","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTreatment of sore gums for the emergence of the first teeth of children (painful tooth eruptions in early childhood).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity confirmed towards the components.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use of the product, especially if prolonged, does not exclude the possibility, although very rare, of sensitization phenomena. Should they occur, suspend the application of the preparation. Keep the product out of the reach of children.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNot reported.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe main side effects that concern the administration of local anesthetics generally manifest themselves at the gastrointestinal level with nausea and vomiting.\u003c\/p\u003e","brand":"Montefarmaco","offers":[{"title":"Default Title","offer_id":51730206523719,"sku":"008891018","price":13.11,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/montefarmaco-otc-spa-dentinale-0-5-0-5-25-g-pasta-gengivale-farmacia-dottor-tili-1213791102.jpg?v=1767140138"},{"product_id":"faringotricina-2-5-mg-20-compresse-orosolubili","title":"Faringothricin 2.5 mg 20 buccal tablets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTopical therapy of stomatitis of bacterial origin.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUse of the product, especially if prolonged, can give rise to sensitization phenomena. In this case it is necessary to interrupt the treatment and institute adequate therapy: similar treatment must be observed in the event of the development of infections caused by non-susceptible germs. \u003cu\u003ePediatric population\u003c\/u\u003e In very early childhood the product should be administered in cases of actual need, under the direct supervision of the doctor. \u003cb\u003ePHARYNGOTRICIN\u003c\/b\u003e \u003cb\u003econtains glucose, lactose and sucrose. \u003c\/b\u003ePatients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known interactions with other medicines.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince thyrothricin is poorly absorbed by the mucous membranes, the possibility of allergic reactions is reduced. Rarely, blackening of the tongue, glossitis, sensitization reactions may occur. \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: www.agenziafarmaco.gov.it\/it\/responsabili.\u003c\/p\u003e","brand":"Sit Laboratorio Farmaceutico","offers":[{"title":"Default Title","offer_id":51730207211847,"sku":"022801017","price":8.55,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/sit-laboratorio-farmac-srl-faringotricina-2-5-mg-20-compresse-orosolubili-farmacia-dottor-tili-1213791099.jpg?v=1767140267"},{"product_id":"benagol-menta-fredda-24-pastiglie","title":"Benagol Cold Mint 24 Tablets","description":"\u003cp\u003e \u003cstrong\u003eBenagol Cold Mint 24 Pastiglie\u003c\/strong\u003e is a medicinal device in tablets to dissolve slowly in the mouth, formulated to offer \u003cstrong\u003erapid relief from the symptoms of sore throat\u003c\/strong\u003e , such as burning, irritation and difficulty swallowing. The presence of antiseptic active ingredients and the \u003cstrong\u003ecold mint flavor\u003c\/strong\u003e give a pleasant sensation of immediate freshness, helping to calm inflammation and protect the oropharyngeal mucosa.\u003c\/p\u003e\n\n\n \u003cp\u003eBenagol lozenges contain \u003cstrong\u003e2,4-dichlorobenzyl alcohol and amylmetacresol\u003c\/strong\u003e , two substances with local antiseptic action, which help to counteract the proliferation of microorganisms responsible for throat irritation. The effect is enhanced by the cold mint flavor, which guarantees an immediate refreshing and balsamic sensation, especially useful in cases of \u003cstrong\u003edry throat, hoarseness or inflammation from sudden changes in temperature or vocal fatigue\u003c\/strong\u003e .\u003c\/p\u003e\n\n\n\u003cp\u003e The \u003cstrong\u003e24-tablet blister\u003c\/strong\u003e format is practical, hygienic and easy to carry. Each tablet should be taken slowly, letting it dissolve in the mouth to prolong the emollient and disinfectant effect. You can take one tablet every 2-3 hours, up to a maximum of 8 tablets per day for adults, unless otherwise indicated by your doctor.\u003c\/p\u003e\n\n\n\u003cp\u003e Benagol Menta Fredda is indicated for \u003cstrong\u003eadults and children over 12 years of age\u003c\/strong\u003e and can be used in case of:\u003c\/p\u003e\n\n\u003cul\u003e\n\n\u003cli\u003e \n\u003cstrong\u003eSore throat\u003c\/strong\u003e associated with viral or bacterial infections\u003c\/li\u003e\n\n\u003cli\u003e \u003cstrong\u003eIrritation from air conditioning, smoke or pollution\u003c\/strong\u003e\n\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eDry throat\u003c\/strong\u003e due to vocal strain or dehydration\u003c\/li\u003e\n\n\u003cli\u003e\n\n \u003cstrong\u003eHoarseness\u003c\/strong\u003e and inflammation of the upper respiratory tract\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\n\n\u003cp\u003e \u003cstrong\u003eBenagol Cold Mint 24 Tablets\u003c\/strong\u003e is the ideal product to always keep with you during seasonal changes, during flu periods or when you are exposed to environmental irritants.\u003c\/p\u003e\n\n","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":51730209833287,"sku":"016242291","price":12.28,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/reckitt-benckiser-h-it-spa-benagol-menta-fredda-24-pastiglie-farmacia-dottor-tili-1213791023.jpg?v=1767154607"},{"product_id":"tantum-verde-bocca-22-5-mg-15-ml-7-5-mg-15-ml-240-ml-collutorio","title":"Tantum Verde mouth 22.5 mg\/15 ml + 7.5 mg\/15 ml 240 ml mouthwash","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAntiseptic, anti-inflammatory and analgesic treatment for irritations of the mouth and gums; in gingivitis and stomatitis. Also indicated before and after tooth extractions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to benzydamine, cetylpyridinium or to any of the excipients listed in section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use, especially if prolonged, of preparations for oropharyngeal use, could give rise to sensitization phenomena. In this case, stop treatment and consult your doctor to institute suitable therapy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo interaction studies have been performed. However, it is advisable to avoid the simultaneous use of other antiseptics.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe table below shows the side effects, by MedDRA systemic organic classification. Undesirable effects are listed using the following frequency scales: very common (≥1\/10); common (≥1\/100, \u003c1\/10); uncommon (≥ 1\/1000, \u003c 1\/100); rare ≥ 1\/10,000, \u003c 1\/1000); very rare (\u003c1\/10,000); not known (frequency cannot be estimated from the available data).\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eCLASSIFICATION BY SYSTEMS AND ORGANS\u003c\/b\u003e | \u003cb\u003eFREQUENCY: SIDE EFFECTS\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eGastrointestinal disorders\u003c\/b\u003e | \u003ci\u003e \u003cu\u003eNot known:\u003c\/u\u003e \u003c\/i\u003e slight numbness in the mouth¹\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSystemic pathologies and conditions relating to the administration site\u003c\/b\u003e | \u003ci\u003e \u003cu\u003eNot known:\u003c\/u\u003e \u003c\/i\u003e phenomena of intolerance to the drug, which manifest themselves with mild and transient burning or irritation at the site of application²\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e \u003csup\u003e1)\u003c\/sup\u003e associated with the local anesthetic activity of benzydamine \u003c\/i\u003e \u003ci\u003e \u003csup\u003e2)\u003c\/sup\u003e phenomena observable with cetylpyridinium, which do not require modifications of the treatment\u003c\/i\u003e \u003cb\u003eReporting of suspected adverse reactions \u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e","brand":"Angelini Pharma","offers":[{"title":"Default Title","offer_id":51730210128199,"sku":"035355015","price":11.31,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-pharma-italia-spa-tantum-verde-bocca-22-5-mg-15-ml-7-5-mg-15-ml-240-ml-collutorio-farmacia-dottor-tili-1213791055.jpg?v=1767154787"},{"product_id":"benactivdolmed-8-75-mg-dose-15-ml-spray-orale-limone-e-miele","title":"BenactivDolMed 8.75 mg\/dose 15 ml lemon and honey oral spray","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBenactivdolmed is indicated for the short-term symptomatic treatment of acute pain in sore throat in adults.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. • Patients who have previously experienced hypersensitivity reactions (e.g. asthma, bronchospasm, rhinitis, angioedema or urticaria) in response to acetylsalicylic acid or other NSAIDs. • Current or previous peptic ulcer\/recurrent hemorrhage (two or more distinct episodes of demonstrated ulceration) and intestinal ulceration. • History of gastrointestinal bleeding or perforation, severe colitis, bleeding or haematopoietic disorders related to previous therapy with NSAIDs. • Last trimester of pregnancy (see section 4.6). • Severe heart failure, severe renal failure or severe hepatic failure (see section 4.4). • Children and adolescents under the age of 18.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects can be minimized by using the lowest effective dose for the shortest duration of treatment needed to control symptoms. \u003cu\u003eInfections\u003c\/u\u003e: Since an exacerbation of infectious inflammations (e.g. development of necrotizing fasciitis) has been described in isolated cases in temporal association with the systemic use of drugs belonging to the NSAID class, the patient is recommended to immediately consult a doctor in the event of the appearance or worsening of signs of a bacterial infection during therapy with flurbiprofen spray. Consideration should be given to whether initiation of antibiotic therapy is indicated. In case of purulent bacterial pharyngitis\/tonsillitis, the patient is advised to consult the doctor for a re-evaluation of the treatment. Treatment should be administered for a maximum of 3 days. If symptoms worsen or new symptoms appear, treatment should be reevaluated. If mouth irritation occurs, treatment with flurbirprofen should be discontinued. \u003cu\u003eElderly population\u003c\/u\u003e: Elderly people experience an increased frequency of adverse reactions to NSAIDs, especially bleeding and gastrointestinal perforation, which may be fatal. \u003cu\u003eRespiratory effects\u003c\/u\u003e: Bronchospasm may be precipitated in patients with or with a previous history of bronchial asthma or allergic disease. Flurbiprofen spray should be used with caution in these patients. \u003cu\u003eOther NSAIDs\u003c\/u\u003e: The use of flurbiprofen spray should be avoided concomitantly with other NSAIDs, including selective cyclooxygenase-2 inhibitors (see section 4.5). \u003cu\u003eSystemic lupus erythematosus (SLE) and mixed connective tissue disease\u003c\/u\u003e: Patients with systemic lupus erythematosus (SLE) and mixed connective tissue disease may have an increased risk of aseptic meningitis (see section 4.8), however this effect is not usually seen with products intended for limited and short-term use such as flurbiprofen spray. \u003cu\u003eCardiovascular, renal and hepatic impairment\u003c\/u\u003e: NSAIDs have been reported to cause various forms of nephrotoxicity, including interstitial nephritis, nephrotic syndrome, and renal failure. The administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and precipitate renal failure. Patients at greatest risk of developing this reaction are those with impaired renal function, cardiac impairment, liver dysfunction, those on diuretic therapy and the elderly; however, this effect is not usually seen with products intended for limited, short-term use such as flurbiprofen spray. \u003cu\u003eHepatic effects\u003c\/u\u003e: Mild to moderate hepatic dysfunction (see sections 4.3 and 4.8). \u003cu\u003eCardiovascular and cerebrovascular effects\u003c\/u\u003e: Before starting treatment in patients with a history of hypertension and\/or heart failure, caution is required (contact your doctor or pharmacist) since fluid retention, hypertension and edema have been reported in association with NSAID therapy. Clinical studies and epidemiological data suggest that the use of some NSAIDs (particularly at high doses and in long-term treatment) may be associated with a slight increase in the risk of arterial thrombotic events (for example myocardial infarction or stroke). There are insufficient data to exclude this risk with flurbiprofen when administered at a daily dose not exceeding 5 doses (3 actuations for each dose). \u003cu\u003eEffects on the nervous system\u003c\/u\u003e: Headache induced by analgesics - In case of prolonged or irregular use of analgesics, headache may occur, which must not be treated by increasing the dose of the medicine. \u003cu\u003eGastrointestinal effects\u003c\/u\u003e: NSAIDs should be administered with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). Gastrointestinal bleeding, ulceration or perforation, which may be fatal, have been reported with all NSAIDs at any time during treatment, with or without warning symptoms or a prior history of serious gastrointestinal events. The risk of gastrointestinal bleeding, ulceration or perforation is higher with increasing doses of NSAIDs, in patients with a history of ulcer, especially if complicated by haemorrhage or perforation (see section 4.3) and in the elderly; however, this effect is not usually seen with products intended for short-term limited use such as flurbiprofen spray. Patients with a history of gastrointestinal toxicity, particularly if elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) to their doctor. Caution should be advised in patients receiving concomitant medicinal products that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid (see section 4.5). If gastrointestinal bleeding or ulceration occurs in patients taking flurbiprofen, treatment should be discontinued. \u003cu\u003eHematological effects\u003c\/u\u003e: Flurbiprofen, like other NSAIDs, can inhibit platelet aggregation and prolong bleeding time. Flurbiprofen spray should be used with caution in patients with potential for abnormal bleeding. \u003cu\u003eDermatological effects\u003c\/u\u003e: Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported very rarely in association with the use of NSAIDs (see section 4.8). Flurbiprofen spray should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. This product contains methyl parahydroxybenzoate and propyl parahydroxybenzoate which may cause allergic reactions (sometimes delayed). This product contains less than 1 mmol (23 mg) sodium per dose, i.e. essentially “sodium-free”. Flavors containing allergens: This product contains flavors containing anisilic alcohol, citral, citronellol, d-Limonene, geraniol and linalool. Anisilic alcohol, citral, citronellol, d-Limonene, geraniol, linalool can cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eFlurbiprofen \u003cu\u003emust be avoided\u003c\/u\u003e in association with\u003c\/b\u003e:\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eOther NSAIDs including selective cyclooxygenase-2 inhibitors\u003c\/i\u003e: | Avoid concomitant use of two or more NSAIDs, as this may increase the risk of adverse effects (especially gastrointestinal adverse events such as ulcers and bleeding) (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eAcetylsalicylic acid (at low doses)\u003c\/i\u003e: | Unless taking low-dose aspirin (not exceeding 75 mg\/day) has been recommended by your doctor, as the risk of adverse events may increase (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eFlurbiprofen must be used \u003cu\u003ewith caution\u003c\/u\u003e in association with\u003c\/b\u003e:\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eAnticoagulants\u003c\/i\u003e: | NSAIDs may potentiate the effects of anticoagulants such as warfarin (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eAntiplatelet agents\u003c\/i\u003e: | There is an increased risk of gastrointestinal ulceration or bleeding (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eAntihypertensive drugs (Diuretics, ACE inhibitors, angiotensin II antagonists)\u003c\/i\u003e: | NSAIDs may reduce the effect of diuretics and other antihypertensive drugs may potentiate nephrotoxicity caused by inhibition of cyclooxygenase, especially in patients with impaired renal function.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eAlcohol\u003c\/i\u003e: | May increase the risk of adverse reactions, especially bleeding in the gastrointestinal tract.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eCardiac glycosides\u003c\/i\u003e: | NSAIDs can exacerbate heart failure, reduce VGR (glomerular filtration rate) and increase plasma glycoside levels - adequate monitoring and, if necessary, dose adjustment is recommended.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eCyclosporine\u003c\/i\u003e: | There is an increased risk of nephrotoxicity.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eCorticosteroids\u003c\/i\u003e: | There is an increased risk of gastrointestinal ulceration or bleeding (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eLithium\u003c\/i\u003e: | There may be an increase in serum lithium levels - adequate monitoring and, if necessary, dose adjustment is recommended.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eMethotrexate\u003c\/i\u003e: | The administration of NSAIDs within 24 hours before or after the administration of methotrexate can lead to high concentrations of methotrexate and an increase in its toxic effects.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eMifepristone\u003c\/i\u003e: | NSAIDs should not be used for 8 - 12 days after administration of mifepristone, as NSAIDs may reduce the effect of mifepristone.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eOral antidiabetics\u003c\/i\u003e: | Alterations in blood glucose levels have been reported (increasing the frequency of checks is recommended).\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003ePhenytoin\u003c\/i\u003e: | Serum levels of phenytoin may increase - adequate monitoring and, if necessary, dose adjustment is recommended.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003ePotassium-sparing diuretics\u003c\/i\u003e: | Concomitant use may cause hyperkalemia.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eProbenecid and Sulfinpyrazone\u003c\/i\u003e: | Medicines containing probenecid and sulfinpyrazone may delay the excretion of flurbiprofen.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eQuinolone antibiotics\u003c\/i\u003e: | Animal data indicate that NSAIDs may increase the risk of seizures associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may be at increased risk of developing seizures.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eSelective serotonin reuptake inhibitors (SSRIs)\u003c\/i\u003e: | There is an increased risk of gastrointestinal ulceration or bleeding (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eTacrolimus\u003c\/i\u003e: | An increased risk of nephrotoxicity is possible when NSAIDs are administered concomitantly with tacrolimus.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eZidovudine\u003c\/i\u003e: | There is an increased risk of haematological toxicity when NSAIDs are administered together with zidovudine.\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePediatric population\u003c\/u\u003e: No additional information available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity reactions to NSAIDs have been reported and these may consist of: (a) non-specific allergic reactions and anaphylaxis; (b) respiratory tract reactivity, e.g. asthma, aggravated asthma, bronchospasm, dyspnoea; (c) various skin reactions, e.g. pruritus, urticaria, angioedema and, more rarely, exfoliative and bullous dermatosis (including epidermal necrolysis and erythema multiforme). Edema, hypertension and heart failure have been reported in association with treatment with NSAIDs. Data are insufficient to exclude this risk with the use of flurbiprofen oral mucosal spray, solution. \u003cb\u003eThe list of adverse effects reported below refers to those recorded with flurbiprofen, used at doses compatible with the OTC classification and for a short period\u003c\/b\u003e. (Very common (≥1\/10), Common (≥1\/100 to \u003c1\/10), Uncommon (≥1\/1,000 to \u003c1\/100), Rare (≥1\/10,000 to \u003c1\/1,000), Very rare (\u003c1\/10,000), Not known (cannot be estimated from the available data)). \u003ci\u003ePathologies of the blood and lymphatic system\u003c\/i\u003e. Not known: anemia, thrombocytopenia. \u003ci\u003eCardiovascular and cerebrovascular diseases\u003c\/i\u003e. Not known: edema, hypertension, heart failure. \u003ci\u003eNervous system disorders\u003c\/i\u003e. Common: dizziness, headache, paraesthesia; Uncommon: drowsiness. \u003ci\u003eRespiratory, thoracic and mediastinal disorders\u003c\/i\u003e. Common: throat irritation; Uncommon: exacerbation of asthma and bronchospasm, dyspnoea, wheezing, oropharyngeal vesicular rash, hypoesthesia of the pharynx. \u003ci\u003eGastrointestinal disorders\u003c\/i\u003e. Common: diarrhoea, mouth ulceration, nausea, oral pain, oral paraesthesia, oropharyngeal pain, oral discomfort (warm or burning sensation, tingling in the mouth); Uncommon: abdominal distension, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, glossodynia, dysgeusia, oral dysesthesia, vomiting. \u003ci\u003ePathologies of the skin and subcutaneous tissue\u003c\/i\u003e. Uncommon: various types of skin rashes, itching; Not known: severe forms of skin reactions such as bullous reactions, including Stevens-Johnson syndrome and toxic epidermal necrosis. \u003ci\u003eGeneral pathologies and conditions relating to the administration site\u003c\/i\u003e. Uncommon: pyrexia, pain. \u003ci\u003eImmune system disorders\u003c\/i\u003e. Rare: anaphylactic reaction. \u003ci\u003ePsychiatric disorders\u003c\/i\u003e. Uncommon: insomnia. \u003ci\u003eHepatobiliary disorders\u003c\/i\u003e. Not known: hepatitis. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":51730210324807,"sku":"048231017","price":13.49,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/reckitt-benckiser-h-it-spa-benactivdolmed-8-75-mg-dose-15-ml-spray-orale-limone-e-miele-farmacia-dottor-tili-1213791050.jpg?v=1767154809"},{"product_id":"tantum-verde-gola-250-mg-100-ml-15-ml-spray-orale","title":"Tantum Verde throat 250 mg\/100 ml 15 ml oral spray","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSymptomatic treatment of irritative-inflammatory states, also associated with oropharyngeal pain (e.g. pharyngitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTantum Verde Gola is contraindicated in patients with known hypersensitivity (asthma, urticaria or allergic type) to flurbiprofen or to any of the excipients listed in paragraph 6.1 and to aspirin or other NSAIDs. In the third trimester of pregnancy. Do not use in patients who have peptic ulcers or who have had them in the past.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAt the recommended doses, any occasional swallowing of Tantum Verde Gola does not cause any harm to the patient as these doses are widely lower than those commonly used in treatments with systemic flurbiprofen. Tantum Verde Gola should be used with caution by patients with non-allergic asthma, in fact cases of bronchospasm have been reported with flurbiprofen in patients with a history of bronchial asthma. The use of the product, especially if prolonged, can give rise to sensitization or local irritation phenomena. In such cases, treatment should be discontinued and appropriate therapy instituted, if necessary. Do not use for prolonged treatments.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are no known interactions with other drugs or otherwise.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThey were reported, in particular \u003cb\u003eafter the administration of formulations for systemic use\u003c\/b\u003e, the following side effects, reported according to the MedDRA systemic and organic classification. The following value scales were used: very common (≥1\/10); common (≥1\/100, \u003c1\/10); uncommon (≥ 1\/1000, \u003c 1\/100); rare ≥ 1\/10,000, \u003c 1\/1000); very rare (\u003c1\/10,000); not known (frequency cannot be estimated from the available data).\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e \u003ci\u003eSystem organ class according to MedDRA\u003c\/i\u003e \u003c\/b\u003e | \u003cb\u003eFrequency not known\u003c\/b\u003e (frequency cannot be estimated from the available data)\u003c\/p\u003e\n\u003cp\u003ePathologies of the blood and lymphatic system | Thrombocytopenia, aplastic anemia, agranulocytosis\u003c\/p\u003e\n\u003cp\u003eImmune system disorders | Anaphylaxis, angioedema, allergic reaction.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders | Depression, confusion, hallucination\u003c\/p\u003e\n\u003cp\u003eNervous system disorders | Dizziness, hemorrhage and cerebrovascular accident, optic neuritis, migraine, paraesthesia, drowsiness.\u003c\/p\u003e\n\u003cp\u003eEye diseases | Visual disturbances\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders | Tinnitus, vertigo\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders | Asthma, bronchospasm, dyspnea\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders | Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melena, haematemesis, ulcerative stomatitis, gastrointestinal haemorrhage, colitis and Crohn's disease, gastritis, peptic ulcer, perforation and gastric ulcer with haemorrhage.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders | Bullous conditions (including, Stevens Johnson Syndrome, toxic epidermal necrolysis, erythema multiforme), skin disorders including rash, pruritus, urticaria, purpura\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders | Renal failure, nephrotoxicity in various forms including interstitial nephritis and nephrotic syndrome\u003c\/p\u003e\n\u003cp\u003eSystemic disorders and conditions relating to the administration site | Annoyance, fatigue\u003c\/p\u003e\n\u003cp\u003eReporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at \u003cu\u003ewww.agenziafarmaco.gov.it\/it\/responsabili\u003c\/u\u003e.\u003c\/p\u003e","brand":"Angelini Pharma","offers":[{"title":"Default Title","offer_id":51730210455879,"sku":"034015026","price":11.63,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/angelini-pharma-italia-spa-tantum-verde-gola-250-mg-100-ml-15-ml-spray-orale-farmacia-dottor-tili-1213791046.jpg?v=1767154966"},{"product_id":"lenident-zeta-2-6-ml-soluzione-dentale","title":"Lenident Zeta 2% 6ml dental solution","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal anaesthetic, analgesic for toothache due to tooth decay, pulpopathy and periodontitis.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIndividual hypersensitivity confirmed towards the product.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNone. Warning: Not to be administered to children under six years of age. Keep out of reach of children.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNone known.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use, especially if prolonged, of products for topical use can give rise to sensitization phenomena. Should they occur, stop applying the preparation and consult your doctor.\u003c\/p\u003e","brand":"Zeta Farmaceutici","offers":[{"title":"Default Title","offer_id":51730210521415,"sku":"025635018","price":6.42,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/zeta-farmaceutici-spa-lenident-zeta-2-6-ml-soluzione-dentale-farmacia-dottor-tili-1213791044.jpg?v=1767155008"},{"product_id":"neo-borocillina-gola-dolore-0-25-15-ml-spray-orale-gusto-menta","title":"Neo Borocillin throat pain 0.25% 15 ml mint flavor oral spray","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNEO BOROCILLINA THROAT PAIN mouthwash \/ NEO BOROCILLINA THROAT PAIN spray for oral mucosa is used in the symptomatic treatment of irritative-inflammatory conditions also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy. NEO BOROCILLINA THROAT PAIN tablets are used in the symptomatic treatment of irritative-inflammatory states also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFlurbiprofen is contraindicated in patients with hypersensitivity (asthma, bronchospasm, urticaria or allergic type) towards flurbiprofen or to any of the excipients, and towards acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). Third trimester of pregnancy. The administration of flurbiprofen is not recommended in breastfeeding mothers. Do not use in patients who have peptic ulcers or who have had them in the past. \u003ci\u003e \u003cu\u003eDo not give the tablets to children under the age of 12\u003c\/u\u003e \u003c\/i\u003e \u003ci\u003e \u003cu\u003eyears.\u003c\/u\u003e \u003c\/i\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAt the recommended doses, when using the medicine in its various pharmaceutical forms, any swallowing does not, in itself, cause any harm to the patient, as these doses are widely lower than those commonly used in treatments with flurbiprofen systemically. In patients with renal, cardiac or hepatic insufficiency, the medicine NEO BOROCILLINA THROAT PAIN should be used with caution. It is recommended not to combine the medicine with NSAIDs. Use of the product, especially if prolonged, can give rise to local sensitization or irritation phenomena; in such cases it is necessary to interrupt the treatment and consult the doctor to institute, if necessary, a suitable therapy. Do not use for prolonged treatments. After a short period of treatment without appreciable results, consult your doctor. \u003cb\u003eNEO BOROCILLINA THROAT PAIN mouthwash and NEO BOROCILLINA THROAT PAIN spray for oral mucosa (all presentations) contain:\u003c\/b\u003e - 960 mg of ethanol per 10 ml of mouthwash. May cause burning sensation on damaged skin. - hydrogenated polyoxide castor oil which may cause localized skin reactions. - parahydroxy benzoates which can cause allergic reactions (even delayed). NEO BOROCILLINA THROAT PAIN 0.25% spray for oral mucosa orange and honey flavor and NEO BOROCILLINA THROAT PAIN 0.25% spray for oral mucosa lemon and honey flavor also contain the coloring sunset yellow (E110), which can cause allergic reactions.NEO BOROCILLINA THROAT PAIN 8.75 mg lozenges (all presentations) contains isomalt: patients suffering from rare hereditary problems of intolerance to fructose, you should not take this medicine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHowever, inform your doctor if you are taking other medicines. As demonstrated in some clinical studies, flurbiprofen may occasionally reduce the diuretic activity of furosemide. Furthermore, flurbiprofen may occasionally interfere with the action of anticoagulant drugs. However, no interaction of flurbiprofen with digoxin, tolbutamide and antacids has been demonstrated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe use of NEO BOROCILLINA THROAT PAIN, especially if prolonged, can give rise to sensitization or local irritation phenomena; in such cases it is necessary to interrupt the treatment and institute, if necessary, a suitable therapy. The following side effects have been reported, particularly after the administration of higher doses systemically: \u003ci\u003e \u003cu\u003ePathologies of the blood and lymphatic system\u003c\/u\u003e \u003c\/i\u003e Thrombocytopenia, aplastic anemia and agranulocytosis. \u003ci\u003e \u003cu\u003eImmune system disorders\u003c\/u\u003e \u003c\/i\u003e Anaphylaxis, angioedema, allergic reaction. \u003ci\u003e \u003cu\u003eNervous system disorders\u003c\/u\u003e \u003c\/i\u003e Dizziness, cerebrovascular accident, visual disturbances, optic neuritis, migraine, paraesthesia, depression, confusion, hallucination, vertigo, discomfort, fatigue and drowsiness. \u003ci\u003e \u003cu\u003eEar and labyrinth disorders\u003c\/u\u003e \u003c\/i\u003e Tinnitus. \u003ci\u003e \u003cu\u003eRespiratory, thoracic and mediastinal disorders\u003c\/u\u003e \u003c\/i\u003e Reactivity of the respiratory tract (asthma, bronchospasm and dyspnea). \u003ci\u003e \u003cu\u003eGastrointestinal disorders\u003c\/u\u003e \u003c\/i\u003e The most commonly observed adverse events are gastrointestinal in nature. The following have been reported after administration of flurbiprofen: nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melena, haematemesis, ulcerative stomatitis, gastrointestinal haemorrhage and exacerbation of colitis and Crohn's disease. Less frequently, gastritis, peptic ulcer, perforation and ulcer bleeding have been observed. \u003ci\u003e \u003cu\u003ePathologies of the skin and subcutaneous tissue\u003c\/u\u003e \u003c\/i\u003e Skin disorders including rash, pruritus, urticaria, purpura and very rarely bullous dermatoses (including Stevens-Johnson syndrome, Toxic Epidermal Necrolysis and Erythema multiforme). \u003ci\u003e \u003cu\u003eRenal and urinary disorders\u003c\/u\u003e \u003c\/i\u003e Nephrotoxicity in various forms, including interstitial nephritis and nephrotic syndrome. As with other NSAIDs, rare cases of renal failure have been reported. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/p\u003e","brand":"Alfasigma","offers":[{"title":"Default Title","offer_id":51730210881863,"sku":"035760038","price":11.35,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/alfasigma-spa-neo-borocillina-gola-dolore-0-25-15-ml-spray-orale-gusto-menta-farmacia-dottor-tili-1213791037.jpg?v=1767164566"},{"product_id":"benagol-pastiglie-con-vitamina-c-gusto-arancia-36-pastiglie","title":"Benagol tablets with vitamin C orange flavour 36 tablets","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAntiseptic of the oral cavity.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substances or to any of the excipients listed in paragraph 6.1. Do not administer to children under 6 years of age. BENAGOL Menthol-Eucalyptol flavor is contraindicated in children with a history of epilepsy or febrile convulsions. Do not administer BENAGOL Cold Mint flavor and BENAGOL Ginger and Spice flavor to children under 12 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS AND PRECAUTIONS FOR USE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBe careful with pre-school children as if the tablets are swallowed whole they may cause choking. In the event of the appearance of sensitization or irritation phenomena, administration should be discontinued and suitable treatment instituted. BENAGOL Menthol-Eucalyptol flavor contains terpene derivatives which, in excessive doses, can cause neurological disorders such as convulsions in infants and children. Treatment with BENAGOL Menthol-Eucalyptol flavor must not be prolonged for more than 3 days due to the risks associated with the accumulation of terpene derivatives, such as \u003ci\u003eexample camphor, cineol, niaouli, wild thyme, terpineol, terpine, citral, menthol and essential oils of pine needles, eucalyptus and turpentine\u003c\/i\u003e (due to their lipophilic properties the rate of metabolism and disposal is not known) in tissues and the brain, in particular neuropsychological disorders. A higher than recommended dose should not be used to avoid an increased risk of adverse drug reactions and disorders associated with overdose (see section 4.9). BENAGOL Menthol-Eucalyptol flavor is flammable, it should not be brought near flames. \u003ci\u003eImportant information about some excipients\u003c\/i\u003e \u003cu\u003eBENAGOL Ginger and Spice flavored tablets, BENAGOL Honey and Lemon flavored tablets\u003c\/u\u003e, \u003cu\u003eBENAGOL Menthol-Eucalyptol flavor tablets, BENAGOL Orange flavor tablets with Vitamin C, BENAGOL Cold Mint flavor tablets contain\u003c\/u\u003e Liquid glucose: - Patients suffering from rare hereditary problems of glucose-galactose malabsorption should not take this medicine. - To be taken into consideration in people suffering from diabetes mellitus: BENAGOL Ginger and Spice flavored tablets contains 1.10 g of glucose per tablet. BENAGOL Honey and Lemon flavored tablets contains 0.98 g of glucose per tablet. BENAGOL Menthol-Eucalyptol flavor tablets contains 1.01 g of glucose per tablet. BENAGOL Tablets with Vitamin C Orange flavor contains 0.97 g of glucose per tablet. BENAGOL Cold Mint flavor tablets contains 1.10 g of glucose per tablet. - Liquid glucose contains sulphites. These medicines can rarely cause serious hypersensitivity reactions and bronchospasm. - Liquid glucose contains wheat starch. These medicines contain only a very small amount of gluten (from wheat starch). These medicines are considered “gluten-free” and are very unlikely to cause problems if the patient has celiac disease. One tablet of BENAGOL Ginger and Spice flavored tablets contains no more than 22.04 micrograms of gluten. One tablet of BENAGOL Honey and Lemon flavored tablets contains no more than 19.52 micrograms of gluten. One tablet of BENAGOL Menthol-Eucalyptol flavor contains no more than 20.26 micrograms of gluten. One tablet of BENAGOL Tablets with Vitamin C Orange flavor contains no more than 19.38 micrograms of gluten. One tablet of BENAGOL Cold Mint flavor tablets contains no more than 22.04 micrograms of gluten. If the patient is allergic to wheat (a condition other than celiac disease) he should not take these medicines. Liquid sucrose: - Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine. - To be taken into consideration in people suffering from diabetes mellitus: BENAGOL Ginger and Spice flavored tablets contains 1.38 g of sucrose per tablet. BENAGOL Honey and Lemon flavored tablets contains 1.44 g of sucrose per tablet. BENAGOL Menthol-Eucalyptol flavor tablets contains 1.50 g of sucrose per tablet. BENAGOL Tablets with Vitamin C Orange flavor contains 1.44 g of sucrose per tablet. BENAGOL Cold Mint flavor tablets contains 1.38 g of sucrose per tablet. \u003cu\u003eBENAGOL Ginger and Spice flavored tablets, BENAGOL Menthol-Eucalyptol flavored tablets\u003c\/u\u003e, \u003cu\u003eBENAGOL Tablets with Vitamin C Orange flavor, BENAGOL Tablets Lemon flavor Without Sugar, BENAGOL Tablets Strawberry flavor Without Sugar\u003c\/u\u003e These medicines contain less than 1 mmol (23 mg) sodium per dose, i.e. essentially 'sodium-free'. \u003cu\u003eBENAGOL Lemon Flavor Tablets Without Sugar and BENAGOL Strawberry Flavor Tablets Without Sugar\u003c\/u\u003e These medicines contain liquid maltitol and isomalt. Patients with rare hereditary problems of fructose intolerance should not take this medicine. They may have a mild laxative effect. The caloric value of maltitol and isomalt is 2.3 kcal\/g. \u003cu\u003eBENAGOL Ginger and Spice flavored tablets\u003c\/u\u003e This medicine contains a flavoring which contains cinnamale, citral, citronellol, eugenol, farfalle, geraniol, isoeugenol and linalool. Cinnamale, citral, citronellol, eugenol, farfalle, geraniol, isoeugenol and linalool can cause allergic reactions. This medicine contains excipients that can cause a warm sensation in the mouth and throat when you suck the lozenge. \u003cu\u003eBENAGOL Honey and Lemon flavored tablets\u003c\/u\u003e This medicine contains a flavoring which contains citral, d-limonene, geraniol and linalool. Citral, d-limonene, geraniol and linalool can cause allergic reactions. This medicine contains honey (invert sugar). Patients suffering from rare hereditary problems of fructose intolerance, or glucose-galactose malabsorption, should not take this medicine. \u003cu\u003eBENAGOL Menthol-Eucalyptol flavor tablets\u003c\/u\u003e This medicine contains a flavoring which contains d-limonene. D-limonene can cause allergic reactions. \u003cu\u003eBENAGOL Orange flavored tablets with Vitamin C\u003c\/u\u003e This medicine contains a flavoring which contains citral, citronellol, d-limonene, geraniol and linalool. Citral, citronellol, d-limonene, geraniol and linalool can cause allergic reactions. This medicine contains 3 mg of propylene glycol per tablet. \u003cu\u003eBENAGOL Lemon flavored tablets without sugar\u003c\/u\u003e This medicine contains a flavoring which contains benzyl alcohol, citral, citronellol, d-limonene, geraniol and linalool. Benzyl alcohol, citral, citronellol, d-limonene, geraniol and linalool can cause allergic reactions. \u003cu\u003eBENAGOL Strawberry flavored tablets without sugar\u003c\/u\u003e This medicine contains a flavoring which contains benzyl alcohol. Benzyl alcohol can cause allergic reactions. This medicine contains 7.30 mg of propylene glycol in each tablet. \u003cu\u003eBENAGOL Cold Mint flavor tablets\u003c\/u\u003e This medicine contains a flavoring which contains benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool. Benzyl alcohol, cinnamyl alcohol, citral, citronellol, d-limonene, eugenol and linalool can cause allergic reactions. This medicine contains 1.89 mg of propylene glycol in each tablet.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBENAGOL Menthol-Eucalyptol flavor must not be used in conjunction with other products (medicines or cosmetics) containing terpene derivatives, regardless of the route of administration (oral, rectal, cutaneous, nasal or inhalation).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBENAGOL Menthol - Eucalyptol flavour: due to the presence of menthol and in case of non-compliance with the recommended doses there may be a risk of convulsions in children and infants. Adverse reactions associated with the use of 2,4 dichlorobenzyl alcohol, amylmetacresol, levomenthol and ascorbic acid are listed below, divided by frequency and organ class. Frequencies are defined as: Very common (≥1\/10); Common (≥1\/100 and \u003c1\/10); Uncommon (≥1\/1000 and \u003c1\/100); Rare (≥1\/10000 and \u003c1\/1000); Very rare (\u003c1\/10000); Not known (frequency cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eClassification by systems and organs\u003c\/b\u003e | \u003cb\u003eFrequency\u003c\/b\u003e | \u003cb\u003eAdverse reactions\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eImmune system disorders | Rare | Hypersensitivity\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders | Rare | Glossitis\u003c\/p\u003e\n\u003cp\u003eNot known | Abdominal pain, nausea, gastrointestinal discomfort\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders | Not known | Skin rash\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":51730211307847,"sku":"016242152","price":16.09,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/reckitt-benckiser-h-it-spa-benagol-pastiglie-con-vitamina-c-gusto-arancia-36-pastiglie-farmacia-dottor-tili-1213791030.jpg?v=1767164668"},{"product_id":"aspi-gola-dol-mal-di-gola-16-pastiglie-arancia-senza-zucchero","title":"Aspi Gola Dol Sore Throat 16 Orange Sugar Free Lozenges","description":"\u003cp\u003e\u003cstrong\u003eAspi Gola Dol Anti-inflammatory Throat Candies\u003c\/strong\u003e is a medicine based on flurbiprofen, formulated in practical tablets to dissolve in the mouth and designed to offer rapid relief from \u003cstrong\u003esore throat\u003c\/strong\u003e, also accompanied by inflammation and persistent pain. His presentation in \u003cstrong\u003econsisting of 16 sugar-free orange flavored tablets\u003c\/strong\u003e makes the treatment particularly suitable for those looking for an effective but delicate action, combined with a pleasant flavor and free of added sugars, also ideal for those following controlled diets or suffering from diabetes.\u003c\/p\u003e\n\u003cp\u003eThe heart of the effectiveness of Aspi Gola Dol lies in the presence of \u003cstrong\u003eflurbiprofen 8.75 mg\u003c\/strong\u003e per tablet, an active ingredient belonging to the class of NSAIDs (non-steroidal anti-inflammatory drugs), recognized for its dual action: \u003cstrong\u003eanti-inflammatory and analgesic\u003c\/strong\u003e. This allows us to intervene not only on the painful symptom, but also on the underlying inflammatory cause, thus treating the oropharyngeal discomfort at its root. The lozenges act locally, slowly dissolving in the mouth and reaching the affected area directly, promoting rapid and prolonged relief.\u003c\/p\u003e\n\u003cp\u003eAspi Gola Dol is particularly indicated for the symptomatic treatment of inflammation of the oropharyngeal cavity of various origins: \u003cstrong\u003ecold sore throat, pharyngitis, tonsillitis, laryngitis\u003c\/strong\u003e, or simply as an adjuvant in case of \u003cstrong\u003eirritation due to vocal efforts or exposure to external agents\u003c\/strong\u003e such as smoke or dry air. Thanks to its targeted effectiveness, it can also be used in case of canker sores or irritated gums, offering an immediate calming and anti-inflammatory action.\u003c\/p\u003e\n\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy should you use Aspi Gola Dol Sore Throat 16 Orange Sugar Free Lozenges? What is it for?\u003c\/h3\u003e\u003cp\u003eSymptomatic treatment of irritative-inflammatory conditions also associated with oropharyngeal pain (e.g. gingivitis, stomatitis, pharyngitis).\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eACTIVE INGREDIENTS AND EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat is the composition of Aspi Gola Dol Mal di Gola 16 Orange Sugar-Free Lozenges?\u003c\/h3\u003e\u003cp\u003eOne tablet contains: \u003cu\u003eActive ingredient\u003c\/u\u003e: flurbiprofen 8.75 mg \u003cu\u003eExcipients with known effects: \u003c\/u\u003eglucose, sucrose For the full list of excipients, see section 6.1.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cp\u003eIsomalt; maltitol, liquid; acesulfame potassium; macrogol 300; potassium hydroxide; ponceau 4R (E-124); yellow orange S (E-110); natural orange flavour; levomenthol.\u003c\/p\u003e\n\u003ch2\u003eDOSAGE\u003c\/h2\u003e\n\u003ch3\u003eHow to take Aspi Gola Dol Mal di Gola 16 Orange Lozenges Without Sugar?\u003c\/h3\u003e\u003cp\u003eUndesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.4). \u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003eAdults\u003c\/i\u003e: 1 tablet every 3-6 hours, as needed. Do not exceed the dose of 8 tablets in 24 hours. \u003ci\u003ePediatric population\u003c\/i\u003e Children over 12 years old: same as adults. Children under 12 years of age: Do not administer to children under 12 years of age (see section 4.3). \u003ci\u003eSpecial populations\u003c\/i\u003e \u003ci\u003eElderly\u003c\/i\u003e: The clinical data currently available are limited, therefore no recommendation regarding posology can be made. Elderly people are at greater risk of serious consequences in case of adverse reactions (see section 4.4). \u003ci\u003ePatients with liver failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate hepatic impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3). \u003ci\u003ePatients with renal failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate renal impairment. Flurbiprofen is contraindicated in patients with severe renal impairment (see section 4.3). \u003cu\u003eMethod of administration\u003c\/u\u003e For oropharyngeal use. Dissolve slowly in your mouth. As with all lozenges, in order to avoid local irritation, flurbiprofen lozenges should also be moved inside the mouth during administration. If mouth irritation occurs, treatment should be discontinued.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003eWhen should Aspi Gola Dol Sore Throat 16 Orange Sugar Free Lozenges not be used and what side effects can it cause?\u003c\/h3\u003e\u003cp\u003eDo not use the medicine in children under 12 years of age. Flurbiprofen is contraindicated in patients with known hypersensitivity to flurbiprofen or to any of the excipients listed in section 6.1. Patients who have previously shown hypersensitivity reactions (e.g. asthma, urticaria, allergy, rhinitis, angioedema, bronchospasm) towards ibuprofen, acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). Flurbiprofen is also contraindicated in patients with a history of gastrointestinal bleeding or perforation related to previous NSAID treatment. Flurbiprofen should not be taken by patients with active or anamnestic ulcerative colitis, Crohn's disease, recurrent peptic ulcer or gastrointestinal haemorrhage (defined as two or more distinct episodes of demonstrated ulceration or bleeding). Flurbiprofen is contraindicated in patients with severe heart failure, severe hepatic failure and renal failure (see section 4.4). Third trimester of pregnancy.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cp\u003eHypersensitivity reactions to NSAIDs have been reported and these may consist of: (a) non-specific allergic reactions and anaphylaxis (b) respiratory tract reactivity, e.g. asthma, aggravated asthma, bronchospasm, dyspnoea (c) various skin disorders, including for example skin rashes of different types, pruritus, urticaria, purpura, angioedema and, more rarely, exfoliative and bullous dermatosis (including necrolysis epidermal and erythema multiforme). The most commonly observed adverse reactions are gastrointestinal in nature. Local use of the medicine, especially if prolonged, can give rise to local sensitization or irritation phenomena. The dissolution of the medicine in tablet form in the oral cavity may be accompanied by sensations of heat or tingling in the oropharynx. In such cases it is necessary to interrupt treatment and institute, if necessary, suitable therapy. The following side effects have been reported, particularly after the administration of formulations for systemic use. They refer to those detected with the use of flurbiprofen used short term and at doses compatible with the classification of self-medication medicines. When treating chronic conditions and for long periods of time, additional side effects may occur. The side effects associated with the use of flurbiprofen are divided below based on system organ classification and frequency. Frequency is defined as: very common (≥ 1\/10), common (≥1\/100, \u003c1\/10), uncommon (≥1\/1,000, \u003c1\/100), rare (≥1\/10,000, \u003c1\/1,000), very rare (\u003c1\/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.\u003c\/p\u003e\u003cb\u003eClassification by systems and organs\u003c\/b\u003e - \u003cb\u003eFrequency\u003c\/b\u003e - \u003cb\u003eAdverse reactions\u003c\/b\u003e\u003cbr\u003eBlood and lymphatic system disorders - Not known - Anemia, thrombocytopenia, aplastic anemia and agranulocytosis\u003cbr\u003eNervous system disorders - Common - Dizziness, headache, paraesthesia\u003cbr\u003eUncommon - Drowsiness\u003cbr\u003eNot known - Cerebrovascular accidents, optic neuritis, migraine, confusional states, dizziness\u003cbr\u003eImmune system disorders - Rare - Anaphylactic reactions\u003cbr\u003eNot known - Angioedema, hypersensitivity\u003cbr\u003eEye disorders - Not known - Visual disturbances\u003cbr\u003eEar and labyrinth disorders - Not known - Tinnitus\u003cbr\u003eCardiac disorders - Not known - Heart failure, edema\u003cbr\u003eVascular disorders - Not known - Hypertension\u003cbr\u003eRespiratory, thoracic and mediastinal disorders - Common - Throat irritation\u003cbr\u003eUncommon - Asthma, bronchospasm and dyspnoea, blisters in the oropharynx, oropharyngeal hypoesthesia\u003cbr\u003eGastrointestinal disorders - Common - Diarrhoea, mouth ulcers, nausea, oral pain, oral paraesthesia, oropharyngeal pain, oral discomfort (hot or burning sensation, tingling in the mouth)\u003cbr\u003eUncommon - Abdominal distension, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, glossodynia, dysgeusia, oral dysesthesia, vomiting\u003cbr\u003eNot known - Melena, haematemesis, gastrointestinal haemorrhage, colitis, exacerbation of Crohn's disease, gastritis, peptic ulcer, gastric perforation, ulcer haemorrhage\u003cbr\u003eSkin and subcutaneous tissue disorders - Uncommon - Rash, pruritus\u003cbr\u003eNot known - Urticaria, purpura, bullous dermatitis (including Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis and Erythema multiforme)\u003cbr\u003eRenal and urinary disorders - Not known - Nephrotoxicity, tubulointerstitial nephritis and nephrotic syndrome, renal failure (as with other NSAIDs)\u003cbr\u003eGeneral disorders and administration site conditions - Uncommon - Pyrexia, pain\u003cbr\u003eNot known - Discomfort, fatigue\u003cbr\u003eHepatobiliary disorders - Not known - Hepatitis\u003cbr\u003ePsychiatric disorders - Uncommon - Insomnia\u003cbr\u003eNot known - Depression, hallucination\u003cp\u003e\u003cb\u003eReporting of suspected adverse reactions. \u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetti-reazione-avversa.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003eWhich medicines or foods can modify the effect of Aspi Gola Dol Sore Throat 16 Sugar-Free Orange Lozenges?\u003c\/h3\u003e\u003cp\u003eCaution should be exercised in patients treated with any of the medicines listed below, as interactions have been reported in some patients. However, inform your doctor if you are taking other medicines. Flurbiprofen should be avoided in association with: - \u003ci\u003eAcetylsalicylic acid\u003c\/i\u003e: unless the intake of acetylsalicylic acid in low doses (not exceeding 100 mg\/day or local prophylactic doses for cardiovascular protection) has been recommended by the doctor; As with other medicinal products containing NSAIDs, concomitant administration of flurbiprofen and acetylsalicylic acid is generally not recommended due to the potential for increased side effects (see section 4.4). - \u003ci\u003eCox-2 inhibitors and other NSAIDs\u003c\/i\u003e: Concomitant use of other NSAIDs, including selective cyclooxygenase-2 inhibitors, should be avoided due to potential additive effects and an increased risk of adverse reactions (see section 4.4)\u003ci\u003e.\u003c\/i\u003e Flurbiprofen should be used with caution in association with: - \u003ci\u003eAnticoagulants:\u003c\/i\u003e NSAIDs may potentiate the effects of anticoagulants such as warfarin (see section 4.4). - \u003ci\u003eAntiplatelet agents\u003c\/i\u003e: increased risk of gastrointestinal bleeding. - \u003ci\u003eSelective serotonin reuptake inhibitors (SSRIs)\u003c\/i\u003e: increased risk of gastrointestinal bleeding. - \u003ci\u003eAntihypertensives (diuretics, ACE inhibitors and angiotensin II antagonists)\u003c\/i\u003e: NSAIDs can reduce the effect of diuretics. Other antihypertensive drugs may potentiate nephrotoxicity caused by cyclooxygenase inhibition, especially in patients with impaired renal function (these patients must be adequately hydrated). - \u003ci\u003eAlcohol\u003c\/i\u003e: may increase the risk of adverse reactions, especially bleeding in the gastrointestinal tract. - \u003ci\u003eCardiac glycosides\u003c\/i\u003e: NSAIDs can exacerbate heart failure, reduce VGR (glomerular filtration rate) and increase plasma levels of glycosides. - \u003ci\u003eCyclosporine\u003c\/i\u003e: increased risk of nephrotoxicity. - \u003ci\u003eCorticosteroids\u003c\/i\u003e: increased risk of gastrointestinal ulcer or haemorrhage with NSAIDs (see section 4.4). - \u003ci\u003eLithium:\u003c\/i\u003e there is evidence for a possible increase in plasma lithium levels. - \u003ci\u003eMethotrexate\u003c\/i\u003e: There may be an increase in plasma levels of methotrexate. - \u003ci\u003eMifepristone\u003c\/i\u003e: NSAIDs should not be used for 8-12 days after administration of mifepristone, as NSAIDs may reduce the effect of mifepristone. - \u003ci\u003eQuinolone antibiotics\u003c\/i\u003e: Animal data indicate that NSAIDs may increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing seizures. - \u003ci\u003eTacrolimus\u003c\/i\u003e: possible increased risk of nephrotoxicity when NSAIDs are administered together with tacrolimus. - \u003ci\u003eZidovudine\u003c\/i\u003e: Increased risk of haematological toxicity when NSAIDs are administered with zidovudine.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003eCan Aspi Gola Dol Mal di Gola 16 Orange Sugar Free Lozenges be used during pregnancy and breastfeeding?\u003c\/h3\u003e\u003cp\u003e\u003ci\u003e \u003cu\u003ePregnancy\u003c\/u\u003e \u003c\/i\u003e Flurbiprofen should not be administered during the first and second trimester of pregnancy unless strictly necessary. \u003ci\u003eThe use of flurbiprofen during the third trimester of pregnancy is contraindicated.\u003c\/i\u003e \u003ci\u003e \u003cu\u003eBreastfeeding\u003c\/u\u003e \u003c\/i\u003e In a limited number of studies, flurbiprofen appears in breast milk in very low concentrations and is unlikely to have negative effects on the breastfed infant. However, administration of flurbiprofen is not recommended in breastfeeding mothers. \u003ci\u003e \u003cu\u003eFertility\u003c\/u\u003e \u003c\/i\u003e There is evidence to suggest that cyclooxygenase\/prostaglandin synthesis inhibitors may cause impairment of female fertility through an effect on ovulation. This is reversible upon discontinuation of treatment.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Aspi Gola Dol Mal di Gola 16 Orange Sugar-Free Lozenges?\u003c\/h3\u003e\u003cp\u003eAt the recommended doses, when using the medicine in its various pharmaceutical forms, any swallowing does not cause any harm to the patient, as the dose of flurbiprofen is significantly lower than that commonly used in systemic treatments. \u003ci\u003eElderly\u003c\/i\u003e: Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal. \u003ci\u003eRespiratory disorders\u003c\/i\u003e Cases of bronchospasm have been reported with flurbiprofen in patients with a history of bronchial asthma or allergies. Flurbiprofen should be used with caution in these patients. \u003ci\u003eOther NSAIDs\u003c\/i\u003e It is advisable not to combine the medicine with other NSAIDs (see section 4.5). \u003ci\u003eSystemic lupus erythematosus (SLE) and mixed connective tissue disease\u003c\/i\u003e Patients with systemic lupus erythematosus and mixed connective tissue disease may have an increased risk of aseptic meningitis (see section 4.8), however this effect is not usually seen with products intended for limited and short-term use such as flurbiprofen. \u003ci\u003eCardiac, hepatic and renal impairment\u003c\/i\u003e The medicine should be used with caution in patients with cardiac, renal or hepatic insufficiency. NSAIDs have been reported to cause various forms of nephrotoxicity, including interstitial nephritis, nephrotic syndrome, and renal failure. The administration of an NSAID can cause a dose-dependent reduction in the formation of prostaglandins and precipitate renal failure. Patients at highest risk of developing this reaction are those with impaired renal function, cardiac impairment, liver dysfunction, those on diuretic therapy and the elderly; however, this effect is not usually observed with products intended for limited and short-term use such as flurbiprofen. \u003ci\u003eCardiovascular and cerebrovascular effects\u003c\/i\u003e Before starting treatment in patients with a positive history of hypertension and\/or heart failure, caution is required (discuss with your doctor or pharmacist), since fluid retention, hypertension and edema have been reported in association with treatment with NSAIDs. Clinical studies and epidemiological data suggest that the use of some NSAIDs, especially at high doses and for long-term treatments, may be associated with a modest increase in the risk of arterial thrombotic events such as myocardial infarction or stroke. There are insufficient data to exclude a similar risk for flurbiprofen. Patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should be treated with flurbiprofen only after careful consideration. Similar considerations must be made before starting long-term treatment in patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidemia, diabetes mellitus, smoking). \u003ci\u003eEffects on the central nervous system\u003c\/i\u003e Analgesic-induced headache. In case of prolonged or irregular use of analgesics, headache may occur, which must not be treated by increasing the dose of the medicine. \u003ci\u003e \u003cu\u003eGastrointestinal effects\u003c\/u\u003e \u003c\/i\u003e Flurbiprofen should be administered with caution to patients with a history of peptic ulcers and other gastrointestinal diseases as these conditions may be exacerbated. The risk of gastrointestinal bleeding, ulcer or perforation is higher with increasing dosage of flurbiprofen in patients with a history of ulcer, particularly if complicated by bleeding and perforation, and in the elderly. These patients should start treatment with the lowest available dose. Gastrointestinal bleeding, ulcer or perforation have been reported with all NSAIDs at any time during treatment. These adverse reactions can be fatal and can occur with or without warning symptoms or in case of a previous history of serious gastrointestinal reactions. Patients with a history of gastrointestinal disease, especially if elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) in the initial stages of treatment. Undesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.2). Caution should be advised in patients receiving concomitant medicinal products that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking flurbiprofen, treatment should be discontinued. \u003ci\u003eDermatological effects\u003c\/i\u003e The use of the medicine, especially if prolonged, can give rise to sensitization or local irritation phenomena. In such cases it is necessary to interrupt the treatment and consult a doctor to institute, if necessary, suitable therapy. Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). Flurbiprofen should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. \u003ci\u003eInfections\u003c\/i\u003e Since isolated cases of exacerbation of inflammation related to infections (e.g. development of necrotizing fasciitis) have been described in temporal association with the systemic use of drugs belonging to the NSAID class, patients are recommended to immediately consult a doctor in case of appearance or worsening of signs of a bacterial infection during flurbiprofen-based therapy. A possible indication for starting antibiotic therapy must be taken into consideration. If mouth irritation develops, treatment should be discontinued. \u003cb\u003eImportant information about some excipients\u003c\/b\u003e ASPI GOLA Lemon and Honey flavored lozenges contain glucose. Patients suffering from rare problems of glucose-galactose malabsorption should not take this medicine. ASPI GOLA Lemon and Honey flavored lozenges contain sucrose. Patients suffering from rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine. Do not use for prolonged treatments beyond 7 days. If you do not notice appreciable results after 3 days of treatment, the cause could be a different pathological condition. In these cases it is advisable to consult your doctor.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cp\u003eGiven the reduced content of the active ingredient and its local use, it is unlikely that overdose situations may occur. \u003cb\u003eSymptoms\u003c\/b\u003e The majority of patients who ingest clinically large quantities of NSAIDs develop nausea, vomiting, gastrointestinal irritation, epigastric pain, or more rarely diarrhea. Tinnitus, headache and gastrointestinal bleeding are also possible. In more severe cases of NSAID intoxication, central nervous system toxicity is observed, manifested by drowsiness, occasionally excitability, blurred vision and disorientation or coma. Occasionally patients develop seizures. In case of severe NSAID intoxication, metabolic acidosis may occur and the prothrombin time\/INR may be prolonged, probably due to interference with the action of coagulation factors present in circulation. Acute renal failure and liver damage may occur. An exacerbation of asthma is possible in asthmatic subjects. \u003cb\u003eTreatment\u003c\/b\u003e Treatment should be symptomatic and supportive and should include maintaining a patent airway and monitoring cardiac function and vital signs until stabilization. Oral administration of activated charcoal and, if necessary, correction of serum electrolytes should be considered if the patient presents within one hour of ingesting a potentially toxic amount. Seizures should be treated with intravenous diazepam or lorazepam if they are frequent or prolonged. Administer bronchodilators for asthma. There is no specific antidote for flurbiprofen.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cp\u003eIt does not interfere with the ability to drive and use machinery.\u003c\/p\u003e\n\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow do you store Aspi Gola Dol Mal di Gola 16 Orange Lozenges Without Sugar?\u003c\/h3\u003e\u003cp\u003eThis medicinal product does not require any particular storage precautions.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Aspi Gola Dol Mal di Gola 16 Orange Sugar-Free Lozenges?\u003c\/h3\u003e\u003cp\u003e16 tablets\u003c\/p\u003e\n\u003ch2\u003eDRUG LEGAL TEXT\u003c\/h2\u003e\n\u003cp\u003eContent responsibility\u003c\/p\u003e\u003cp\u003eThis sheet contains information that is not intended to replace a doctor's diagnosis or advice, as only the doctor can draw up any prescription and give therapeutic indications. All contents must be understood and are of an exclusively informative nature and aimed exclusively at bringing to the attention of customers or potential customers in the pre-purchase phase of the products sold through this site. In case of pathologies, disorders or allergies it is always best to consult your doctor first.\u003c\/p\u003e\u003cp\u003ePlease note\u003c\/p\u003e\u003cp\u003eThe product names, ingredients and percentages indicated in the descriptions are purely indicative and may be subject to changes or updates by the manufacturing companies. Due to the impossibility of adapting to these updates in real time, the photos and technical information of the products included on Dottortili.com may differ from those shown on the label or otherwise disseminated by the manufacturing companies. The only identification element appears to be the ministerial code MINSAN. The online pharmacy Dottortili.com does not guarantee the truthfulness and timeliness of the information published and declines any responsibility for any errors, omissions or failure to update the same. Dottortili.com assumes no responsibility for damages of any nature that may arise from access to the information published.\u003c\/p\u003e\u003cp\u003eData source: Farmadati Italia\u003c\/p\u003e\u003cp\u003eWebsite: www.farmadati.it\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia database is used by almost all pharmacies, parapharmacies, herbalist shops, health shops, large-scale retail trade, computerized doctors, etc. thanks to the guarantee of historical reliability, seriousness and professionalism of the company on the national territory.\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia S.r.l management system complies with the requirements of the UNI EN ISO 9001:2015 standards for quality management systems and UNI CEI ISO\/IEC 27001:2017 for information security management systems.\u003c\/p\u003e","brand":"Bayer","offers":[{"title":"Default Title","offer_id":51730213798215,"sku":"050316037","price":9.63,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/bayer-spa-aspi-gola-dol-mal-di-gola-16-pastiglie-arancia-senza-zucchero-farmacia-dottor-tili-1213791354.jpg?v=1767156225"},{"product_id":"bactoblis-30-compresse-orosolubili-probiotico-gola","title":"Bactoblis 30 orodispersible tablets probiotic throat","description":"\u003cp\u003e\n\u003cstrong\u003eBactoblis 30 buccal probiotic throat tablets\u003c\/strong\u003e it's a \u003cstrong\u003efood supplement\u003c\/strong\u003e innovative, designed for \u003cstrong\u003ethroat wellbeing\u003c\/strong\u003e and the protection of \u003cstrong\u003ebacterial flora of the oral cavity\u003c\/strong\u003e. Each tablet contains a selected strain of \u003cstrong\u003eStreptococcus salivarius K12 (BLIS K12)\u003c\/strong\u003e, a \u003cstrong\u003elactic ferment\u003c\/strong\u003e specific that promotes the balance of the oral microflora and helps to strengthen the \u003cstrong\u003eimmune defenses\u003c\/strong\u003e local. Thanks to its targeted action, Bactoblis is particularly suitable for \u003cstrong\u003eprevention of pharyngitis and tonsillitis\u003c\/strong\u003e, helping to reduce the frequency of respiratory infections and maintain throat health, especially in the most critical periods.\n\u003c\/p\u003e\n\u003cp\u003e\nLe \u003cstrong\u003ebuccal tablets\u003c\/strong\u003e of Bactoblis are easy to take: they dissolve slowly in the mouth, ensuring a gradual and prolonged release of the active ingredients directly into the \u003cstrong\u003eoral cavity\u003c\/strong\u003e. The product is suitable for both \u003cstrong\u003echildren and adults\u003c\/strong\u003e, ideal for a \u003cstrong\u003edaily use\u003c\/strong\u003e and for those who want natural support in \u003cstrong\u003eprevention of throat infections\u003c\/strong\u003e. Bactoblis is \u003cstrong\u003egluten free\u003c\/strong\u003e and presents a pleasant \u003cstrong\u003estrawberry flavour\u003c\/strong\u003e, making consumption pleasant even for the little ones.\n\u003c\/p\u003e\n\u003cp\u003e\nChoose \u003cstrong\u003eBactoblis\u003c\/strong\u003e means to rely on a \u003cstrong\u003eoral probiotic\u003c\/strong\u003e of the latest generation, designed to support the health of the throat and immune system, offering effective protection against infections and promoting the natural balance of oral bacterial flora.\n\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy should you use Bactoblis 30 buccal probiotic throat tablets? What is it for?\u003c\/h3\u003e\u003cp\u003eFood supplement based on the probiotic Streptococcus salivarius K12 (BLIS K12), in buccal tablets, formulated to promote the balance of the microflora of the oral cavity and support the natural local immune defenses at the throat level.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eMEDIA ANALYSIS\u003c\/h2\u003e\n\u003ch3\u003eWhat does Bactoblis 30 buccal probiotic throat tablets contain?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eAverage values* per tablet\u003c\/strong\u003e\u003cbr\u003eStreptococcus salivarius Blis K12: 1 billion CFU**\u003c\/p\u003e\u003cp\u003e*The content in live and viable cells refers to the correctly stored product. If the product is correctly stored, the live cell content is maintained until the end of validity date.\u003cbr\u003e**Colony Forming Units.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Bactoblis 30 buccal probiotic throat tablets?\u003c\/h3\u003e\u003cp\u003eTake 1 tablet per day for at least 90 days of treatment. The tablets are orosoluble. They should be dissolved in the mouth until completely dissolved, in the evening, before going to bed, after brushing your teeth. They must not be chewed or dissolved in water. It is advisable not to drink or ingest anything immediately after administration.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Bactoblis 30 buccal probiotic throat tablets?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eLegal warnings\u003c\/strong\u003e\u003cbr\u003eDo not exceed the recommended daily dose.\u003cbr\u003eKeep out of reach of children under three years of age.\u003cbr\u003eSupplements are not intended as substitutes for a varied and balanced diet and a healthy lifestyle.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow do you store Bactoblis 30 buccal probiotic throat tablets?\u003c\/h3\u003e\u003cp\u003eBactoblis contains live lactic ferments, sensitive to heat: it is therefore recommended to avoid exposure to heat sources or temperature changes, to store it away from light and, preferably, at a temperature between +2°C and +8°C and to transport it at temperatures lower than 25°C for periods not exceeding 48 hours. The minimum shelf life refers to the product correctly stored, in intact packaging.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Bactoblis 30 buccal probiotic throat tablets?\u003c\/h3\u003e\u003cp\u003ePack of 30 buccal tablets\u003c\/p\u003e","brand":"Pharmextracta","offers":[{"title":"Default Title","offer_id":51749042389319,"sku":"925813925","price":24.95,"currency_code":"EUR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/pharmextracta-spa-bactoblis-30-compresse-orosolubili-probiotico-gola-farmacia-dottor-tili-1213791311.jpg?v=1767156969"},{"product_id":"claremase-orale-20-flaconi-gola-irritata","title":"Claremase oral 20 bottles sore throat","description":"\u003cp\u003e\n\u003cstrong\u003eClaremase oral 20 bottles sore throat\u003c\/strong\u003e it's a \u003cstrong\u003efood supplement\u003c\/strong\u003e formulated to offer targeted support in case of \u003cstrong\u003esore throat\u003c\/strong\u003e and to encourage \u003cstrong\u003efunctionality of the microcirculation\u003c\/strong\u003e. Its composition is based on a synergy of \u003cstrong\u003ebromelain\u003c\/strong\u003e at high concentration (2,500 GDU\/g, extracted from the stem of Ananas comosus) and \u003cstrong\u003eliposomal vitamin C\u003c\/strong\u003e, two ingredients known for their beneficial properties. Bromelain is a \u003cstrong\u003enatural anti-inflammatory\u003c\/strong\u003e which helps reduce throat inflammation and support the \u003cstrong\u003edrainage of body fluids\u003c\/strong\u003e, proving useful even in case of \u003cstrong\u003etired and heavy legs\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003cp\u003e\nThe \u003cstrong\u003evitamin C\u003c\/strong\u003e present in oral Claremase contributes to the normal formation of collagen, essential for the health of blood vessels and skin, and strengthens the immune defenses. This supplement is particularly suitable in case of \u003cstrong\u003ereduced intake of bromelain\u003c\/strong\u003e in the diet or of \u003cstrong\u003eincreased need\u003c\/strong\u003e due to stressful situations, inflammation or convalescence. The wording is \u003cstrong\u003egluten and lactose free\u003c\/strong\u003e, also suitable for those with food intolerances.\n\u003c\/p\u003e\n\u003cp\u003e\nClaremase oral 20 bottles is ideal for those looking for a \u003cstrong\u003emicrocirculation supplement\u003c\/strong\u003e and for the \u003cstrong\u003edrainage of liquids\u003c\/strong\u003e, offering valid help against \u003cstrong\u003ethroat inflammation\u003c\/strong\u003e and promoting general well-being. Each package contains \u003cstrong\u003e20 single-dose vials\u003c\/strong\u003e 15 ml, practical to take and easy to always carry with you.\n\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy do you use Claremase oral 20 bottles sore throat? What is it for?\u003c\/h3\u003e\u003cp\u003eFood supplement based on highly concentrated bromelain and liposomal vitamin C, formulated for the well-being of the throat and to promote the drainage of body fluids; Vitamin C contributes to normal collagen formation and supports immune defenses.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Claremase Oral 20 bottles contain sore throat?\u003c\/h3\u003e\u003cp\u003ePurified water; sweetener: fructose; bromelain 2,500 GDU\/g (from Ananas comosus, stem), liposomal vitamin C (ascorbic acid), glycerin, lecithin \u003cstrong\u003esoy\u003c\/strong\u003e (E322), maltodextrin (E1400), sorbitol (E420), flavouring, xanthan gum (E415); preservatives: potassium sorbate, sodium benzoate.\u003c\/p\u003e\u003cp\u003eWithout \u003cstrong\u003egluten\u003c\/strong\u003e e \u003cstrong\u003elactose\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eMEDIA ANALYSIS\u003c\/h2\u003e\n\u003ch3\u003eWhat does Claremase oral 20 bottles contain sore throat?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eAverage values per 100 ml and vial\u003c\/strong\u003e\u003cbr\u003eBromelain: 6.67 g per 100 ml; 1 g per vial\u003cbr\u003eVitamin C: 3,333 mg per 100 ml; 500 mg (625% NRV*) per vial\u003c\/p\u003e\u003cp\u003e*VNR: Nutrient Reference Values.\u003c\/p\u003e\u003cp\u003e*VNR: Nutrient Reference Values\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Claremase oral 20 bottles sore throat?\u003c\/h3\u003e\u003cp\u003e1 vial per day unless otherwise prescribed by a doctor.\u003cbr\u003eShake the vial before use.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Claremase oral 20 bottles sore throat?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWarnings\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eWe do not recommend using the product in case of proven hypersensitivity to one of the ingredients listed.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eLegal warnings\u003c\/strong\u003e\u003cbr\u003eDo not exceed the recommended daily dose.\u003cbr\u003eKeep out of reach of children under three years of age.\u003cbr\u003eSupplements are not intended as substitutes for a varied and balanced diet and a healthy lifestyle.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow to store Claremase oral 20 bottles sore throat?\u003c\/h3\u003e\u003cp\u003eThe product must be stored at a temperature not exceeding 30°C, in a dry place and away from light and heat sources.\u003cbr\u003eThe expiry date indicated refers to the product in unopened packaging, correctly stored.\u003cbr\u003eValidity with intact packaging: 24 months.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Claremase oral 20 bottles sore throat?\u003c\/h3\u003e\u003cp\u003e20 vials of 15 ml.\u003cbr\u003eTotal net weight: 345 g.\u003c\/p\u003e","brand":"Damor","offers":[{"title":"Default Title","offer_id":51749047828807,"sku":"988148146","price":18.91,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/farmaceutici-damor-spa-claremase-orale-20-flaconi-gola-irritata-farmacia-dottor-tili-1213791281.jpg?v=1767157668"},{"product_id":"aftamed-gel-10-ml-afta-gengivale","title":"Aftamed gel 10 ml gum aphtha","description":"\u003cp\u003e\n\u003cstrong\u003eAftamed gel 10 ml gingival aphthae\u003c\/strong\u003e it's a \u003cstrong\u003especific oral gel\u003c\/strong\u003e for the treatment of \u003cstrong\u003ecanker sores\u003c\/strong\u003e and of \u003cstrong\u003eoral lesions\u003c\/strong\u003e like them \u003cstrong\u003eaphthous ulcers\u003c\/strong\u003e and the \u003cstrong\u003eaphthous stomatitis\u003c\/strong\u003e. Thanks to his \u003cstrong\u003epatented formula based on high molecular weight hyaluronic acid\u003c\/strong\u003e, this product offers a \u003cstrong\u003elong-lasting protection\u003c\/strong\u003e on the lesion, favoring a \u003cstrong\u003erapid reduction of pain\u003c\/strong\u003e and accelerating the natural processes of \u003cstrong\u003ehealing of canker sores\u003c\/strong\u003e. The protective action of Aftamed gel helps \u003cstrong\u003erehydrate the gum tissues\u003c\/strong\u003e and to reduce the number of lesions, improving oral comfort from the first applications.\n\u003c\/p\u003e\n\u003cp\u003e\nThe \u003cstrong\u003egel consistency\u003c\/strong\u003e allows one \u003cstrong\u003etargeted local application\u003c\/strong\u003e directly on the inflamed gums or on the areas affected by canker sores, guaranteeing immediate and prolonged relief. \u003cstrong\u003eAftamed gel\u003c\/strong\u003e it is harmless if ingested and can be used several times a day, above all \u003cstrong\u003eafter meals\u003c\/strong\u003e, to keep the area protected and promote \u003cstrong\u003etreatment of canker sores\u003c\/strong\u003e. The presence of \u003cstrong\u003exylitol\u003c\/strong\u003e and other hydrating components helps to keep the oral mucosa in optimal conditions, reducing the risk of relapses.\n\u003c\/p\u003e\n\u003cp\u003e\nIdeal for those who suffer from \u003cstrong\u003eoral pain\u003c\/strong\u003e due to \u003cstrong\u003egingival canker sores\u003c\/strong\u003e or \u003cstrong\u003emouth lesions\u003c\/strong\u003e, \u003cstrong\u003eAftamed gel 10 ml\u003c\/strong\u003e represents an effective and safe solution for the daily well-being of the oral cavity. The practical 10 ml format makes it convenient to always carry with you, for a \u003cstrong\u003equick and discreet treatment\u003c\/strong\u003e at any time of the day.\n\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Aftamed gel 10 ml for gum disease used? What is it for?\u003c\/h3\u003e\u003cp\u003eOral gel based on high molecular weight hyaluronic acid, indicated for the treatment of canker sores and oral lesions such as aphthous ulcers and aphthous stomatitis; offers long-lasting protection on the lesion, promoting pain reduction and oral comfort.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Aftamed gel 10 ml for gum disease contain?\u003c\/h3\u003e\u003cp\u003eHigh Molecular Weight Hyaluronic Acid (Sodium Salt), Aqua, Xylitol, Cellulose Gum, Propylene Glycol, PEG-40 Hydrogenated Castor Oil, Sodium Benzoate, Polyvinyl Alcohol, Carbomer (Polycarbophil), Sodium Hydroxide, Dichlorobenzyl Alcohol, Aroma, CI 15985, Acid Blue 9 (CI 42090).\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Aftamed gel 10 ml for gum disease?\u003c\/h3\u003e\u003cp\u003eApply 2-3 times a day, or more as needed, after meals, for a week or until symptoms disappear.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Aftamed gel 10 ml for gum disease?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWarnings\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eAvoid use in case of individual hypersensitivity to the ingredients.\u003cbr\u003eAvoid use if the product appears visibly damaged.\u003cbr\u003eIf symptoms persist, consult your doctor.\u003cbr\u003eDo not use after the expiry date.\u003cbr\u003eAfter use, remove any product residues from the container before closing it.\u003cbr\u003eThis product is for personal use.\u003cbr\u003eKeep out of reach of children.\u003cbr\u003eThe validity period refers to the intact and correctly stored product.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Aftamed gel 10 ml for gum disease stored?\u003c\/h3\u003e\u003cp\u003eValidity of intact packaging: 36 months.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Aftamed gel 10 ml for gum disease?\u003c\/h3\u003e\u003cp\u003e10ml.\u003c\/p\u003e","brand":"Menarini","offers":[{"title":"Default Title","offer_id":51821888209223,"sku":"943303507","price":12.56,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/a-menarini-ind-farm-riun-srl-aftamed-gel-10-ml-afta-gengivale-farmacia-dottor-tili-1213790667.jpg?v=1767163410"},{"product_id":"curasept-gel-afte-rapido-dna-10-ml","title":"Curasept rapid DNA canker sore gel 10 ml","description":"\u003cp\u003e\n\u003cstrong\u003eCurasept rapid DNA canker sore gel 10 ml\u003c\/strong\u003e it's a \u003cstrong\u003eprotective gel\u003c\/strong\u003e specifically formulated to offer a \u003cstrong\u003equick relief from canker sores\u003c\/strong\u003e and give them \u003cstrong\u003emouth lesions\u003c\/strong\u003e of small dimensions, such as aphthous stomatitis, injuries from trauma or vitamin deficiencies. Thanks to his \u003cstrong\u003einnovative DNA technology\u003c\/strong\u003e, this medical device creates a protective barrier that \u003cstrong\u003ereduces pain\u003c\/strong\u003e, protects and hydrates the wound, promoting a \u003cstrong\u003efaster healing\u003c\/strong\u003e of canker sores and small oral lesions.\n\u003c\/p\u003e\n\u003cp\u003e\nThe \u003cstrong\u003eVegan Friendly formulation\u003c\/strong\u003e of Curasept rapid DNA foot-and-mouth gel 10 ml is alcohol-free, does not burn and does not irritate, guaranteeing a delicate and safe local application even on the most sensitive mucous membranes. The gel does not alter the perception of flavors, making it ideal for daily use in case of \u003cstrong\u003esingle or small canker sores\u003c\/strong\u003e, herpes labialis and other small lesions of the mouth. The practical 10 ml tube allows precise and targeted application, ensuring a \u003cstrong\u003eeffective and comfortable treatment\u003c\/strong\u003e for the well-being of your mouth.\n\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy do you use Curasept DNA rapid canker sore gel 10 ml? What is it for?\u003c\/h3\u003e\u003cp\u003eGel medical device indicated for the rapid relief of canker sores and small lesions of the mouth (aphthous stomatitis, lesions due to trauma or vitamin deficiencies) and herpes labialis; creates a protective barrier that reduces pain and promotes the healing of mucous membranes.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Curasept DNA rapid canker sore gel 10 ml contain?\u003c\/h3\u003e\u003cp\u003eCalcium\/sodium PVM\/MA copolymer, hydrolyzed DNA\/RNA, sodium hyalorunate, allantoin, glycyrrhetinic acid, Ruscus aculeatus root extract, Leptospermum scoparium branch\/leaf oil, Melaleuca alternifolia leaf oil.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Curasept DNA rapid canker sore gel 10 ml?\u003c\/h3\u003e\u003cp\u003eApply a small amount of gel, 2-3 times a day for a week, directly on the injured part inside the mouth, with the help of the applicator supplied or a clean, dry finger, or a cotton swab. Do not rinse your mouth for at least an hour.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Curasept rapid DNA canker sore gel 10 ml?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWarnings\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eExternal use. Do not ingest. Keep out of reach of children. In children under 6 years, use under the supervision of an adult.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Curasept rapid DNA canker sore gel 10 ml stored?\u003c\/h3\u003e\u003cp\u003eStore away from heat sources.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Curasept rapid DNA canker sore gel 10 ml?\u003c\/h3\u003e\u003cp\u003e10 ml tube.\u003c\/p\u003e","brand":"Curasept","offers":[{"title":"Default Title","offer_id":51821895844167,"sku":"981110556","price":11.16,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/curasept-spa-curasept-gel-afte-rapido-dna-10-ml-farmacia-dottor-tili-1213790822.jpg?v=1767155650"},{"product_id":"gengigel-gel-gengivale-20-ml","title":"Gengigel gum gel 20 ml","description":"\u003cp\u003e\n\u003cstrong\u003eGengigel gingival gel 20 ml\u003c\/strong\u003e it's a \u003cstrong\u003eoral medical device\u003c\/strong\u003e class IIa, specifically formulated for the treatment and protection of \u003cstrong\u003einflamed gums\u003c\/strong\u003e and to encourage \u003cstrong\u003ehealing of oral tissues\u003c\/strong\u003e. Thanks to the presence of \u003cstrong\u003ehyaluronic acid\u003c\/strong\u003e high purity, Gengigel carries out an action \u003cstrong\u003esoothing, healing and repairing\u003c\/strong\u003e on the gums, making it particularly suitable in case of \u003cstrong\u003egingivitis, bleeding gums, gum bags, gum recession\u003c\/strong\u003e e \u003cstrong\u003egingival lesions\u003c\/strong\u003e due to trauma, prosthetics, orthodontic appliances or dental interventions.\n\u003c\/p\u003e\n\u003cp\u003e\nIts innovative formula contributes to \u003cstrong\u003eregenerate and protect the gums\u003c\/strong\u003e, accelerating the processes \u003cstrong\u003ehealing\u003c\/strong\u003e and reducing discomfort caused by inflammation or small wounds. Gengigel gingival gel is also ideal as \u003cstrong\u003esupport after professional dental cleaning, tooth extractions or interventions on the oral mucosa\u003c\/strong\u003e. The practical format from \u003cstrong\u003e20ml\u003c\/strong\u003e allows targeted and hygienic application, perfect for daily use after main meals.\n\u003c\/p\u003e\n\u003cp\u003e\nChoose Gengigel gingival gel for an action \u003cstrong\u003equick, effective and delicate\u003c\/strong\u003e in the \u003cstrong\u003egum care\u003c\/strong\u003e, to encourage \u003cstrong\u003ehealing and regeneration of gum tissue\u003c\/strong\u003e and maintain the health of your mouth every day.\n\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Gengigel gingival gel 20 ml used? What is it for?\u003c\/h3\u003e\u003cp\u003eGingival gel based on high purity hyaluronic acid, medical device indicated for the treatment and protection of inflamed gums; It has a soothing, healing and repairing action, being useful in cases of gingivitis, bleeding gums, gum recession and injuries due to trauma, prostheses, orthodontic appliances or dental interventions.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Gengigel gingival gel 20 ml contain?\u003c\/h3\u003e\u003cp\u003eHyaluronic acid 0.025%; xylitol; excipients.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Gengigel gingival gel 20 ml?\u003c\/h3\u003e\u003cp\u003eApply three to five times a day after main meals, having ensured correct dental hygiene. Continue applications for 3-4 weeks until symptoms disappear. For each application, rinse your mouth with 10 ml of liquid, equal to one dose, for 1-2 minutes. The product is ready for use, so it does not need to be diluted. After application, it is recommended not to introduce food or liquids into the oral cavity for approximately 30 minutes to avoid premature removal of the product.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Gengigel gingival gel 20 ml?\u003c\/h3\u003e\u003cp\u003e20 ml bottle.\u003c\/p\u003e","brand":"Menarini","offers":[{"title":"Default Title","offer_id":51821899743559,"sku":"900904513","price":13.21,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/a-menarini-ind-farm-riun-srl-gengigel-gel-gengivale-20-ml-farmacia-dottor-tili-1213790762.jpg?v=1767166247"},{"product_id":"mucosamin-spray-orale-30-ml-mucosa-orale","title":"Mucosamin oral spray 30 ml oral mucosa","description":"\u003cp\u003e\n\u003cstrong\u003eMucosamin oral spray 30 ml oral mucosa\u003c\/strong\u003e it's a \u003cstrong\u003emedical device\u003c\/strong\u003e specifically formulated to offer a \u003cstrong\u003eeffective protection and regenerating support for the oral mucosa\u003c\/strong\u003e. Thanks to its composition based on \u003cstrong\u003ehyaluronic acid\u003c\/strong\u003e and essential amino acids such as glycine, L-proline, L-leucine and L-lysine hydrochloride, this \u003cstrong\u003eoral fluid gel\u003c\/strong\u003e promotes collagen formation and accelerates the repair process of damaged tissues. Its action is particularly suitable for \u003cstrong\u003etreatment of oral mucositis\u003c\/strong\u003e that may arise during \u003cstrong\u003echemotherapy\u003c\/strong\u003e, \u003cstrong\u003eradiotherapy\u003c\/strong\u003e or combined treatments, offering a \u003cstrong\u003erapid relief from pain and burning\u003c\/strong\u003e associated with lesions and ulcerations of the mouth.\n\u003c\/p\u003e\n\u003cp\u003e\nThe \u003cstrong\u003espray formulation\u003c\/strong\u003e of Mucosamin allows a \u003cstrong\u003eeasy application even in the most difficult to reach areas\u003c\/strong\u003e of the oral cavity, ensuring uniform coverage and targeted action on the most sensitive areas. The product works by creating one \u003cstrong\u003eprotective layer\u003c\/strong\u003e which reduces sensitivity to external agents, hydrates the mucosa and contributes to \u003cstrong\u003emaintenance of optimal physiological conditions\u003c\/strong\u003e of the mouth. Mucosamin oral spray is ideal for those who need a \u003cstrong\u003eregenerating and protective treatment of the oral mucosa\u003c\/strong\u003e, both in the presence of \u003cstrong\u003eoral lesions\u003c\/strong\u003e that for the \u003cstrong\u003eprevention and relief from irritative conditions\u003c\/strong\u003e caused by mucositis.\n\u003c\/p\u003e\n\u003cp\u003e\nBy choosing \u003cstrong\u003eMucosamin 30 ml\u003c\/strong\u003e you opt for an advanced and proven effective solution, developed for \u003cstrong\u003epromote healing of ulcerated areas\u003c\/strong\u003e and improve the quality of life even during oncological therapies. The product is made according to the highest safety and quality standards, resulting well tolerated and suitable for daily use for \u003cstrong\u003eprotection and hydration of the oral mucosa\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Mucosamin oral spray 30 ml oral mucosa used? What is it for?\u003c\/h3\u003e\u003cp\u003eSpray medical device based on hyaluronic acid and amino acids, indicated for the protection and regenerating support of the oral mucosa in case of mucositis linked to chemotherapy or radiotherapy; promotes collagen formation and tissue repair, offering relief from pain and burning.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eINGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat ingredients does Mucosamin oral spray 30 ml oral mucosa contain?\u003c\/h3\u003e\u003cp\u003ePurified water, sodium hyaluronate, glycine, L-proline, L-leucine, L-lysine hydrochloride, methyl 4 - hydroxybenzoate sodium salt, propyl 4 - hydroxybenzoate sodium salt, propylene glycol, tetrasodium EDTA.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eHOW TO USE\u003c\/h2\u003e\n\u003ch3\u003eHow do I use Mucosamin oral spray 30 ml oral mucosa?\u003c\/h3\u003e\u003cp\u003eApply an even layer by spraying several times until the entire affected area is covered. The application can be repeated several times a day (three-four) depending on the extent of the symptoms.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Mucosamin oral spray 30 ml oral mucosa?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWarnings\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eIt is contraindicated in case of proven hypersensitivity to the components. There are no known phenomena of overdose. There are no known side effects. There are no known interactions with drugs and medicinal substances. Although no side effects are known, in cases of pregnancy and breastfeeding the doctor must decide whether to prescribe the application. Mucosamin Spray is a product characterized by good tolerability.\u003cbr\u003eThe expiry date refers to the closed and correctly stored product.\u003cbr\u003eDo not use after the expiry date.\u003cbr\u003eDo not sterilize.\u003cbr\u003eDo not use if the package is open or damaged.\u003cbr\u003eDo not use in case of proven hypersensitivity to the components.\u003cbr\u003eKeep out of reach of children.\u003cbr\u003eIn case of adverse reactions, stop treatment and consult your doctor.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Mucosamin oral spray 30 ml oral mucosa stored?\u003c\/h3\u003e\u003cp\u003eMucosamin spray must be stored at a temperature between 8° and 30°. Do not store in the fridge. Store in a cool, dry place, away from humidity and heat sources.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Mucosamin oral spray 30 ml oral mucosa?\u003c\/h3\u003e\u003cp\u003eGlass bottle with cannula dispenser - Spray 30 ml.\u003c\/p\u003e","brand":"Professional Dietetics","offers":[{"title":"Default Title","offer_id":51821906264391,"sku":"920582297","price":23.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/professional-dietetics-mucosamin-spray-orale-30-ml-mucosa-orale-farmacia-dottor-tili-1254215762.jpg?v=1786736019"},{"product_id":"neoborocillina-mal-di-gola-senza-zucchero-20-pastiglie","title":"NeoBorocillina Sore Throat Without Sugar 20 Tablets","description":"\u003cp\u003e\u003cstrong\u003eNeoBorocillina Sore Throat Without Sugar 20 Tablets\u003c\/strong\u003e it's a \u003cstrong\u003eantiseptic medicine for the oropharyngeal cavity\u003c\/strong\u003e in \u003cstrong\u003etablets\u003c\/strong\u003e to slowly dissolve in the mouth. Each tablet contains two active ingredients: \u003cstrong\u003e2,4-dichlorobenzyl alcohol\u003c\/strong\u003e \u003cstrong\u003e1.2 mg\u003c\/strong\u003e e \u003cstrong\u003esodium benzoate\u003c\/strong\u003e \u003cstrong\u003e20 mg\u003c\/strong\u003e, the latter equivalent to 17 mg of benzoic acid.\u003c\/p\u003e\u003cp\u003eThe\u003cstrong\u003e2,4-dichlorobenzyl alcohol\u003c\/strong\u003e is a surface antiseptic from the chlorophenol group, used in formulations for the oral cavity for its action on the bacterial load of the mucous membranes of the mouth and throat. The \u003cstrong\u003esodium benzoate\u003c\/strong\u003e it is the sodium salt of benzoic acid and supports the first with its own antiseptic activity: there are 20 mg in the tablet, corresponding to 17 mg of benzoic acid.\u003c\/p\u003e\u003cp\u003eThe wording \u003cstrong\u003esugar free\u003c\/strong\u003e this is what distinguishes these tablets from the traditional version of the range: instead of sucrose they are there \u003cstrong\u003emannitol\u003c\/strong\u003e e \u003cstrong\u003easpartame\u003c\/strong\u003e as sweeteners. They complete the formula \u003cstrong\u003ementhol\u003c\/strong\u003e, \u003cstrong\u003emint essence\u003c\/strong\u003e, \u003cstrong\u003eeucalyptol\u003c\/strong\u003e e \u003cstrong\u003ecitral\u003c\/strong\u003e, which give the tablet the fresh and balsamic note characteristic of the product.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eNeoBorocillin\u003c\/strong\u003e is a brand of \u003cstrong\u003eAlphasigma\u003c\/strong\u003e. The packaging is from \u003cstrong\u003e20 tablets\u003c\/strong\u003e in PVC, PE and PVDC blisters heat-sealed to aluminium, and the product belongs to the field of medicines for \u003cstrong\u003esore throat\u003c\/strong\u003e and for the antiseptic hygiene of \u003cstrong\u003eoropharyngeal cable\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy should you use NeoBorocillina Sore Throat Without Sugar 20 Tablets? What is it for?\u003c\/h3\u003e\u003cp\u003eAntiseptic of the oropharyngeal cavity.\u003c\/p\u003e\n\u003ch2\u003eACTIVE INGREDIENTS AND EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat is the composition of NeoBorocillina Sore Throat Without Sugar 20 Tablets?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eActive ingredients\u003c\/strong\u003e\u003cbr\u003eEach tablet contains 2,4-dichlorobenzyl alcohol 1.2 mg and sodium benzoate 20 mg, equivalent to 17 mg of benzoic acid.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eExcipients\u003c\/strong\u003e\u003cbr\u003eMagnesium stearate, precipitated silica, menthol, mint essence, eucalyptol, citral, naefco peppermint, aspartame, polyvinylpyrrolidone K30, mannitol.\u003c\/p\u003e\n\u003ch2\u003eDOSAGE\u003c\/h2\u003e\n\u003ch3\u003eHow to take NeoBorocillin Sore Throat Without Sugar 20 Tablets?\u003c\/h3\u003e\u003cp\u003eSlowly dissolve one lozenge in your mouth every 2-3 hours, up to a daily maximum of 8 lozenges.\u003c\/p\u003e\u003cp\u003eDo not exceed the recommended doses.\u003c\/p\u003e\n\u003ch2\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003eWhen should NeoBorocillin Sore Throat Without Sugar 20 Tablets be used and what side effects can it cause?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eContraindications\u003c\/strong\u003e\u003cbr\u003eHypersensitivity to the active substances or to any of the excipients. Contraindicated in children under two years of age, with a predisposition to laryngospasm and convulsions. Due to the presence of aspartame, the product is contraindicated in cases of phenylketonuria.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSide effects\u003c\/strong\u003e\u003cbr\u003eVery rarely: hypersensitivity reactions, feeling of dizziness, respiratory failure, glottis edema, vomiting, malaise, sweating, arm edema, pulmonary edema, eyelid edema, face edema, urticaria, haemolytic anaemia, jaundice.\u003c\/p\u003e\n\u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003eWhich medicines or foods can modify the effect of NeoBorocillina Sore Throat Without Sugar 20 Lozenges?\u003c\/h3\u003e\u003cp\u003eAvoid the simultaneous use of other antiseptics.\u003c\/p\u003e\n\u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003eCan NeoBorocillina Sore Throat Without Sugar 20 Lozenges be used during pregnancy and breastfeeding?\u003c\/h3\u003e\u003cp\u003eIn pregnant and breastfeeding women, the product should be administered in case of real need and under the direct supervision of a doctor.\u003c\/p\u003e\n\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of NeoBorocillina Sore Throat Without Sugar 20 Tablets?\u003c\/h3\u003e\u003cp\u003eDue to the presence of menthol, the product is contraindicated in children under two years of age with a predisposition to laryngospasm and convulsions.\u003c\/p\u003e\u003cp\u003eEach tablet contains 3.22 mg of sodium, equal to 25.76 mg at the maximum daily dose.\u003c\/p\u003e\u003cp\u003eProlonged use may give rise to sensitization phenomena.\u003c\/p\u003e\n\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is NeoBorocillin Sore Throat Sugar Free 20 Tablets stored?\u003c\/h3\u003e\u003cp\u003eStore at temperatures not exceeding 30 degrees centigrade.\u003c\/p\u003e\u003cp\u003eThe validity period is 5 years.\u003c\/p\u003e\n\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of NeoBorocillina Sore Throat Without Sugar 20 Tablets?\u003c\/h3\u003e\u003cp\u003e20 sugar-free tablets in PVC, PE and PVDC blisters opaque with titanium dioxide, heat-sealed to aluminum foil.\u003c\/p\u003e\n\u003ch2\u003eDRUG LEGAL TEXT\u003c\/h2\u003e\n\u003cp\u003eContent responsibility\u003c\/p\u003e\u003cp\u003eThis sheet contains information that is not intended to replace a doctor's diagnosis or advice, as only the doctor can draw up any prescription and give therapeutic indications. All contents must be understood and are of an exclusively informative nature and aimed exclusively at bringing to the attention of customers or potential customers in the pre-purchase phase of the products sold through this site. In case of pathologies, disorders or allergies it is always best to consult your doctor first.\u003c\/p\u003e\u003cp\u003ePlease note\u003c\/p\u003e\u003cp\u003eThe product names, ingredients and percentages indicated in the descriptions are purely indicative and may be subject to changes or updates by the manufacturing companies. Due to the impossibility of adapting to these updates in real time, the photos and technical information of the products included on Dottortili.com may differ from those shown on the label or otherwise disseminated by the manufacturing companies. The only identification element appears to be the ministerial code MINSAN. The online pharmacy Dottortili.com does not guarantee the truthfulness and timeliness of the information published and declines any responsibility for any errors, omissions or failure to update the same. Dottortili.com assumes no responsibility for damages of any nature that may arise from access to the information published.\u003c\/p\u003e\u003cp\u003eData source: Farmadati Italia\u003c\/p\u003e\u003cp\u003eWebsite: www.farmadati.it\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia database is used by almost all pharmacies, parapharmacies, herbalist shops, health shops, large-scale retail trade, computerized doctors, etc. thanks to the guarantee of historical reliability, seriousness and professionalism of the company on the national territory.\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia S.r.l management system complies with the requirements of the UNI EN ISO 9001:2015 standards for quality management systems and UNI CEI ISO\/IEC 27001:2017 for information security management systems.\u003c\/p\u003e","brand":"Alfasigma","offers":[{"title":"Default Title","offer_id":54137676300615,"sku":"022632107","price":11.5,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/alfasigma-spa-1-2-mg-20-mg-pastiglie-senza-zucchero-20-pastiglie-in-blister-pvc-pe-pvdc-al-farmacia-dottor-tili-1244017771.jpg?v=1790944536"}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/collections\/Frame_53_20.svg?v=1784273322","url":"https:\/\/www.dottortili.com\/en\/collections\/anti-inflammatory-drugs-for-mouth-throat-and-gums.oembed?page=2","provider":"Farmacia Dottor Tili","version":"1.0","type":"link"}